Louisiana State University

LSU Digital Commons
LSU Doctoral Dissertations

Graduate School

2012

Synthesis, cellular studies, and computational analysis of
porphyrin and BODIPY conjugates with affinity for epidermal
growth factor receptor
Alecia Michelle McCall
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations
Part of the Chemistry Commons

Recommended Citation
McCall, Alecia Michelle, "Synthesis, cellular studies, and computational analysis of porphyrin and BODIPY
conjugates with affinity for epidermal growth factor receptor" (2012). LSU Doctoral Dissertations. 1829.
https://digitalcommons.lsu.edu/gradschool_dissertations/1829

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It
has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU
Digital Commons. For more information, please contactgradetd@lsu.edu.

SYNTHESIS, CELLULAR STUDIES, AND COMPUTATIONAL ANALYSIS OF
PORPHYRIN AND BODIPY CONJUGATES WITH AFFINITY FOR EPIDERMAL
GROWTH FACTOR RECEPTOR

A Dissertation

Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy
In

The Department of Chemistry

By
Alecia Michelle McCall
B.S., Xavier University of Louisiana, 2007
May, 2012

!

!

DEDICATION
This is dedicated to my parents, Richard and Phelecia McCall, as well as my three
siblings, Richard the II, Alesyn, and Rick. This is also dedicated to my grandparents, Lee
Densor Anderson, Thedorice Anderson, Emma McCall, and Robert McCall, who, although not
present, ultimately propelled me to succeed in all that I do because I had the chance to get the
education they desired for future generations.

!

ii

!

ACKNOWLEDGEMENTS
I thank God first for giving me an opportunity that many people never have, but also, I
am so happy that I have found absolute peace in Him, and this has helped me get through this
process.
I would like to give my sincere thanks to my advisor, Professor M. Graça H. Vicente. Dr.
Vicente has been a true mentor to me throughout this process. I am very fortunate to have Dr.
Vicente as an advisor because she is very kind and by far one of the most supportive people I
have ever met. Additionally, Dr. Vicente has thoroughly trained me in synthetic porphyrin
chemistry and I will use all of the tools that she taught me in the next phase of life. She has been
very uplifting, especially when I did not believe that I could accomplish syntheses. I will
absolutely never forget her mentorship, kindness, optimism, and knowledge.
I would also like to thank my dissertation committee members, Professor Kevin M.
Smith, Professor Isiah Warner, Professor Bin Chen, and Professor Rhett Stout for their advice
during my graduate school process. It has been a pleasure to speak with Professor Smith about
porphyrin chemistry as well. I have learned so much from him. Dr. Warner has been a great
mentor since I began my studies at LSU. Dr. Warner has graciously given me advice and led me
to pursue postdoctoral work. Dr. Warner is always available to assist minority students in the
department and I truly appreciate his advice.
I would also like to thank my collaborative research groups: Dr. Azeem Hasan for the
HRMS and MALDI-TOF-TOF analyses; Dr. Dale Treleaven and Dr. Thomas Weldeghiorghis in
the LSU NMR Facility; Dr. Seetharama Jois at the University of Louisiana at Monroe.
The members of the Vicente and Smith Research Groups have been very helpful to me
throughout my research. I would particularly like to thank Krystal R. Fontenot for being such a
!

iii

!

great friend and assisting me in learning peptide chemistry. It has been an honor to work with all
of the members of the Vicente and Smith Groups: Dinesh Bhupathiraju, Jaime Hayes, Moses
Ihachi, Benson Ongorora, Haijun Wang, Timsy Uppal, Waruna Jindasa, Javoris Hollingsworth,
and Xiaoke Hu. I would also like to thank previous group member, Hairong Li, for assisting me
with learning how to use the Dionex HPLC.
Lastly, I would like to thank my family members: my dad (Richard, Sr.), my mom
(Phelecia), my sister (Alesyn), my youngest brother (Andy), and my older brother (Rick), who
have always been available to talk to me whenever I might have been feeling as though this
journey was too rough. Their support, even though they are far away in Michigan, has meant so
much to me since I have been in Louisiana for undergraduate and graduate studies. I love you,
no matter what!

!

iv

!

TABLE OF CONTENTS
DEDICATION ................................................................................................................................. ii
ACKNOWLEDGEMENTS ............................................................................................................ iii
LIST OF ABBREVIATIONS ........................................................................................................ vii
ABSTRACT ..................................................................................................................................... x

CHAPTER 1. INTRODUCTION TO PORPHYRINS AND BODIPYS ........................................1
1.1 Fundamental Concepts of Naturally Occurring Porphyrins .................................................................1
1.2 Physico-chemical Properties of Porphyrins .........................................................................................2
1.3 Porphyrin Syntheses .............................................................................................................................4
1.4 Physico-chemical Properties of BODIPYs ..........................................................................................7
1.5 BODIPY Syntheses ..............................................................................................................................8
1.6 Medicinal Applications of Porphyrins and Related Derivatives ........................................................10
1.7 In vivo Imaging ..................................................................................................................................11
1.8 Epidermal Growth Factor Receptor ...................................................................................................12
1.9 Molecular Dynamics and Ab Initio Computational Calculations ......................................................13
1.10 References ........................................................................................................................................18

CHAPTER 2. SYNTHESIS OF MESO-SUBSTITUTED TETRAPHENYLPORPHYRINS AS
FLUOROPHORES IN EGFR TARGETED CONJUGATES .......................................................22
2.1 Syntheses of meso-Substituted Porphyrins ........................................................................................22
2.2 Synthesis of Mono-amino and Mono-carboxyl Tetraphenylporphyrins via the Lindsey Method .....22
2.3 Synthesis of Polymethoxy Tetraphenylporphyrins via the Lindsey Conditions ................................25
2.4 Synthesis of Propargyl Porphyrins for Use in These Applications ....................................................28
2.4.1 Synthesis of 5-(4-propargylphenyl)-10,15,20-tri(4-hydroxyphenyl)porphyrin .......................29
2.5 Synthesis of PEGs and Pegylated porphyrins ....................................................................................30
2.5.1 Structures and Synthesis of PEG Linkages ...............................................................................30
2.5.2 Synthesis of 5-PEG ...................................................................................................................33
2.6 Conclusions ........................................................................................................................................35
2.7 Experimental ......................................................................................................................................36
2.8 References ..........................................................................................................................................49

CHAPTER 3. BENZYLIDENEMALONONITRILE- AND QUINAZOLINE-BASED
PORPHYRIN CONJUGATES ......................................................................................................52
3.1 The Development of Small Tyrphostin Ligands with Affinity for EGFR .........................................52
3.2 Description of Benzylidenemalononitriles (BMNs) ..........................................................................57
3.2.1 Synthesis, Characterization, and Cell Studies of BMNs .................................................................58
3.3 Description of Quinazolines...............................................................................................................63
3.3.1 Synthesis and Characterization of Quinazolines .......................................................................63
3.4 In Silico Studies on Tyrphostin-Based Porphyrin Conjugates...........................................................67
3.4.1 MM and Docking of Tyrphostin-Based Porphyrin Conjugates ................................................67
3.5 Conclusion .........................................................................................................................................85
!

v

!
3.6 Experimental ......................................................................................................................................86
3.7 References ..........................................................................................................................................98

CHAPTER 4. SYNTHESIS, CHARACTERIZATION AND COMPUTATIONAL STUDIES OF
PORPHYRIN-PEPTIDIC CONJUGATES FOR USE AS IN VIVO IMAGING AGENTS FOR
COLORECTAL CANCERS (CRC) ............................................................................................102
4.1 Introduction ......................................................................................................................................102
4.1.1 Prior Synthesis of Porphyrin-Peptide Conjugates ...................................................................102
4.1.2 Conjugation of Porphyrin to Bovine Serum Albumin (BSA) Protein ....................................105
4.1.3 Types of Peptidic Molecules Utilized in This Project.............................................................106
4.2 Synthesis of Porphyrin-Peptide Conjugates Using Peptides with Affinity for EGFR .....................107
4.2.1 Synthesis of Peptides EGFR L1 and EGFR L2.......................................................................107
4.2.2 Synthesis of Porphyrin-Peptide Conjugates ............................................................................110
4.2.3 Preliminary Cell Studies for Porphyrin-Peptide Conjugates...................................................114
4.3 Synthesis of Porphyrin-BSA Conjugate ..........................................................................................117
4.4 Selected Computational Studies of Porphyrin-Peptide Conjugates .................................................119
4.4.1 MM2 Force Field Application for Porphyrin-Peptide Conjugates..........................................120
4.4.2 AutoDOCK4 for Porphyrin-Peptide Conjugates.....................................................................120
4.5 Conclusion .......................................................................................................................................124
4.6 Experimental ....................................................................................................................................125
4.7 References ........................................................................................................................................136

CHAPTER 5. BODIPY PEPTIDOMIMETIC CONJUGATES TARGETED TOWARD HER-2
AS THERAPEUTIC AGENTS FOR BREAST CANCER .........................................................140
5.1 The Importance and Versatility of BODIPYs ..................................................................................140
5.2 BODIPY Syntheses ..........................................................................................................................142
5.2.1 BODIPY Synthesis from Pyrrole and Aromatic Aldehyde .....................................................143
5.2.2 BODIPY Synthesis from Pyrroles and Acylated Compounds (Acetone, Acid Chlorides, and
Anhydrides) ......................................................................................................................................144
5.2.3 BODIPY Synthesis from Ketopyrroles ...................................................................................145
5.3 HER-2 and its Implication in Breast Cancer ....................................................................................147
5.4 Development and Biological Studies of HERP5 Peptidomimetic ...................................................149
5.4.1 Computational Development of HERP5 .................................................................................151
5.4.2 Antiproliferative Activity of HERP5 ......................................................................................152
5.5 Synthesis of BODIPY-HERP5 Conjugates......................................................................................153
5.5.1 Synthesis of BODIPY-HERP5 tert-Butyl Ester Terminated Conjugate .................................153
5.5.2 Synthesis of BODIPY-HERP5 Rink Amide Conjugate ..........................................................155
5.5.3 Synthesis of BODIPY-HERP5 Wang Conjugate ....................................................................156
5.6 Conclusion .......................................................................................................................................158
5.7 Experimental ....................................................................................................................................158
5.8 References ........................................................................................................................................169

VITA ............................................................................................................................................. 173

!

vi

!

LIST OF ABBREVIATIONS
Abbreviation

Chemical Name

BF3.Et2O

Boron trifluoro diethyl
etherate

Chemical Structure
O
B
F

F
F

BODIPY

BOron DIPYrromethene;
4,4-Difluoro-4-bora-3a,4adiaza-s-indacenes

N

B

N

F F

CN

BMN

Benzilidenemalononitrile

CRC

Colorectal Cancer

DBU

1,8-Diazabicycloundec-7-ene

R

CN

NA
N

N

!

DCM

Dichloromethane

DDQ

2,3-Dichloro-5,6Dicyanobenzoquinone

DIBAL-H

Di-iso-butyl aluminum
hydride

DIEA

Diisopropylethylamine

DMF

Dimethylformamide

vii

!

EGFR

Epidermal Growth Factor
Receptor

NA

ESI-MS

Electrospray Ionization
Mass Spectrometry

NA

HER-2

Human Epidermal Growth
Factor Receptor 2

NA

HOBt

1-hydroxybenzotriazole

HOMO

Highest Occupied Molecular
Orbital

NA

IC50

Half maximal inhibitory
concentration

NA

LUMO

Lowest Unoccupied
Molecular Orbital

NA

MP

Moller-Plessett 2

NA

NaNO2

Sodium nitrite

NIR

Near Infrared (Range)

NA

NMR

Nuclear Magnetic
Resonance

NA

PDT

Photodynamic therapy

NA

PEG

Polyethylene glycol
O

p-chloranil

2,3,5,6-tetrachloro-pbenzoquinone

Cl

Cl

Cl

Cl
O

!

viii

!
CH3

!

PhCH3

Toluene

RHF

Restricted Hartree Fock

NA

SPPS

Solid Phase Peptide
Synthesis

NA

TBTU

O-(Benzotriazol-1-yl)N,N,N’,N’tetramethyluronium
tetrafluroborate

TFA

Trifluoroacetic acid

TLC

Thin Layer
Chromatography

TMSBr

Trimethylsilyl bromide

TPP

5,10,15,20tetraphenylporphyrin

TsCl

para-toluene sulfonyl
chloride

UV-VIS

Ultraviolet-visible
spectroscopy

ix

NA

NA

!

ABSTRACT

Chapter 1 is a description of the basic fundamental concepts of porphyrins and
BODIPYs, (including synthetic methodologies), a general mechanism of the processes of EGFR,
and computational concepts that are elaborated upon in future chapters.
Chapter 2 is a discussion solely on the porphyrins that were synthesized to be used as
fluorophores for EGFR-targeted conjugates, both peptidic and non-peptidic. The porphyrins
were primarily synthesized via the Lindsey method as well as by O-alkylation of tetrahydroxy
porphyrins. Synthesis of PEG linkages are discussed as well through three methodologies.
Chapter 3 is a presentation of the synthesis, characterization, cellular studies, and
computational analysis of porphyrin-tyrphostin conjugates that will be used as potential in vivo
imaging agents for CRC. Two tyrphostin molecules that have affinity for EGFR, the BMNs and
quinazolines, were synthesized and conjugated to PEG and or a porphyrin-PEG.
Chapter 4 is a report of the development of porphyrin-peptide conjugates using two
peptides, EGFR L1 (a six amino acid peptide) and EGFR L2 (a twelve amino acid peptide). The
peptides differ in charge, length, and hydrophobic character. Porphyrin-peptide conjugates were
synthesized via SPS or SNS methods using typical peptide coupling agents. Cellular studies are
also reported.
Chapter 5 is a presentation of the synthesis and characterization of novel BODIPYpeptidomimetic conjugates. The peptidomimetic was designed computationally. Two methods
of conjugation are described: SNS with a tert-butyl ester protected peptidomimetic, and SPS.
This work was done in collaboration with Professor S. Jois at University of Louisiana-Monroe.
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CHAPTER 1. INTRODUCTION TO PORPHYRINS AND BODIPYS
1.1 Fundamental Concepts of Naturally Occurring Porphyrins
Porphyrins and their derivatives are typically highly fluorescent, aromatic molecules. The
biocompatibility of the porphyrin macrocycle, its derivatives, and precursors (e.g. pyrroles), has
been extensively studied and referenced through the literature." In consideration of basic animal
and plant life, heme (Figure 1.1) and chlorophyll-a (Figure 1.2), respectively, are porphyrin
derivatives. Heme proteins are responsible for the transportation, storage, and activation of
oxygen, the terminal electron acceptor for all aerobic respiration.2 Conversely, chlorophyll-a
plays an important role in electron transfer and energy conversion in plants during
photosynthesis, by capturing the light energy necessary for this process.2 It has also been
illustrated that early life forms consist of porphyrin derivatives, potentially implicating their
involvement in life on other planets, due to their high stability and versatility throughout
evolutionary history.3

Me

Me

N

N
Me

Fe
N

N

N

N
Mg

Me

N

N
Me

MeO2C

Me

HO2C

HO2C

O

O
O

Figure 1.1. Structure of Heme.

Figure 1.2. Structure of Chlorophyll-a.

Heme porphyrins are biologically synthesized through a mechanism using deltaaminolevulinic acid as a precursor and are transformed into protoporphyrin IX.4 It was first
believed that these molecules were formed in vivo from glycine. This fundamental amino acid
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then reacted with a C4 compound to form the basic carbon skeleton of porphyrin. The
intermediate becomes important in a decarboxylation process, which then undergoes a series of
reactions to form porphyrin.5 Delta-aminolevulinic acid is then metabolized to porphobilinogen
and porphyrin. Shemin and Russell first discovered the role of delta-aminolevulinic acid in
1953.5 However, after further investigation, it was observed that eight enzymes are used to form
the heme structure. These enzymes are first enabled in the mitochondria. After a series of
reactions within the cytoplasm, the enzymes return to the mitochondria for heme formation. Any
reaction regarding the biosynthesis of porphyrin, more specifically, heme, will take place in
erythropoietic cells (red blood cells) or the liver parenchymal cells. The cyclic tetrapyrrole
intermediates formed through this biosynthetic pathway are porphyrinogens (that are then rapidly
oxidized to produce porphyrin, or chlorin, in the case of chlorophylls). Often, these structures
contain some type of acetic or propionic acid on the carbon atoms of the pyrrolic carbons.4
Depending on the porphyrin (uroporphyrin, coprotoporphyrin, or protoporphyrin) there will be a
production of one of the three aforementioned naturally occurring porphyrins. Nonetheless, the
exact synthesis of biologically relevant porphyrins would not have been realized without the
work of Küster, who proposed the first structure of porphyrin in 1912.5-6! This structure was
challenged and corrected by Hans Fisher, “the grandfather of porphyrin chemistry,” for which he
was awarded the Nobel Prize.6
1.2 Physico-chemical Properties of Porphyrins
The porphyrin macrocycle possesses a 22-pi electron count with only 18-pi electrons
involved in the aromatic structure. This organization allows for six varying delocalized pathways
that obey Huckel’s Rule (4n+2) (Figure 1.3).1, 7 In fact, the aromaticity of the porphyrin gives
several distinguishing characteristics in analysis of their physico-chemical properties.
!
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The

proton NMRs of any porphyrin gives information about its aromaticity.

There is intense

shielding of the internal N-H protons because of the anisotropic effect. These N-H protons can
be observed between -2 to 4 ppm. Additionally, the external, or peripheral protons are most
readily observed between 8 and 10 ppm.

Figure 1.3. Delocalized Electron Pathways of the Porphyrin Macrocycle.

Porphyrins have characteristic UV-VIS spectra displaying a Soret band, an intense
absorption at approximately 400 nm, depending on the substituents at the porphyrin periphery.
The subsequent Q-bands are generally observed between 480-700 nm.1 Porphyrins are classified
by their specific UV-VIS spectra. The porphyrins described in this document are primarily etiotype.7 The intensities of Q-bands are: IV>III>II>I, where IV corresponds to the Q-band at the
shortest wavelength and Q-band I corresponds to the band at the longest wavelength.7 This type
is characteristic of porphyrins in which six or more of the beta-positions are substituted with
groups without pi electrons, such as alkyl groups or hydrogens.
The 5,10,15,20-tetraphenylporphyrin, or TPP (1.4), is the parent molecule for these
studies (1.4). As observed in the figure, the structure is named according to the substituents at
the meso, or methine bridges, of the porphyrin macrocycle. The addition of the phenyl rings to
the porphyrin provides more conjugation due to partial overlap of pi-orbitals, despite the phenyl
rings’ perpendicular position relative to the porphyrin ring, and therefore generally gives higher
fluorescence intensity at longer emission wavelengths.

Fluorescence is a highly sensitive

method of detection; the observed red shift in wavelengths, compared to the spectrum of the
basic porphyrin macrocycle, implies that the molecule may be used in medicinal applications
!
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such as diagnoses of early cancers, for treatment in photodynamic therapy (PDT) and in vivo
imaging, as to reduce background autofluorescence from blood and plasma, as discussed in
Section 1.6.8

Figure 1.4. Structure of TPP and nomenclature system.

1.3 Porphyrin Syntheses
It is important to note three primary methods of synthesizing TPP and its derivatives, the
porphyrin of choice for this study. These methods are those proposed by Rothemund and
Menotti,9 Adler and Longo,10 with the most recent procedure devised by Lindsey.11 A variety of
meso-substituted porphyrins can be prepared containing hydrophilic substituents such as –OH, OMe, as well as others, and extend conjugation of the porphyrin to further red shift absorbance
and emission spectra. Three general methodologies known to prepare TPP and derivatives
involve various conditions (harsh, high temperatures to mild, room temperatures) and give the
target porphyrins in unequal yields. While there are also other methods to synthesize mesosubstituted porphyrins, these methods chiefly involve a mixed condensation mechanism to obtain
the desired product(s).
!
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Rothemund and Menotti synthesized TPP varying ratios of pyrrole and benzaldehyde at
high temperatures and the first description of their syntheses was noted in 1935.2, 12 The first
synthesis used 0.44 M pyrrole and 0.58 M benzaldehyde in methanol at 90-95oC for 30 hours. A
yield of 0.9% yield was achieved for TPP (Scheme 1.1), mainly due to formation of a chlorin
contaminant in 10-20%. Chlorin, a dihydroporphyrin, can simply be transformed into porphyrin
by an oxidation step. Later, in 1941, Rothemund and Menotti elaborated upon an improved
synthesis of meso-TPP.9

H

CHO
NH

MeOH, 90 - 95oC, 30 h

+

N

N
H

N

NH

HN

N

N

H

H

H

HN

+

~ 0.9%

10% - 20%
Oxidation
- 2e-, - 2 H+

Scheme 1.1. Rothemund and Menotti Synthesis of TPP.
This new attempt at the synthesis of TPP by Rothemund and Menotti consisted of combining
benzaldehyde and pyrrole in a sealed tube at 150oC, using pyridine as the solvent. The highest
yield obtained under these conditions was 11%.9, 12
Adler and Longo10 used a milder set of conditions to synthesize TPP, as it had been noted
that the concentration of reagents, temperature, acidity, and the availability of oxidant each
played a significant role in this synthesis. The product was obtained by refluxing pyrrole and
benzaldehyde in propionic acid at 141oC for 30 minutes (Scheme 1.2). Molecular oxygen was
!
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R

CHO

R

NH

1. Propionic acid, reflux

+
N
H

N
R

R
2. Air (oxidation)

HN

N

R = H, OCH3, or OH

R

Scheme 1.2. Adler and Longo Synthesis of TPP.
used to oxidize the intermediate porphyrinogen macrocycle. The yield for the Adler-Longo
method was 20% ± 3% for TPP.10 This method gives higher yield of TPP, but does not allow the
preparation of TPP derivatives containing sensitive groups on the meso-phenyl substituents.
Therefore, the most recent method for synthesis of TPP is the Lindsey method (Scheme
1.3).13 This method employs a more versatile approach to obtain derivatives, containing sensitive
substituents, of interest. Lindsey and co-workers realized that six different products, of the
forms A4, A3B, cis-A2B2, trans-A2B2, AB3, and B4 (Scheme 1.3) could be synthesized by
dissolving two different benzaldehydes and pyrrole in a dilute solution of dichloromethane (~10-2
M). A Lewis acid catalyst, such as BF3.Et2O or, an acid, TFA, is added to the reaction mixture
(~10-3 M). The Lindsey product is a colorless porphyrinogen that must be oxidized to porphyrin
with p-chloranil or DDQ.11 This is the most effective method to synthesize TPP, with a yield of
up to 55% - a dramatic increase from previous approaches. With this procedure, benzaldehydes
functionalized with, A-benzaldehydes were of the following names: methyl-4-formylbenzoate,
3,4,5-trimethoxybenzaldehyde, and 3,5-dimethoxybenzaldehyde.

The B-benzaldehyde was

simply benzaldehyde. Syntheses were optimized by varying the stoichiometry of the A- and Bbenzaldehydes, in relation to the ratio of pyrrole. Products were isolated using column
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chromatography. This method allowed for increased hydrophilic substituents on the phenyl rings
of the porphyrin, which must be accounted for in regard to the potential of our molecules to be
biologically relevant for in vivo imaging and as therapeutic agents.

CHO

H

CHO

A

1. Acid, 25oC

+

+

N

H
H

H

N
H

B

NH

H

H

N

HN

H H
a colorless porphyrinogen
2. Oxidation (DDQ or p-chloranil), 25oC

A

NH N
N HN

A

+

A

A

NH N
N HN

B

+

B

B

NH N
N HN

B

NH N
N HN

B

B

+

B

NH N
N HN

+

A

NH N
N HN

B

A

A
B

A
A

+

B

A

A

A

B

B

Scheme 1.3. Lindsey Synthesis of TPP.

1.4 Physico-chemical Properties of BODIPY
BODIPYs, or 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacenes (Scheme 1.4), have been
illustrated to be influential to scientists due to their versatility. These molecules were first
synthesized by Treibs & Kreuzer in 1968, however, BODIPYs did not gain widespread
recognition until the 1980s.14 The BODIPY structure is a combination of the s-indacene and the
dipyrromethene.15
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1

8

7

2

6
N

N

5

B

F

1

8

2

6
N

N

5

3

B

F

F

F

3
"

Scheme 1.4. BODIPY Structure.

Position 8 is termed the “meso-position,” while positions 1, 2, 6, and 7 are termed the
“beta-positions.” The “alpha- positions” are at numbers 3 and 5. Coined less formally as
“porphyrin’s little sister,”15a BODIPYs have numerous attractive characteristics, and as a
consequence, interest in this field has increased exponentially over the past several years. For
example, the number of journal articles published in 2006 was nearly double of the decade
before.15a This illustrates that due to the BODIPY’s intricacies, a revolutionary method of
developing new materials and fluorescent tagging agents can be constantly improved upon. The
primary aspects of BODIPYs that secure their attractiveness as fluorescent agents are the
following: they are stable in many environments (acidic, basic, various temperatures), they have
high fluorescence quantum yields (almost 1.0 in most solvents), they possess high molar
extinction coefficients, and have inconsequential triplet state formation (a quality of important
consideration in discussion of their fluorescence capabilities).15-16 BODIPYs are also being used
in various medicinal and materials applications.17
1.5 BODIPY Syntheses
Treibs and Kreuzer synthesized the first BODIPY by first constructing the
dipyrromethene fragment followed by complexation with boron trifluoro diethyl etherate.14 This
may be achieved by a condensation reaction, which is very similar to the synthesis of porphyrin
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(Scheme 1.5). An !-substituted pyrrole and an electrophilic carbonyl compound are combined to
form a dipyrromethane. This is done in acidic conditions using TFA or a Lewis acid, in a solvent
most suitable for solubility of the pyrrole and carbonyl compound. This reaction proceeds at
room temperature and produces the dipyrromethane backbone of BODIPY. The next step is to
oxidize the dipyrromethane unit by using DDQ or p-chloranil. The BODIPY used for these
studies

is

4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoic

acid,

a

compound which is commercially available.
R1

R4-CHO

R2
NH

NH
R3

Oxidation

R1

R4

R1
R2

R2

Acid

R3

R1

R4

R1

R2

R2
NH

HN

HN
R3

R3

R3

Base

BF3.Et2O

R1

R4

R1

R2

R2
N

N
B

R3
F

R3
F

Scheme 1.5. Synthesis of BODIPY.
Subsequent complexation of the pyrrolic nitrogens to boron using boron trifluoro diethyl
etherate in base completes the synthesis of BODIPY. The overall yield for synthesis of a
symmetric BODIPY was approximately 22%, although the Vicente group can produce BODIPYs
in 55-90% yields.18 These yields vary depending upon the nature of the substituents on the
pyrrole and aldehyde.
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1.6 Medicinal Applications of Porphyrins and Related Derivatives
Porphyrins have proven to be efficacious in medical screening and treatment of cancer.
Most notable may be their use in PDT, a cancer treatment which consists of a photosensitizer
(porphyrin derivative) that is injected into the body, localizes in the tumor cells, and after
irradiation with light, becomes highly cytotoxic to the tumor cells.19
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H
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Figure 1.7. Structure of VisudyneTM.

Two porphyrin-based pharmaceuticals, Photofrin® (Figure 1.6) and VisudyneTM (Figure
1.7) are FDA approved and have been used for several years for the treatment of cancer.19-20
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1.7 In vivo Imaging
Cancer imaging is becoming a primary consideration as preventative medicine for CRC.
Our design of imaging agents is for them to be used in confocal laser endomicroscopy (CLE), a
staunch improvement upon colonoscopy and other methods in screening for CRC. PDT and
previous research in the Vicente group has illustrated the efficacy of porphyrins as potential in
vivo imaging agents and PDT agents with low dark cytotoxicity.17e, 20a, 21
The technique of in vivo imaging employs a type of visual apparatus to obtain a view of
the colon. In years past, the medicine has developed several approaches to enhance the view of
the colon. One of the more notable methods is that of flexible sigmoidoscopy. The endoscope is
then advanced under direct vision and moved around the various bends in the lower bowel. The
exam usually is very short and more importantly, the patient does not have to be sedated.
Another advantage of flexible sigmoidoscopy is that polyps and tumors can be detected at early
stages.22 Additional methods of in vivo imaging are standard colonoscopy, chromoendoscopy,
both of which have proven somewhat effective in detection of colorectal cancers.22

Scheme 1.6. Mechanism of CLE.26
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CLE is our means of arriving to successful in vivo imaging of CRC. CLE (Scheme 1.4)
provides better spatial resolution than colonoscopy. Using laser light, which is incorporated into
the tip of an endoscope, a laser light is emitted onto the mucosal surface of colorectal tissues and
into deeper portions of the mucosal layer. CLE has been illustrated to be effective clinically as
well. In a study published by Kiesslich and colleagues, it was found that CLE could determine a
change in a particular polyp with 97.4% sensitivity, 99.4% specificity, and 99.2% accuracy.23
Conversely, other imaging agents, such as cresyl violet and fluorescein, stain tumor cells nonselectively, with normal and cancerous cells being colored.20d, 24 Besides this fact, these are
ineffective due to their poor water solubility, lower quantum yields, and emit at lower
wavelengths that are not close to the NIR-range. This research, then, is advantageous in that
fluorescent porphyrin molecules can be synthesized and used to selectively label CRC tumor
foci.
1.8 Epidermal Growth Factor Receptor (EGFR)
EGFR (Figure 1.8), a single polypeptide chain consisting of 1186 amino acid residues,
has been found to be an integral piece in attempting to find an effective treatment for CRC and
other cancers. EGFR is found in 98% of colon cancers and are abundantly over-expressed on
small cancers.25
Activated first by binding of growth factor ligands (i.e. EGF), in eukaryotic cells, EGFR
undergoes dimerization, then stimulates its inherent protein-tyrosine kinase activity, thereby
catalyzing the phosphorylation of tyrosine residues.25a, 26 EGFR overexpression is a mutation that
could cause uncontrolled cell proliferation and is therefore associated with cancer.26 The
discovery of EGFR’s importance to CRC and other cancers has led to the discovery of peptidic
ligands, with high specificity for the receptor. Erbstatin, a tyrphostin derivative known to inhibit
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the EGFR tyrosine kinase domain, and the 4-anilinoquinones, most notably called the
quinazolines inhibit the receptor via a similar mechanism.25, 27 EGFR and its family of receptors
(HER-2/ERBB2, ERBB3, ERBB4) have been recognized as critical proteins involved in
carcinogenesis.!

Figure 1.8. EGFR Heterodimer.27

1.9 Molecular Dynamics and Ab initio Computational Calculations
Computational chemistry has proven to be a propitious method in proceeding with
synthesis of molecules believed to be medicinally beneficial. Molecular dynamics (MD) and
quantum mechanics (QM) ab initio methods were used to understand energy conformations,
relative water solubility, and relative electronic stability for our selected molecules. These
methods include: AutoDock/AutoDock Vina (MD), Restricted Hartree-Fock (RHF; QM) and
Moller-Plessett (MP; QM).
The molecular dynamics computations were conducted on larger porphyrin conjugates,
all of the tyrphostins and peptides selected for this dissertation research.
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The software,

AutoDock and its counterpart, AutoDock Vina (noted herein as “Vina”), were used to
concentrate on one ligand (the peptide or tyrphostin), one enzyme (EGFR) binding.28 The ligand
with the lowest binding energy may illustrate that the ligand is the most stable for the EGFR
active site. The data consists of a list of all molecules ranked according to their binding energies.
These results were gathered using three tools: a docking algorithm, the enzymatic target, and a
ligand library consisting of the porphyrin conjugates of interest.
AutoDock and Vina are the docking algorithms by which the binding energies of the
ligands were determined in their possible orientations. The concept behind the method is that of a
Lamarkian genetic algorithm; the ligand models as a chromosome, which in this case consists of
its own genetic characteristics (location, orientation, and conformation).28-29 The enzyme remains
stationary, while the ligand “walks” around the enzyme. This “walk” takes place in a grid box
(1.9), the search area centered on a region of interest on the enzyme. As the ligand makes its trek,
the ligand is actually producing an offspring, each being an attempt to find the most stable
conformation within the proposed active site (Figure 1.9).30

n +1
y

Atom

n +1
z

n +1
x

Figure 1.9. AutoDock Gridbox.28
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Figure 1.10. Hess’ Law for Protein-Ligand Docking.
The above diagram accounts for Hess’ Law (1.10) by the following equation for the binding free
energy in solution:

"Gbinding, solution = "Gbinding, vacuo + "Gsolvation (EI) - "Gsolvation (E+I)
Equation 1. Determining "Gbinding, Hess’ Law
The rate of this reaction is measured using:

K i = e(" G

/RT)

bind

, where R=8.314 J/mol K and T=temperature in Kelvin.
Equation 2. Reaction Rate Equation

As previously stated, our enzymatic target structure is that of pure EGFR. This structure
is easily obtainable from the Protein Data Bank (PDB). While this methodology has been
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successful in determining potential drug interactions within an active site of an enzyme, this
must only be used as an introduction to the design of novel pharmaceuticals. Many obstacles
arise in computational work due to the complexity of the potential interactions between the
ligand and the enzyme. Since binding energies are ranked according to the scoring function,
false positives may occur. AutoDock 4 uses the AMBER force field, while Vina uses its own
parameterized force field. Due to this fact, there may be flaws within the force field itself. Even
improper consideration of the ligand or enzyme’s orientation, location, and conformation can
impact the overall calculation. If, however, one is able to obtain a lead compound within a
nanomolar concentration, this proves the efficacy of computational work. Although AutoDock
may be used more frequently among those in academia,32 every study conducted on simulation
software does not prove better than others. Therefore, these studies must be used to enrich
ligands for novel porphyrin conjugate design.33 Using the crystal structure of EGFR, AutoDock
and Vina, which were both developed at the Scripps Research Institute and are both now highly
utilized tools in drug discovery, were used to observe potential interactions.
Conversely, the ab initio methods begin with the fundamental “basis set.” The basis set is a
representation of the atomic orbital, centered on a particular nucleus.29 It has been observed that
a combination of Slater-type orbitals and Gaussian-type orbitals give better energy
approximations.29 This is how the minimal basis set is constructed; it takes into account the
number of functions required to accommodate all the filled orbitals in each atom of the molecule.
The absolute minimum basis set, STO-3G, is important, as it provides an initial visualization of
the molecular geometry for a particular molecule.34 In addition to these considerations, it must be
realized that these minimum basis sets do not account for valence electron activity, which can
highly determine the energetic state of the molecule. Therefore, using a split valence double zeta
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basis set, such as 3-21G, accounts for three Gaussians (core orbitals), two contracted valence
electrons and one diffuse valence electron orbital. If, however, electrons could potentially be
attracted to other nuclei in a particular molecule, polarization functions must be introduced.34
These types of basis sets are notated by addition of an asterisk (*). The anionic nature of a
molecule is considered using diffuse functions toward a basis set. This is accounted for by
addition of a plus (+). This function allows basis sets to deal with any significant electron
density that is located away from the atomic nucleus.34
One of the main methods of ab initio calculation used was Restricted Hartree-Fock
(RHF). With this method, we must consider the Variational Principle, which states that the
energy calculated from an approximation to the true wavefunction will always be greater than the
true energy, where a lower energy value obtained implies a more accurate wavefunction.29
Electrons are able to ‘see’ each other and allowed to feel electronic effects, such as electronelectron repulsion. The main disadvantage of Hartree-Fock theory is that these electrons are
assumed to move within the average potential of the other electrons, when in actuality, these
electrons tend to avoid each other more than theory suggests, thereby giving a lower energy,
when this may not be the case.35 Essentially, Hartree-Fock is a deliberately approximate theory.35
Conversely, Moller and Plesset attempted to include electron correlation in their method,
which must be considered. The “many-body perturbation theory” can occasionally give energies
that are lower than the actual energy. This level of theory is computationally intensive and
usually requires that geometries are optimized before using it.

In quantum mechanics

computational analysis, this theory incorporates the issue of electron correlation.35
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The molecular dynamics and ab initio methods used for these studies gave a thorough
understanding of these molecules’ electron interactions and properties. This will assist in the
future design and synthesis of porphyrin peptidic and non-peptidic conjugates for improvement
of in vivo imaging techniques of CRC.
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CHAPTER 2. SYNTHESIS OF MESO-SUBSTITUTED TETRAPHENYLPORPHYRINS
AS FLUOROPHORES IN EGFR TARGETED CONJUGATES
2.1 Syntheses of meso-Substituted Porphyrins
Since the improvement on the synthesis of TPP by Adler and Longo,1 then by Lindsey,2 it
is evident that the development of TPP has been heavily studied over the past fifty years. In order
to synthesize derivatives of TPP, several methods have been used in addition to those described
by Adler, Longo and Lindsey, such as the [2+2] and [3+1] methodologies.3 The MacDonald
[2+2] synthesis requires the condensation of two dipyrromethanes or dipyrromethenes, while the
[3+1] intermediate methodology consists of the reaction between a tripyrrane and a
monopyrrole.3 The enrichment of these methods allows for the achievement of higher yields for
asymmetrical porphyrin molecules. In this work, we will concentrate on the methods of
asymmetrical porphyrin synthesis, specifically beginning with the Lindsey method.2
2.2 Synthesis of Mono-amino and Mono-carboxyl Tetraphenylporphyrins via the Lindsey
Method
The synthesis of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (2-3) was similar to that
reported by Luguya et al (Scheme 2.1).4 However, the overall yield was lower (15%), maybe due
to differences introduced in the protocol. TPP (2-1) was synthesized using Lindsey’s conditions
using pyrrole, benzaldehyde, and methyl-4-formylbenzoate with boron trifluorodiethyl etherate
and subsequent oxidation using DDQ. To continue the synthesis, TPP was nitrated using NaNO2
in acidic conditions, promoting formation of the nitrate electrophile and thus electrophilic
aromatic substitution. The nitro group was then reduced using SnCl2 in HCl to afford monoamino porphyrin 2-3, which was then subjected to a nucleophilic reaction with diglycolic
anhydride to give the carboxylic acid terminated porphyrin 2-4. The carboxylic acid terminus
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would have allowed for conjugation to peptides and a PEG linker. Unfortunately, the many
attempts to improve overall yield of 2-3 did not work.
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OH

OH

Although the yield from adding the diglycolic anhydride was very high (98%), there was
not enough material to continue further. Therefore, an alternative synthesis was conducted,
beginning with porphyrin 2-5, which was prepared using a mixed aldehyde condensation with
pyrrole and benzaldehyde, as shown in Scheme 2.1. Using porphyrin 2-5 as the starting material
in DIEA, a coupling reaction followed, using HOBt, TBTU, and glycine tert-butyl ester. In this
manner, one amide bond was formed in very high yield (Scheme 2.2). The addition of the
glycine also provides space between large porphyrin, PEG linker or biomolecule for conjugation.
This also increases yields of conjugations of porphyrin to the biomolecules of choice for these
studies. To produce the carboxylic acid terminated porphyrin 2-7, the Boc-protected porphyrin
(2-6) was deprotected with TFA in DCM. The alternative method shown in Scheme 2.2 gives
similar terminal carboxyl functionality for coupling of the porphyrin to amine groups on a linker
or peptide. However, the overall difference in structure is important to note between compounds
2-4 and 2-7; compound 2-4 contains a total of seven atoms in a chain with five hydrogen
bonding atoms potentially effecting future conjugation, while compound 2-7 contains a total of
five atoms in a chain with four hydrogen bonding atoms. It is also important to illustrate the
presence of two additional carbon atoms in the short 2-4 linkage, while 2-7 only contains one
additional carbon atom.
While the porphyrins used consisted of only one substituent at the para-position of one of
the phenyl rings of the TPP derivatives, another, more hydrophilic porphyrin was synthesized
using the method of mono-functionalization, more specifically, through O-alkylation.

This

method consisted of using commercially available 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin (2-8), as shown in Scheme 2.3. Previously in our group,5 this reaction was conducted
in anhydrous DMSO using a slightly different protocol than the one illustrated in Scheme 2.3.
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To activate the hydroxyl groups of 2-8, K2CO3 was used first, but after initial lower yields (2%5%) for the O-alkylation reaction, Cs2CO3 was used. The reaction was conducted in DMF and it
was evident that the use of Cs2CO3 greatly improved the yield of the reaction. Cs2CO3 has been
demonstrated to be more soluble in organic solvents and is at least ten times more soluble in
aprotic organic solvents, such as DMSO or DMF.6 Cs2CO3 is also more basic in comparison to
K2CO3.7 The difference in this O-alkylation reaction, in comparison to the published procedure,
is mostly in the time of the reaction;5 instead of conducting the reaction at 60oC, the reaction was
done at 70oC for 4 hours and the activation of hydroxyl groups took place for approximately 30
minutes. The yield for the new reaction conditions ranged from 20%-39%.
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2.3 Synthesis of Polymethoxy Tetraphenylporphyrins via Lindsey Conditions
In Chapter 1, Section 1.8, two tyrphostin-based molecules were mentioned as having
affinity for EGFR. One class of molecule, the benzylidenemalononitriles (BMN), contains
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several hydroxyl substituents (Figure 2.2). Through 3D-QSAR studies, it was evidenced that
these hydroxyl moieties are important for affinity of these molecules for EGFR.8 In terms of
binding modes, it was illustrated that in the active site of EGFR 1 and EGFR 2, having the
polyhydroxy groups on the phenyl ring favors binding.8b This is because these compounds
resemble tyrosine and erbstatin-type analogs, which were found to have affinity for this
receptor.8a In fact, based on computational studies, the phenolic ring is a requirement of the
BMN tyrphostin to have any activity toward the receptor.8c With these facts, it was hypothesized
that by incorporating more hydrophilic substituents, such as hydroxyl groups, into our design of
novel in vivo imaging agents, we could mimic the structure of the tyrphostin BMNs and also
increase water solubility of our porphyrin conjugates, which could also inhibit aggregation of the
porphyrin conjugate in aqueous media.

Tyrphostin AG82
(IC = 3 µM)

Tyrphostin AG18
(IC = 35 µM)

50

50

Figure 2.2. Structures of Tyrphostins Containing BMN
It is evident from Figure 2.2 that one tyrphostin, AG18, has two hydroxyl groups on the
phenyl ring, while the other, AG82, has three. They also have different IC values, with AG82
50

having the highest affinity for EGFR in this particular study.8a This would imply that the
potential of synthesizing porphyrins with three hydroxyl groups on the phenyls of TPP-based
porphyrins might show more promising results in comparison with only two hydroxyl groups on
the phenyls.
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Several attempts at synthesizing the trimethoxyporphyrin using a mixed condensation
with pyrrole, methyl-4-formylbenzoate, and 3,4,5-trimethoxybenzaldehyde were done (Table
2.1, Scheme 2.4). To optimize the condensation reaction, several ratios of pyrrole, methyl-4formylbenzoate, and 3,4,5-trimethoxybenzaldehyde were used to achieve the highest yields for
porphyrin 2-11 using Lindsey conditions.2 The reaction began with the starting materials in a
4:1.5:3 (pyrrole: 3,4,5-trimethoxybenzaldehyde: methyl-4-formylbenzoate) ratio.

Methoxy-

protected hydroxyl groups were used for several reasons. Primarily, using protected hydroxyl
groups is easier to purify by column chromatography, as more polar compounds tend to be
retained on the silica gel.

Additionally, it has been reported that using a higher ratio of

aldehydes with the Lindsey method of porphyrin synthesis does not generally give good yields of
the target porphyrins.9 Therefore, in using methoxy groups, higher yields were expected for this
synthesis. Other methods for achieving more polar porphyrin compounds tend to use higher
temperatures and propionic acid, yet still achieving low yields.9 As shown in Table 2.1, the best
ratio of aldehydes and pyrrole was that of Method C. It seems that the ratio of the electron
withdrawing methyl ester benzaldehyde (methyl-4-formylbenzoate) may have some effect on the
overall yield in conjunction with the more electron donating trimethoxybenzaldehyde. A higher
ratio of methyl ester benzaldehyde may have simply been less reactive when compared to the
other benzaldehyde. The unequal ratios gave unequal yields of all possible porphyrins, however,
the ratios of Method C gave the highest yield for the target porphyrin 2-11 containing only one
methyl ester group.
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Table 2.1. Ratios of Starting Materials for the Synthesis of 5,10,15-(3,4,5trimethoxyphenyl)-20-(4-methoxycarbonylphenyl) porphyrin (2-11).
Ratio
Ratio of
Ratio of 3,4,5Method
of
Methyl-4Approximate
trimethoxybenzaldehyde
Type
Pyrrole formylbenzoate
Yield
(mmol)
(mmol)
(mmol)
A
3
4
1.5
<1%
B
6
4
1.5
5%
C
6
4
0.7
9%
D
9
4
1.5
<1%
2.4 Synthesis of Propargyl Porphyrins for Use in These Applications
The use of the propargyl functionality has been used to facilitate the “click chemistry,” or
Huisgen 1,3-dipolar cycloaddition,10 to create a triazole linkage between porphyrins (and their
respective carbohydrate conjugates for improvements in PDT) and other types of molecules.11
The linkage allows for azide-terminated molecules (such as PEGs) to be easily conjugated
without any side products and minimal purification (e.g. crystallization or distillation).10 The
addition of PEGs to porphyrins and other fluorophores has become important due to the
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improvement of these molecules to be used in biological applications, such as PDT and in vivo
imaging. This section will discuss the synthesis of these propargyl porphyrins.
2.4.1 Synthesis of 5-(4-propargylphenyl)-10,15,20-tri(4-hydroxyphenyl)porphyrin
Porphyrin was synthesized for future use in “click chemistry” reactions with azideterminated PEGs. These PEGs would be used to conjugate epidermal growth factor peptide (EGF
peptide) as a comparison to smaller porphyrin-peptide conjugates that were synthesized and will
be discussed in Chapter 4. It was also thought that in synthesizing this porphyrin, there could
be additional synthetic usage by converting the propargyl group for a malononitrile substituent,
which is in the tyrphostin series of porphyrin conjugates (Chapter 3). This procedure was
modified from one noted previously in our group, by using Cs2CO3 as the base in DMF or THF,
then alkylation with propargyl bromide or propargyl chloride, which stirred for 4 hr under
nitrogen (Scheme 2.5). The initial reaction with propargyl chloride in DMF was completely
unsuccessful, most likely due to the lower reactivity of chloride compared to bromide, and that
DMF was used, which tends to inhibit SN2 reactions.

However, when the reaction was

conducted in THF with propargyl bromide (80% in toluene), the reaction went to completion,
OH

OH

1.

K2CO3

Cl

DMF, RT

N

NH

OH

HO
N

NH

N

N

HN

O

HO

HN

2.

Cs2CO3

Br

THF, 4h, 50oC
(35%)

OH

OH

2-8

2-12

Scheme 2.5. Synthesis of a Propargyl-Terminated Porphyrin via Mono-OAlkylation of Tetra-Hydroxyl Porphyrin.
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with the production of other alkylated products, which were separated on column
chromatography using CHCl3/ethyl Acetate (8:2) in 35% yield.
2.5 Synthesis of PEGs and Pegylated Porphyrins
This research uses strategies to improve the delivery of fluorescent porphyrin or BODIPY
molecules to CRC cells as well as advance small tumor detection using confocal laser
microscopy. The approach involves conjugation of two types of biomolecules, a small peptide
ligand or tyrphostin derivative, to the porphyrin via a PEG linker (3-, 4-, or 5-PEG). This is an
important component of the fluorescent conjugates. PEGs are soluble synthetic polymers that
have properties suitable for medicinal applications. Furthermore, it has been shown that PEGs
increase water-solubility, decrease aggregation, and enhance cellular uptake of the conjugates.12
Journals such as Biomacromolecules have recently published articles to describe the importance
of the PEG to biologically active molecules.13 The PEG is an essential piece of our porphyrin
conjugate, which has been analyzed both biologically and computationally in our group.
Previous computational studies suggested that a linker consisting of at least 15 atoms would
favor an extended conformation of the conjugates, which may favor receptor binding.14
2.5.1 Structures and Synthesis of PEG Linkages
Due to the improvements in the pharmaceutical industry regarding drug delivery directly
to a specific organelle or type of tumor cell, there has also been development of PEG linkers to
attach to these drugs. Porphyrins tend to aggregate in aqueous media because of their primarily
hydrophobic backbone.15 In order to alleviate some of these issues, three types of linkers were
used. The first two, tert-butyl 12-amino-4,7,10-trioxadodecanoate (NH2-3PEG-tBu) and Fmoc1-amino-4,7,10-trioxa-tridecanamine succinimic acid (Fmoc-3PEG), were conjugated to
porphyrins (Figures 2.3 A and B, respectively).
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Figure 2.3. Structures of Commercially Available PEGs Used in This Study - (A)
Tert-butyl 12-amino-4,7,10-trioxadodecanoate (NH2-3PEG-tBu) and
(B) Fmoc- 1-amino-4,7,10-trioxa-tridecanamine succinimic acid (Fmoc-3PEG).
The first coupling of PEG was conducted to conjugate porphyrin 2-7 to amine-terminated
PEG linkers. A 15-atom PEG linker, or NH2-3PEG-tBu, is available commercially from SigmaAldrich. It contains a free amino terminus that allows coupling to the carboxylic acid group of
porphyrin 2-7 using the aforementioned peptide-coupling agents and conditions: HOBt, TBTU,
and DIEA, in DMF (Scheme 2.6). Porphyrin-PEG 2-13 was then deprotected with TFA (2-14),
washed with cold anhydrous ether several times, then carried on to conjugations to the small
biomolecules used in this study that have an affinity for EGFR (peptides, BMNs, quinazolines as
described in Chapters 3 and 4). The compound, 2-13, has not been reported in previous
literature, and after coupling the PEG to the porphyrin, a yield of 60% was achieved after
normal-phase column chromatography, using ethyl acetate as the primary eluent (Scheme 2.6).
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A second coupling of the PEG was conducted with porphyrin 2-10. Similar coupling
procedure was used with DIEA, HOBt, and TBTU. However, the high polarity of this compound
required purification by RP-HPLC, yet was obtained in moderate yield (18%). Pegylated
porphyrin 2-15 can also be used in future conjugations to biomolecules such as peptides,
proteins, and tyrphostins. Scheme 2.7 highlights the procedure to obtain the target porphyrin.
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Scheme 2.7.
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O

2.5.2 Synthesis of 5-PEG
Ab initio calculations, using RHF//6-31G* computational method on Gaussian 03, and
molecular dynamics calculations, using the Gasteiger-Huckel model designed within the Tripos
Force Field in SYBYL 7.016 of a porphyrin conjugate suggest that a 5-PEG linker would favor a
more open conformation of the conjugate.16 This preliminary computational study was conducted
solely to assess the effect the PEG may have on the entire conjugate. Several methods were
followed to synthesize the 5-PEG.
The 5-PEG synthesis was attempted using various methods to obtain optimum synthesis
conditions, as described in Schemes 2.6, 2.7, and 2.8.

The first step, as reported by

Thumshirn,17 protects one end of hexaethylene glycol 2-16 using tert-butyl diazoacetate,
reaching optimum reaction time of 15 minutes, which was monitored by TLC. A shorter
reaction time than was previously reported, minimized the formation of di-tert-butyl ester side
product, which decreases the yield of the target product, as seen by TLC. The second step of this
synthesis was to produce the tosylate of the unprotected alcohol using TsCl in Et3N (Scheme
2.7). In comparison with previous attempts to protect the free alcohol using the mesylate,14 it
was found that the tosylate is more stable and readily detected by UV light, which would assist in
determining reaction completion via TLC.18 NaN3 was then used to displace the tosylate
functionality, followed by the reduction of the azide to the amino group. The reduction of azide
used 10% Pd/C catalyst under hydrogen. ESI-MS and TLC were conducted at each step without
purification. The crude product was highly impure and was difficult to purify due to many polar
and non-polar products evident on the TLC plate.
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Scheme 2.8. Method 1 - Synthesis of 5-PEG.
In an attempt to decrease the number of side products, another attempt to synthesize the
5-PEG was conducted, beginning with TsCl. Reaction completion of the first step occurred
within 20 minutes. Evidence of the di-substituted tosylate, the mono-substituted tosylate, and the
starting material 2-16 were present by TLC and by MS analysis of the crude oil. NaN3 was
added to the reaction flask. The reaction mixture was heated under reflux for 2.5 hours as
reported.14,

17

Reduction was, again, conducted using the Pd/C catalyst under hydrogen

atmosphere. TLC indicated several compounds were present (Scheme 2.9). New compounds that
were not obtained in Scheme 2.8 are circled.
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Scheme 2.9. Method 2 – Synthesis of 5-PEG.
Another strategy introduced iodination of the alcohol, which should have made for a
better leaving group (Scheme 2.10). New compounds that were not obtained in Scheme 2.8 or
Scheme 2.9 are circled. Tert-butyl diazoacetate was first added to 2-16, thereby adding a tertbutyl ester protecting group. Iodination followed, which was done by adding PPh3, imidazole,
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and I2, (respectively in that order) to replace the primary alcohol with iodide. Substitution of the
iodide with azide and subsequent reduction with Pd/C catalyst remained the same. TLC was
used to observe product formation and relative purity. While only two spots were visible by
TLC, purification was difficult, as observed by

1

H NMR after purification by flash

chromatography as well as HPLC. The triphenylphosphine reagent is highly non-polar and did
not separate from the other products. This method was abandoned, due to these issues.19 !
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Scheme 2.10. Method 3 – Synthesis of 5-PEG.
It seems that the best method for the synthesis of the 5-PEG is to follow Scheme 2.8, as
10% yield of the crude product was obtained. According to Scheme 2.9, product was also
obtained, but in a lower amount in comparison to that obtained from Scheme 2.8.
2.6 Conclusions
This chapter is a presentation of the synthesis of porphyrins and their pegylated products.
The porphyrin mostly used for the conjugation of biomolecules as described in Chapters 3 and
4 are the TPP derivatives, 2-7 and 2-14. These porphyrins were conjugated to the peptidic
conjugates, which will be discussed in chapter 3. Additionally, the types of PEGs used in this
project were discussed. There were essentially three types of PEGs used, the Fmoc-3PEG, NH23PEG-tBu, and 5-PEG. As noted previously, the PEG is very important to the overall stability
and water-solubility of the conjugate within aqueous media.
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2.7 Experimental
Synthesis of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (2-3): To a solution of 2-1
(0.100 g, 0.163 mmol), which was prepared by mixed condensation of distilled pyrrole and
benzaldehyde, in TFA (10 mL), NaNO2 (0.020 mg, 0.29 mg) was added. After 3 minutes stirring
at room temperature, the reaction mixture was poured into water (100 mL) and extracted with
DCM (6x25 mL). The organic layer was washed with saturated aqueous Na2CO3 and water,
dried with anhydrous MgSO4, filtered, and concentrated. The residue was purified on a small
plug of silica gel, eluting with dichloromethane. Solvent was evaporated and residue recovered.
The residue was dissolved in concentrated HCl (10 mL) and while stirring, SnCl2 (0.220 g, 0.975
mmol) was carefully added. This mixture was heated to 65oC for 1 h under nitrogen before
being poured into cold water (100 mL). The aqueous solution was neutralized with ammonium
hydroxide until pH 8. The aqueous solution was extracted with dichloromethane until colorless.
The organic layer was dried with anhydrous MgSO4, filtered, and concentrated under vacuum.
Residue was purified on silica gel column using DCM/hexanes (1:1) for elution. The final
residue was recrystallized from DCM and methanol yielding 15% of 5-(4-Aminophenyl)10,15,20-triphenylporphyrin. ESI-MS 630.25 [M+H]+, calculated for For C44H31N5 629.75. 1H
NMR, 13C NMR, and absorbance spectra were identical to that presented in literature.4
Synthesis of Porphyrin 2-4: To a solution of 2-3 (0.200 g, 0.317 mmol) in 1 mL DMF,
diglycolic anhydride (0.055 g, 0.476 mmol) was added. Reaction mixture was stirred overnight
at room temperature under nitrogen atmosphere. After reaction completion, the mixture was
diluted with 10 mL chloroform, followed by hexanes, until precipitation occurred.

The

precipitate was filtered and washed with water to remove residual anhydride. Precipitate was
dried under vacuum, yielding 98% of desired porphyrin. HRMS-ESI m/z 746.6725 [M+H];

!

36

calculated for C48H35N5O4 745.82. 1H NMR (400 MHz, CDCl3): d 4.25 (s, 2H), 4.38 (s, 2H),
7.75-7.79 (m, 9H, m-, p-Ph-H), 8.20-8.14 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.31 (d, 2H, o-Ar-H,
J=5.96 Hz), 8.84 (s, 4H, !-H), 8.89 (d, 2H, !-H, J=4.5 Hz).

13

C NMR and absorbance spectra

were identical to that presented in the literature.4
Synthesis of 5-(4-methyoxycarbonylphenyl)-10,15,20-triphenylporphyrin (2-5): To a round
bottom flask was added benzaldehyde (0.500 g, 3.0 mmol), methyl-4-formylbenzoate (0.387 g,
1.5 mmol), and freshly distilled pyrrole (0.421 g, 4.0 mmol) under argon at room temperature.
The mixture stirred for 10 minutes. BF3.Et2O was added (0.20 mL) and the reaction stirred for 2
h. Argon was turned off and 400 mg of DDQ was added to reaction mixture. After stirring for 45
minutes at room temperature, the solution was quenched with aqueous NaHCO3 until the
aqueous layer was colorless (approx. 10-15 times). A silica plug was used to remove
polymerized products. TLC was used to find the best solvent system. A final flash
chromatography in Hexanes/DCM (3:7) was done to yield the mono-substituted methyl ester
triphenylporphyrin in 9% yield. A deprotection of the methyl ester with 2 M NaOH (200 mL, 2.0
mol) in DMF and subsequent acidification with 1 M HCl until pH 2.0, yielded porphyrin 2-5.
HRMS-ESI m/z 659.2614 [M+H]+; calculated for C45H30N4O2 658.75. 1H NMR was identical to
that in literature.20
Synthesis of Porphyrin 2-6: To a solution of porphyrin 2-5 was added DIEA (0.3 mL, xs) and 2
mL DMF. Flask was sonicated to ensure porphyrin solubility. After 5 minutes, HOBt (0.03076
g, 0.07587 mmol) and TBTU (0.07312 g, 0.7587 mmol) were added to the flask. The reaction
stirred for 15 minutes. Glycine tert-butyl ester hydrochloride (0.1178 g, 0.1138 mmol) was
added to the flask. The reaction was stirred at room temperature. To remove DMF, the RBF
was placed under high vacuum to remove residual DMF or co-evaporated with hexanes at 60oC.
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Flash column chromatography was conducted using 50:50 EtAc: CH2Cl2 for elution and yielded
90%. HRMS-ESI m/z 772.3282 [M+H]; calculated for C51H41N5O3 771.90. 1H NMR (400 MHz,
CDCl3): d -2.76 (s, 2H), 1.60 (s, 9H), 4.11-4.15 (q, 1H, J=7.3 Hz), 4.33-4.34 (d, 2H, J=4.88 Hz),
6.97-6.99 (t, 1H, J=4.88 Hz), 7.73-7.78 (m, 9H, m-, p-Ph-H), 8.21-8.24 (m, 8H, 6 o-Ph-H, 2 mAr-H), 8.31 (d, 2H, o-Ar-H, J=5.96 Hz), 8.80 (s, 2H, !-H, J=4.8 Hz), 8.87 (s, 4H, !-H), 8.88 (d,
2H, !-H, J=4.8 Hz).

13

C NMR (400 MHz): 28.16, 42.75, 118.54, 120.37, 120.53, 125.48,

126.73, 127.79, 133.32, 134.56, 134.71, 142.07, 145.86, 169.41, 169.47. UV-VIS (chloroform)
"max (L mol!1 cm!1) 425 (195,600), 525 (17,100), 558 (12,200), 599 (10,200), 656 (8,200).

Synthesis of Porphyrin 2-7: To deprotect 2-6, a solution of the tert-butyl protected porphyrin
(0.200 g, 0.2591 mmol) in 3 mL of dichloromethane was added 4.25 mL of TFA (57.3598
mmol), and the final mixture was stirred at room temperature for 4 h. After removal of the
solvent under vacuum overnight, the residue was triturated and washed with Et2O (3 times at 8
minutes each, via centrifugation and decanting of ether) to afford porphyrin as a green solid in
quantitative yield. Reaction product was used immediately for conjugation of the NH2-3PEG-tBu
linker. Proton NMR was conducted in deuterated acetone; ESI-MS conducted. HRMS-ESI m/z
358.6380 [M+2H]2+, 716.2666 [M+H]+; calculated for C47H33N5O3 715.80. 1H NMR (400 MHz,
(CD3)2CO): -2.81 (s, 2H), 4.02 (broad, 2H), 4.07-4.11 (q, 1H), 7.45 (broad t, 1H), 7.78-7.80 (m,
9H, m-, p-Ph-H), 8.23-8.34 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.29-8.31 (d, 2H, o-Ar-H, J=5.96 Hz),
8.88 ((broad) d, 8H, !-H). UV-VIS (chloroform) "max (L mol!1 cm!1) 425 (144,470), 523
(13,015), 561 (3,100), 597 (2,600), 657 (2,200).
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Figure 2.4. 1H NMR of Porphyrin 2-6.
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Figure 2.5. 13C NMR of Porphyrin 2-6.
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Figure 2.6. 1H NMR of Porphyrin 2-7.
Synthesis of 5-(4-(2-phenoxy)phenyl)-10,15,20-tris(4-hydroxyphenyl)porphyrin (2-9): To a
round bottom flask was added 2-8 (0.600 g, 0.8837 mmol) and Cs2CO3 (0.533 g, 1.636 mmol) in
anhydrous DMF or THF. This was stirred for 30 minutes before tert-butyl bromoacetate (0.319
g, 1.636 mmol) was added. The flask was heated to 70oC and stirred for 4 hours before the
solvent was evaporated and purified on normal-phase silica with DCM/EtAc (1.5:0.5).
Recrystallization with DCM/Hexanes yielded 39% of 2-9. To deprotect 2-9, a solution of it
(0.0251 g, 0.0266 mmol) in 3 mL of dichloromethane was added 3 mL of TFA and the final
mixture was stirred at room temperature for 4 h. After removal of the solvent under vacuum
overnight, the residue was triturated and washed with Et2O (3 times at 8 minutes each, via
centrifugation and decanting of ether) to afford porphyrin as a green solid in quantitative yield.
MALDI-MS of 2-9 m/z 816.046 [M+Na], calculated for C50H40N4O6 792.88. 1H NMR (400
MHz, CD3OD): 1.29 (s, 9H), 4.51 (s, 3H), 7.21-7.24 (d, 6H, o-Ph-H, m-Ar-H, J=8.5 Hz), 7.34!
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7.37 (d, 3H, J=8.5 Hz), 8.01-8.03 (d, 6H, o-Ar-H, J=8.5 Hz), 8.12-8.14 (d, 2H, !-H, J=8.5 Hz)
8.90 (m, 8H, !-H).
Synthesis of Porphyrin 2-10: To deprotect 2-9, a solution of the tert-butyl protected porphyrin
(0.200 g, 0.2591 mmol) in 3 mL of dichloromethane was added 4.25 mL of TFA (57.3598
mmol), and the final mixture was stirred at room temperature for 4 h. After removal of the
solvent under vacuum overnight, the residue was triturated and washed with Et2O (3 times at 8
minutes each, via centrifugation and decanting of ether) to afford porphyrin as a green solid in
quantitative yield. Reaction product was used immediately for conjugation to the 3-PEG linker.
MALDI-TOF-MS of 2-10 m/z 816.056 [M+Na]+, calculated for C46H32N4O6 736.77.
Synthesis of 5-(4-methoxycarbonylphenyl)-10,15,20-tris(3,4,5-trimethoxyphenyl)porphyrin
(2-11): To a round bottom flask was added 3,4,5-trimethoxybenzaldehyde (0.100 g, 6.0 mmol),
methyl-4-formylbenzoate (0.097 g, 0.7 mmol), and freshly distilled pyrrole (0.023 g, 4.0 mmol)
under argon at room temperature. The mixture stirred for 10 minutes. BF3.Et2O was added (0.01
mL) and the reaction stirred for 2 h. Argon was turned off and 400 mg of DDQ was added to
reaction mixture. After stirring for 45 minutes at room temperature, the solution was quenched
with aqueous NaHCO3 until the aqueous layer was colorless (approx. 10-15 times). A silica plug
was used to remove polymerized products. TLC was used to find the best solvent system. A final
flash chromatography in hexanes/DCM/EtAc (1.5:1:1) was done to yield the mono-substituted
methyl ester triphenylporphyrin in 9% yield. MALDI-MS m/z 943.802 [M+H]; calculated for
C55H50N4O11 942.35.
Synthesis of 5-(4-propargylphenyl)-10,15,20-tri(4-hydroxyphenyl)porphyrin (2-12): To a
round bottom flask was added 2-8 (0.020 g, 0.0295 mmol) and Cs2CO3 (0.010 g, 0.0295 mmol)
in anhydrous THF. Propargyl bromide (in 80% toluene) was added (0.0168 g, 0.118 mmol) and

!

41

the reaction proceeded for 2 h. The products were separated on column chromatography using
CHCl3/Ethyl Acetate (8:2) with 35% yield. MALDI-MS m/z 717.028 [M+H]; calculated for
C47H32N4O4; 1H NMR (400 MHz, MeOD): d -2.78 (s, 2H), 3.77 ppm (s, 1H, alkyne-H), 5.11
ppm (s, 2H, CH2), 4.95 ppm (s, 3H, OH), 7.47-7.52 (m, 6H, m-Ph-H), 8.30-8.47 (m, 6H, o-Ph-H)
8.79-8.81 ppm (m, 4H, m-, o-Ar-H), 8.97 ppm (m(s), 8H, !-H).

13

C NMR (400 MHz, CDCl3):

29.59, 56.28, 61.23, 112.88, 120.19, 127.87, 131.02, 131.19, 131.29, 131.65, 134.40, 137.39,
137.79, 146.86, 151.33, 167.23.
Synthesis of Porphyrin 2-13: To a solution of tert-butyl ester-deprotected porphyrin, 2-7
(0.0064g, 8.95109E-06 mmol) in DMF (1 mL) was added DIEA (8.43188753E-06 g,
5.3702629E-05 mmol, 0.011364 uL), HOBt (0.0012093 mg, 8.95109E-06 mmol), and TBTU
(0.0028741 mg, 8.95109E-06 mmol). The mixture was stirred for 5 minutes, then NH2-3PEGt

Bu (0.0024826 mg, 8.95109E-06 mmol) was added, and stirring continued for 48 hours at room

temperature. Reaction was monitored via TLC after each 24 hour interval. The reaction mixture
was diluted with 20 mL of ethyl acetate, washed with water (3 x 40 mL), and dried over
anhydrous MgSO4. Solvent was evaporated under vacuum. The target porphyrin was purified
by flash chromatography on silica gel using 100% ethyl acetate for elution, yielding 40.3%60.1% of tert-butyl ester of porphyrin. HRMS-ESI m/z 975.8 [M+H]+, calculated for C60H58N6O7
974.44. 1H NMR (400 MHz, CDCl3): d -2.78 (s, 2H), 1.46 (s, 9H), 2.53-2.57 (t, 2H, J=6.4 Hz),
3.59-3.60 (m, 2H, J=4.0 Hz), 3.69 ((broad) m, 9H), 3.77-3.78 (t, 2H, J=6.4 Hz), 4.32-4.33 (d, 2H,
J=4.84 Hz), 6.81-6.84 (m, 1H), 7.45-7.47 (t, 1H, J=4.0 Hz), 7.74-7.79 (m, 9H, m-, p-Ph-H), 8.218.25 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.30-8.32 (d, 2H, o-Ar-H, J=5.96 Hz), 8.78-8.79 (d, 2H, !-H,
J=4.3 Hz), 8.85-8.87 ((broad), m, 6H, !-H).

13

C NMR (250 MHz, CDCl3): 28.00, 36.15, 39.49,

43.36, 68.84, 69.57, 70.37, 70.54, 120.24, 125.50, 126.60, 127.66, 131.14, 133.11, 134.43,
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134.54, 141.93, 145.70, 167.53, 168.81. UV-VIS (chloroform) "max (L mol!1 cm!1) 425
(436,000), 524 (13,010), 557 (5000), 598 (1,100), 657 (100).
Synthesis of Porphyrin 2-14: Deprotection of the tert-butyl group occurred in a solution of
TFA (1 mL) and DCM (1 mL) for 4 hours. After removal of the solvent under vacuum overnight,
the residue was triturated and washed with Et2O (3 times at 8 minutes each, via centrifugation
and decanting of ether) to afford porphyrin as a green solid in quantitative yield. Conjugations to
biomolecules continued. HRMS-ESI m/z 920.0213 [M+H]+, calculated for C56H50N6O7 919.03
1

H NMR (400 MHz, CDCl3): -2.75 (s, 2H), 2.53-2.56 (m, 2H), 3.46-3.50 (m, 2H), 3.59-6.63

((broad) m, 9H), 3.72-3.75 (m, 2H), 4.22-4.24 (d, 2H, J=5.5), 7.52-7.54 (m, 1H), 7.84-7.87 (m,
8H, m-, p-Ph-H), 8.26-8.27 (d, 8H, o-Ph-H, m-Ar-H, J=6.7 Hz), 8.39-8.40 (d, 2H, o-Ar-H,
J=4.3), 8.42 ((broad) s, 1H), 8.88-8.90 (m, 8H, !-H). UV-VIS (chloroform) "max (L mol!1 cm!1)
425 (183,450), 524 (12,075), 559 (7,925), 600 (6,550), 657 (5,875).
Synthesis of 5-PEG 2-17: Hexaethylene glycol (0.847g, 3.00 mmol) and tert-butyl diazoacetate
(0.217g, 2.00 mmol) were combined in dry DCM under nitrogen atmosphere. Three drops of
boron triflate diethyl etherate were added to the mixture. The reaction was stirred for 15
minutes. After this time, another three drops of BF3-Et2O were added and the mixture was
stirred for 15 minutes. TLC was used to monitor the reaction. After reaction completion,
reaction was diluted with ethyl acetate, washed with brine, and dried over anhydrous magnesium
sulfate, dried and concentrated. The reaction was submitted to ESI-MS to confirm presence of
product. HRMS-ESI m/z [M+Na]+ 419.2233, calculated for C18H36O9 396.47.
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Figure 2.6. ESI-MS of 2-17.
Synthesis of 5-PEG 2-18: Crude 2-17 was co-evaporated with toluene. Dry DCM was added to
crude mixture. Et3N (3.035 g, 30 mmol) and trimethylamine hydrochloride (0.1911 g, 2 mmol)
were added to RBF. Reaction flask was put in iced bath and temperature reached 0oC. Tosyl
chloride was dissolved in vial with dry DCM. This mixture was added dropwise to RBF over 10
minutes while the RBF remained in ice bath. The ice bath was removed after final addition of
tosyl chloride (after 10 minutes). Reaction mixture stirred for an additional 60 minutes at room
temperature. TLC was used to monitor the reaction. After reaction completion, the mixture was
washed with 1 N H2SO4, aqueous NaHCO3, and aqueous NaCl. Reaction was dried with
MgSO4, filtered and concentrated.

The sample was continued to the next step without

purification.
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Synthesis of 5-PEG 2-19: The crude material 2-18 was co-evaporated with toluene (3x50 mL)
and stirred under reflux with sodium azide (0.06501 g, 1 mmol) in DMF (1 mL) for 2.5 hours at
110oC. Reaction was brought to room temperature. The mixture was taken up in ethyl acetate
(2x50 mL) washed with brine (3x50 mL), dried with MgSO4, filtered, and concentrated. HRMSESI m/z 367.37 [M-tButyl]+, 446.2088 [M+Na]+, calculated for C18H35N3O8 421.49.

Figure 2.7. ESI-MS of 2-19.
Synthesis of 5-PEG 2-20: Crude material 2-19 was dissolved in ethanol: chloroform (10:1 mL).
Palladium 10 wt. percent on carbon (100 mg) was added to RBF under hydrogen atmosphere for
12 hours. The catalyst was removed by filtration over celite and filtrate was concentrated.
Residue was taken up in ethyl acetate (70 mL) and extracted with potassium hydrogen sulfate (1
N, 1x100 mL, 2x50 mL). Aqueous layers were combined and made caustic with sodium
carbonate. These layers were then extracted with chloroform (1x100 mL, 2x50 mL), dried with
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MgSO4, filtered via gravity filtration, then concentrated to give the product. ESI-MS was used to
observe presence of product. HRMS-ESI m/z 396.259 [M+H]+, calculated for C18H37NO8
395.49.

Figure 2.8. HRMS ESI of 2-20.
Synthesis of 5-PEG 2-21: Hexaethylene glycol (0.1483 g, 0.504 mmol) and dry DCM were
added to RBF.

Triethylamine (101.19 g, 1.008 mmol) and trimethylamine hydrochloride

(0.09557 g, 1.00 mmol) were added to RBF. Reaction flask was put in ice bath and temperature
reached 0oC. Tosyl chloride was dissolved in vial with dry DCM. This mixture was added
dropwise to RBF over 10 minutes while the RBF remained in ice bath. After the last drop was
added, the ice bath was removed. Reaction was monitored via TLC every 10 minutes or until
initial formation of the monosubstituted product was formed. After reaction completion, the
reaction mixture was washed with H2SO4 (1 N, 2x50 mL), saturated NaHCO3 (1x100 mL), and
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brine (1x70 mL). Organic product was dried with anhydrous MgSO4, filered, then concentrated.
The sample was continued to the next step without purification. ESI-MS m/z 533.2935 [M+2K]+,
592.3044 [M+3K+Na]+, calculated for C19H34O10S 454.53.

Figure 2.9. ESI-MS of 2-21.
Synthesis of 5-PEG 2-22: Crude compound 2-21 (0.870 mg) was combined with 4 mL dry DMF
and NaN3 (0.1950 mg, 3 mmol). The reaction mixture was heated to 100oC for 2.5 hr, then
cooled to room temperature. The mixture was taken up in ethyl acetate (2x50 mL) washed with
brine (3x50 mL), dried with MgSO4, filtered, and concentrated. Sample was submitted to ESIMS for analysis. HRMS-ESI m/z 308.1807 [M+Na]+, calculated for C12H35N3O6 307.34.
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Figure 2.10. ESI-MS of 2-22.
Synthesis of 5-PEG 2-23: Immediately following crude production of 2-17, to dry DCM (10
mL) was added in order: triphenylphosphine (0.8993 g, 3.429 mmol), imidazole (0.2334 g, 3.429
mmol), and iodine (0.4381 g, 3.429 mmol). A solution of the alcohol, 7, in 7 mL of dry DCM
was added and the mixture was stirred at room temperature for 2 hours. The solvent was
removed in vacuo, then resuspended in DCM. To remove the iodine, a small silica plug was
sued. The crude product was obtained as a yellow oil. TLC was used to monitor the reaction.
ESI-MS was used to observe presence of product. HRMS-ESI m/z 529.13 [M+Na]+, calculated
for C18H35IO8 506.37.
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Figure 2.11. ESI-MS of 2-23.
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CHAPTER 3. BENZYLIDENEMALONONITRILE- AND QUINAZOLINE-BASED
PORPHYRIN CONJUGATES
3.1 The Development of Small Tyrphostin Ligands with Affinity for EGFR
Tyrphostins are a class of molecules that were developed to inhibit functions of EGFR, a
member of the tyrosine kinase family.2 The tyrosine kinases are important in cellular regulation
by phosphorylating tyrosine residues or any exogenous substrates for the kinase.2 If there are
problems in cell signaling of a tyrosine kinase, this often renders the kinase hyperactive,
implicating these proteins in illnesses such as CRC, psoriasis, non-small cell lung cancer
(NSCLC), chronic myeloid leukemia, gastrointestinal stromal tumors, acute kidney failure, and
even septic shock.3 Much work has been conducted on most of the tyrosine kinases, including
EGFR, through extensive characterization1b and development of small molecules to prevent
their hyperactivity.2, 4 Tyrphostins (TYRosine PHOSphorylation Inhibitors) specifically inhibit
phosphorylation of the receptor, which is believed to be the first step in signal transduction
across the plasma membrane.2 Subsequently, messages are sent to inner cytoplasmic enzymes
that are affiliated with the receptor.4k The accuracy of this process is dependent upon the
continuity of each messenger, or enzyme, to deliver the correct message. Over-expression of
EGFR or any other tyrosine kinase is caused by one mutation, which delivers a persistent,
sustained signal, leading to amplification of that receptor.4k Therefore, it is believed that if this
initial step is regulated, over-expression of the receptor should cease.4o This concept has
become a modality for developing molecules to impede over-expression using specifically
designed inhibitors that may be effective in two ways; the inhibitors will competitively inhibit
phosphorylation by binding to the ATP site or they may compete with various substrates which
become phosphorylated through the process of cell signaling.4a, 4k, 5 Gazit and Levitzki are
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recognized for coining the term “tyrphostins,” but also devising a name for this design
methodology – “signal transduction therapy.”4k,

5

The initial inhibitors were designed from

natural flavones, isoflavones, ansamycins and epidithiodioxopiprazines.4k, 4m This list includes
the molecules erbstatin (Figure 3.1a), which is the most notable of these compounds, as well as
genistein (Figure 3.1b), quercetin (Figure 3.1c), lavendustin A, and luteolin.4k, 4m These natural
compounds were found to be unspecific for only one type of protein tyrosine kinase (PTK)
family member (each inhibited multiple PTKs, which would increase cytotoxicity),4k, 4m have
low potencies,4k and in many cases, are considered difficult to synthesize synthetically.6
Tyrphostins, however, have shown great promise as selective inhibitors for EGFR. Their
selectivity varies, with some molecules having affinity for the ATP site, while others are
substrate-competitive inhibitors. In any case, these molecules could potentially serve as ligands
conjugated to porphyrins to improve current in vivo imaging agents.
OH
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Figure 3.1. Structures of Erbstatin (3.1 a), Genistein (3.1 b), and Quercetin (3.1 c).
In designing new in vivo imaging agents, it is important to note some clinical results of
the successful EGFR-targeted agents in order to further illustrate their potential efficacy.
Results of orally administered tyrphostins used in conjunction with intravenously administered
monoclonal

antibodies

(mAbs)

illustrate

that

some

have

achieved

marketability

(vandetanib/Capresa),7 while others are still undergoing clinical trials.7a, 8 Several issues arise in
assessment of the non-mAb agents. First, these molecules are highly lipophilic, which implies
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that their water-solubility is low and have increased potency.7a Additionally, in order to achieve
the highest rate of affinity for EGFR over-expressing tumors, these tyrphostins must be used
with another method of treatment.7b Also, in terms of tyrphostin specificity for the ATP site or
as a substrate-competitive molecule, another consideration must be made. It is known that most
tyrosine kinase inhibitors, like tyrphostins, target the ATP-binding site, which is known as a
“Type 1” inhibitor.1c This is the most common type of tyrphostin that has been developed to
date and gives the structural basis for how our molecules (BMN- and quinazoline-based
porphyrin conjugates) were designed (Figure 3.2 a, b). While this may be a promising approach
for developing tyrphostin-based agents, the tyrosine kinase family is comprised of over 500
different species, yet the ATP-binding site is conserved in most of these kinases.4k, 7b Therefore,
in order to achieve specific binding of tyrphostins at the ATP site, higher dosages of the
tyrphostin must be administered, which subsequently increases cytotoxicity levels.4k, 7b Other
classes of tyrphostin-based molecules have been developed, however, that give alternative
methods to treat EGFR over-expressing cancers. The “Type 2” inhibitors have an affinity for
EGFR in its “inactive conformation,” or when it has not homo- or hetero-dimerized with
another receptor.1c Allosteric tyrphostin inhibitors do not actually bind at the ATP site of
EGFR, but usually at a site close to this area.1c The allosteric type tends to be more specific for
each EGFR family member. EGFR is responsible for cell proliferation and each EGFR family
member has a specific signal that it sends to the nucleus, which differentiates it from its other
members. There are also tyrphostins that interact covalently within the ATP site, causing
irreversible inhibition. These molecules, however, might be too toxic for human use.1c The low
IC50 values of tyrphostins suggest higher affinity of a tyrphostin for cells that over-express
EGFR. Current in vivo imaging agents are particularly ineffective due in part to their high
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cytotoxicity and lack of tumor cell specificity. These facts have brought great insight to the
design of our porphyrin-based tyrphostin conjugates, which should lead to a balance of
lipophilic and hydrophilic properties as well as a high specificity for CRC, which is necessary
for an improved in vivo imaging agent.
To synthesize a highly specific, porphyrin-based tyrphostin conjugate as a potential in
vivo imaging agent, two types of tyrphostin molecules were synthesized: one ring-BMNs, which
have the scaffold illustrated in Figure 3.2 a, and two ring quinazolines, shown in Figure 3.2 b.
The importance of key hydrogen bonding, electrostatic and hydrophobic interactions of BMNs
and quinazolines with EGFR have been considered using the crystal structure of EGFR obtained
by Stamos, et al.1 Positions R1 and R2 of the benzene ring of the BMNs (Figure 3.2 c) are
substituents that are located in the “Solvent Accessible Area.”1b One cyano group of
malononitrile or cyanoacetamide (at position R3) hydrogen bonds with a water molecule located
near “Hydrophobic Pocket II” next to residue Thr766.1a Conversely, binding of the quinazoline
(Figure 3.2 d) at the EGFR ATP site shows N1 hydrogen bonding interactions with Met769,1c, 9
while N3 hydrogen bonds with a water molecule located near residue Thr766.1b The R1 group
on the aniline of the quinazoline can vary (Br, Cl, methyl), although binding activity varies with
each change of substituent at position R1 in different EGFR kinases.9 The groups at R1 direct the
aniline ring of the quinazoline into “Hydrophobic Pocket II.”1b While substituents labeled as R2
and R3 may also vary, these positions of the quinazoline (positions 6 and 7, as labeled in Figure
3.2 b) are electron donating substituents that protrude into the “Solvent Accessible Area.”1b
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Figure 3.2. BMN Scaffold (3.2a), Quinazoline Scaffold (3.2b), Potential Binding of BMN
(3.2c) or Quinazoline (3.2d) in ATP active site (inspired by Stamos et al, Kamath et al, and
Zhang et al)1
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3.2 Description of Benzylidenemalononitriles (BMNs)
Gazit and colleagues designed the initial BMN tyrphostins after developing a molecular
platform based on erbstatin (Figure 3.1 a).2-3,

4k, 4o

Erbstatin was first isolated from an

actinomycete by Umezawa et al in the mid-1980s.4n The BMN was one of the main scaffolds of
the “first generation” of tyrphostins.2, 4n BMNs are a combination of tyrosine and erbstatin,
which are both phenolic molecules and also contain two additional carbons on one side of the
phenol.2 The basic pharmacophore in the “first generation” tyrphostins is shown in Figure 3.3,
the malononitrile moiety. According to Gazit, two cyano substituents were found to increase the
biological activity of all the tyrphostin compounds.2 Many tyrphostins have been studied. For
example, tyrphostins AG18 and AG82 both showed high affinity for EGFR and low IC50 values
in EGFR over-expressing cells.2 This shows that the malononitrile moiety is important for the
activity of BMNs and their derivatives. However, the rationale behind this substituent’s activity
has not been completely determined. Scientists have proposed that due to the large
electronegativity of the cyano (CN) group alone, it can be considered a “pseudohalogen,” or a
molecule that behaves in the same way that a halogen would (e.g. inductively electronwithdrawing and is relatively higher in electronegativity compared to other groups). Halogens,
however, are pi-donors, while the CN groups are not, and actually tend to act more like aryl
groups (extending the pi-systems).10 A thorough discussion of the relative activities of BMNs in
comparison with quinazoline tyrphostin derivatives will be presented in Section 3.5. In any
case, the BMN family contains substituents that clearly impact the affinity of this molecule for
the ATP site of EGFR. Many of the BMNs are commercially available, such as those shown in
Figure 3.4, however, a group (such as an amino group must be introduced for conjugation to a
carboxylic acid-terminated porphyrin.
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Figure 3.3. Pharmacophore Moiety of Tyrphostin BMNs.
(a) Tyrphostin AG18
(IC = 35 µM)

(b) Tyrphostin AG82
(IC = 3 µM)
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Figure 3.4. Structures of Tyrphostins AG18 (3.4 a) and AG82 (3.4 b).
3.2.1 Synthesis, Characterization, and Cell Studies of BMN
Synthesis

of

BMN

3-3

consisted

of

a

Knoevenagel

condensation

of

4-

aminobenzaldehyde with malononitrile or cyanoacetamide in EtOH.11 A small amount of
piperidine was used to catalyze the condensation, yielding bright yellow crystals. However,
while the reaction is well known and simple to accomplish, the target product (3-3) was only
obtained in low yields containing mainly starting material, according to NMR, MS, and x-ray
crystallography. Therefore, another starting material was used, 4-nitrobenzaldehyde (3-1). In
this case, the nitro group was reduced to an amine group and the aldehyde was converted to a
malononitrile (3-3) or cyanoacetamide (3-6); both of these functional groups have been
implicated as moieties that have high affinity for EGFR.2 After reduction of the nitro group to
the amine, the molecule was conjugated to a carboxylic acid-terminated PEG to yield 3-4. This
process, however, also gave very low yields and the reaction mixture was difficult to purify.
However, from mass spectrometry analysis, it was observed that the crude product was
synthesized, and by TLC, a band illustrating a lower polarity than the BMN yet higher than the
free PEG suggesting that the product was obtained (Scheme 3.1 a, b). It is important to note
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that product 3-5 obtained significantly different yields than 3-2 via the typical Knoevenagel
condensation reagents (the electron deficient cyano reagent in combination with the aldehyde,
3-1). Compound 3-5 was obtained in much higher yield using urea (10 mol%) as catalyst. The
lower yield obtained from the initial Knoevenagel condensation conditions for compound 3-5
may have occurred due to the fact that there is a potential for 3-5 to form both the E and Z
isomers, although the Z isomer should be more favorable, due to the presence of the bulky
aromatic group on one side of the double bond. Using urea as the catalyst in solvent-free
conditions gives higher product yields. The urea can be washed away in water, therefore
facilitating the purification step.12
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Scheme 3.1. Synthesis of Pegylated Malononitrile BMN (a) and Cyanoacetamide (b).
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Because of the importance of the malononitrile functionality, we investigated whether
this functional group alone and attached to a porphyrin could yield a conjugate that had affinity
for EGFR. The synthesis of this molecule is illustrated in Scheme 3.2. Previously, a porphyrin
was synthesized containing the PEG linker described in Chapter 2 (porphyrin 2-14). Porphyrin
2-14 was first solubilized in dry DCM then Et3N was added. The temperature of the solution
was brought down to 0oC and TMSBr was added to facilitate formation of the silyl ester
intermediate. Formation of the silyl ester was observed by TLC. The reaction temperature was
then decreased to -78oC then subjected to reduction with 1 equivalent of DIBAL-H for
approximately 3 minutes.13 Formation of the aldehyde was observed by TLC and ESI-MS,
however, most of the product was reduced to the alcohol, resulting low yields of the target
aldehyde. The aldehyde-terminated porphyrin was then subjected to the Knoevenagel
condensation described previously (Scheme 3.1). TLC confirmed the aldehyde was converted
to malononitrile.11
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Scheme 3.2. Synthesis of Malononitrile-terminated Pegylated Porphyrin.
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To observe the efficacy of this molecule in cells, 3-7 was added to HEp2 cells (human
epidermoid carcinoma, and larynx cancer cell line)14 by Dr. Xiaoke Hu. HEp2 cells were plated
onto glass chamber slides and were exposed to 10 !M of conjugate 3-7 over 18 h. Cell cultures
were supplemented with organelle markers for endoplasmic reticulum (ER-Tracker Blue-White
DPX, purchased from Molecular Probes, Figures 3.5 c, d), lysosomes (LysoSensor DND-189,
purchased from Molecular Probes, Figures 3.5 e, f), mitochondria (MitoTracker Green FM,
purchased from Molecular Probes, Figures 3.5 g, h), and Golgi network (BODIPY FL C5ceramide, purchased from Molecular Probes, Figure 3.5 i, j). Phase-contrast microscopy15 (as
well as an overlay) was used to view the porphyrin in cells (Figures 3.5 a, b). Following
incubation, the cells were washed 3 times with PBS and live-imaged using a Zeiss Axiovert 200
fluorescence microscope fitted with a Texas Red filter set (to capture porphyrin conjugate
fluorescence), an FITC filter set (to capture MitoTracker and LysoSensor probes), and a DAPIcompatible filter set (to capture ER-Tracker probes). The images were acquired with a Zeiss
Axiocam MRM CCD camera fitted to the microscope. Conjugate 3-7 localized primarily in the
lysosomes (Figures 3.5 e, f), which is an important target for porphyrin-based medicinal
agents.16 Future studies will include conducting the Knoevenagel condensation alone with the
acid without the reduction to aldehyde. The molecule produced will serve as a comparison to
conjugate 3-7.
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Figure 3.5. Subcellular
Localization of Conjugate 3-7.
Description of
Fluorescent Dyes:
(a) phase contrast,
(b) overlay of compound and
phase contrast,
(c) ER tracker fluorescence,
(d) overlay of organelle tracer [c]
with compound fluorescence
(e) LysoSensor Green
fluorescence,
(f) overlay of organelle tracer [e]
with compound fluorescence
(g) MitoTracker Green
fluorescence,
(h) overlay of organelle tracer [g]
with compound fluorescence
(i) BODIPY FL C5-Ceramide,
(j) overlay of organelle tracer [i]
with compound fluorescence.
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3.3 Description of Quinazolines
The first description of quinazolines emerged from Gazit et al in 1996, after extensive
work on the BMNs. This scaffold was developed to compare monocyclic compounds to
bicyclics, which are more rigid in structure.4f However, the work of chemists at Parke-Davis
Pharmaceuticals (now a subsidiary of Pfizer, Inc.) brought the synthesis of the quinazolines to
light with the preparation of PD153035 (Figure 3.6 a), a highly potent inhibitor of EGFR overexpressing cells.17 The molecules designed in this work are derivatives of PD153035. Based on
the design shown in Figure 3.6 a, we synthesized a porphyrin conjugate containing the bicyclic
structures shown in Figure 3.6 (b, c). These molecules were also investigated computationally
to assess their potential binding at the ATP active site of EGFR.
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N
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(b)
Figure 3.6. Structure of PD153035 (a), Synthesis of Quinazoline through Pyrimidine (b),
Synthesis of Quinazoline through Phenyl (c).
(a)

3.3.1 Synthesis and Characterization of Quinazolines
Based on work published from chemists at Parke-Davis Pharmaceuticals,4b,

17a

we

synthesized the quinazoline through the pyrimidine ring because: 1) The synthesis was simple
and previously described; a short linker was added to the pyrimidine ring and then the porphyrin
was easily conjugated at its terminal carboxylic acid;4b 2) It was illustrated that hydrophilic
methoxy groups proved to increase affinity for the active site compared with other quinazoline
derivatives;4b, c, 17a and 3) The importance of the pyrimidine nitrogen at position 1, as well as the
short NH spacer might be important for binding within the pocket.4b, c, 17a We believed that the
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pegylated porphyrin (2-14) would favor solubility in aqueous solutions, decrease aggregation,
and have favorable conformation for interaction with the receptor.1c, 4b, 4e, 17b However, the task
of this synthesis and purifications proved to be quite difficult. Scheme 3.3 shows the
methodology used for the quinazoline synthesis. Beginning with the anthranilic acid 3-8, 2amino-4,5-dimethoxybenzoic acid, a heat catalyzed cyclization with formamidine hydrochloride
occurred to yield 3-9 in 70% yield.4b A Vilsmeier reaction with oxalyl chloride with 3-9
yielded 3-10 in 97% yield. Compound 3-10 was subjected to two methods to yield the final
quinazoline, 3-12. First, 3-10 was subjected to a simple nucleophilic substitution with N-Boc
ethylenediamine.

However, after changing the solvents (2-propanol, DMF, and toluene),

varying the temperature (25oC-70oC), and duration of the reaction (1h-48h), only a crude
mixture containing the product in low yield was achieved, as illustrated by ESI-MS analysis.
Purification on silica gel chromatography was unsuccessful, despite using several eluants and
separations in varying ratios of eluants. Therefore, an alternative route was developed. Using
3-10, free ethylenediamine was added to the reaction mixture to achieve the product, 3-12. This
synthesis also proved to be difficult. Solvents (DMF, toluene), temperatures (25oC-60oC), and
duration of the reaction (1h-48h) were varied. The best combination of variables yielded 30%
of 3-12, in DMF at 60oC for 1 h. Increasing the reaction time did not increase the yield. The
crude was analyzed by ESI-MS, purified by silica gel column chromatography, followed by
purification by HPLC using a gradient of MeOH and water. The product (3-12) after HPLC,
gave 30% yield of a brown solid.
After characterization of 3-12 by use of MS and NMR, it was then conjugated to
porphyrin 2-14, using typical peptide coupling conditions, DIEA/HOBt/TBTU, for two days in
DMF. However, the yield after purification by silica gel column chromatography was low. The
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product was purified using varying solvent gradients in this order: EtAc (80%)/DCM
(10%)/MeOH

(10%),

EtAc/CHCl3/MeOH

EtAc

(70%)/iPrOH

(1:1:0.1),

(30%),

EtAc

(60%)/iPrOH

EtAc/CHCl3/MeOH/iPrOH

(40%),

(1:1:0.1:0.1),

EtAc/CHCl3/MeOH/iPrOH (1:1:0.1:0.2). Approximately 35 fractions were collected and
analyzed by TLC. One of the later fractions (#24) contained the product and did not contain
any additional spots on the TLC. While this proved to be quite challenging, the product was
obtained, although in moderate yield (16%). Compound 3-13 was identified by UV-VIS and
mass spectroscopy, and proton NMR. This synthesis is being repeated to optimize yield.
Methods have been developed to increase the yield of 3-13, such as using DMSO as the solvent
for the synthesis of 3-12, as well as conjugating 3-12 to the Fmoc-3PEG (shown in Scheme 3.1)
before conjugation to a carboxylic acid-terminated porphyrin (2-7).
Because of the challenges encountered in the synthesis of conjugate 3-13, another
quinazoline, 3-19, was prepared to allow for conjugation of porphyrin 2-14 to the quinazoline
through its phenyl ring (Scheme 3.4). Figure 3.8 illustrates the structure of this porphyrin
conjugate, 3-19, which, in comparison to PD153035, is similar.! ! Beginning with anthranilic
acid, 3-14, a similar heat catalyzed cyclization with formamidine hydrochloride took place to
yield 60% of 3-15. A Vilsmeier reaction with oxalyl chloride occurred to give 3-16 in 50%
yield. Compound 3-17 was synthesized using 3-bromoaniline in basic conditions (Cs2CO3) and
under reflux for 1 h to yield 40% of product. The nitro group at position 7 of the quinazoline
was reduced using same procedure illustrated in Scheme 3.1, by using SnCl2 and HCl under
reflux for 12 h to yield 42% of target quinazoline 3-19. The products in Scheme 3.4 were
characterized by NMR and experimental spectra were in agreement with the literature.
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Figure 3.8. Structure of Conjugate 3-19.
3.4 In Silico Studies on Tyrphostin-Based Porphyrin Conjugates
BMN- and quinazoline-based porphyrin conjugates were subjected to computational
calculations, more specifically, through molecular docking. While ab initio predictions can give
insight toward the overall electronic properties of our molecules, it is not advantageous to
conduct quantum mechanics (QM) calculations on large porphyrin conjugates because these are
computationally expensive.18 Although QM is more accurate in terms of determining energy
conformations,

molecular

mechanics

(MM)

methods,

approximate

energy/geometry

values/conformations, resulting in faster computational determinations of lowest energy
conformations.18 This section presents an analysis of tyrphostin molecules and their porphyrin
conjugates as rationale for these molecules to be used as in vivo imaging agents for EGFR overexpressing CRC.
3.4.1 Molecular Mechanics and Docking of Tyrphostin-Based Porphyrin
Conjugates
Porphyrin-tyrphostin conjugate affinity for the EGFR active site was investigated by
first, optimizing the geometry of the conjugate using MM2 employed in ChemBio3D19 or
MacroModel,20 and then, subjected to Vina for docking. For this study, the large size and
potential interactions of the porphyrin-tyrphostin conjugates was minimized before preparing
the conjugates for docking studies. Because these conjugates are not “peptidic” in nature,
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energy minimization was conducted using MM2 method (vacuum) in MacroModel20 or Chem
Bio 3D19 software. The criteria for these calculations are listed in Table 3.1. The MM2 method
is used for energy and geometry optimization of organic molecules, especially due to the fact
that ab initio methods for this large molecule takes substantial computer time.18
Table 3.1. Molecular Study Generation – Part 1
Parameter

Value

Force Field

MM2

Max. No. of Iterations

10,000

Convergence Criteria

0.01 cal/mol Å

Dielectric Constant

1 (for vacuum)

After obtaining the optimized conformers, AutoDock Vina21 (noted as “Vina”) was
employed. Vina has become of great use to many non-theoreticians because of its ease of use,
lower computational time, and accessibility. Rather than use a force field such as AMBER,22
which is employed in AutoDock 4,23 another is considered in Vina – an empirical free energy
force field, which is essentially the summation of free energies from its dispersion forces
(!Ggauss), repulsion forces (!Grepulsion), hydrogen bonding (!Ghbond), hydrophobic interactions
(!Ghydrophobic), and lastly, the number of torsions (!Gtors).21 Improper consideration of the
ligand’s orientation, location, and conformation can impact the overall calculation in terms of
time and resulting conformations. However, certain precautions were taken for computational
studies with porphyrin-tyrphostin conjugates in Vina. First, the “search space”21 was restricted
to the EGFR ATP site to minimize computational time. Literature illustrates that the space of
the ATP site of EGFR is located at the 760-800 numbered residues.1b A search space of only 28
x 24 x 22 Å was used to restrict the conjugated tyrphostin within the “search space.” A test
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calculation was conducted to assess the viability of Vina for calculations. The crystal structure
of EGFR (PDB ID: 1M17), which contains the ligand, erlotinib (Figure 3.9 a) was obtained
from the Protein Data Bank. The erlotinib ligand was removed from the EGFR ATP site using
AutoDockTools.21, 23 An MM2 energy minimized structure of erlotinib was docked using Vina.
The third conformer obtained from Vina was less than 5 Å in from each hydrogen bond length
compared to the original erlotinib ligand (Figure 3.11 a) crystallized with EGFR,1b with a 24%
increase in hydrogen bond distance at the aniline bromine of erlotinib with Thr766 (from 4.85 Å
to 5.33 Å) and a 10% increase in hydrogen bond distance at N1 position of the quinazoline with
Met769 (from 3.53 Å to 4.36 Å), compared to literature distance values at these sites.1b The
other eight (8) conformers of the erlotinib test screen in Vina were unfavorable in relation to
1M17. The results of this test calculation are listed in Table 3.2 and presented in Figures 3.9
(b, c, d).
With promising results from the test calculation of the quinazoline, erlotinib (Figure 3.9
a) in Vina, porphyrin-tyrphostin conjugates (3-4a, 3-6a, 3-7, 3-13, 3-19) were first, minimized
using MM2 in MacroModel,20 then docked in Vina. For each porphyrin-tyrphostin conjugate,
the number of rotatable bonds changed depending on the terminal ligand (see Table 3.4, column
2). The search space remained the same (28 x 24 x 22 Å). The average computational docking
time was approximately 6.5 hours for each porphyrin-tyrphostin conjugate. PyMol was used to
visualize molecules and their lowest energy conformations in EGFR.24
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Figure 3.9. (a) Structure of erlotinib. (b) [1, blue] Most conformationally favorable erlotinib structure
(compared to the co-crystallized ligand, erlotinib, in PDB ID: 1M172). [2, yellow] Erlotinib conformation
obtained from PDB ID: 1M17.2 (b) Visualization of 3.11(a) in ATP Site of EGFR. (c) Distances from
Thr766 and Met769.
The docking results of the two BMN-based porphyrin conjugates (3-4a and 3-6a) gave
significant insight toward understanding the potential of these molecules to bind at the ATP site
of EGFR (Figures 3.10 and 3.11). The conformation of conjugate 3-4a (Figure 3.10 a)
illustrates that the structure of this conjugate is constrained. The phenyl ring of the terminal
BMN is far from the porphyrin, suggesting potential pi-interactions may not be a problem for
binding to the ATP site. However, the placement of the conjugate is not in alignment with the
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predicted “hinge region” of EGFR;1b this binding is actually in the “A-loop,” or activation loop
region, which in terms of this form of EGFR, does not contain the phosphorylated tyrosines that
are required for EGFR cell signaling; however, this is the usual site for this phosphorylation.1b
For 3-4a, we hypothesized that the cyano groups of the malononitrile would be important for
halogen bonding – and this is the case. The cyano group positioned closest to Thr830 (termed
CN-1, due to its placement closest to the two carbons in the phenyl ring of BMN) is only 3.80 Å
away, a favorable distance for halogen bonding. This interaction suggests that the cyano
substituent is necessary for binding. The other cyano moiety has a favorable interaction with
Phe832, and is in closer proximity (2.65 Å). In terms of the porphyrin, the interactions are less
favorable. It was hypothesized that the phenyls of TPP should interact heavily with
phenylalanine or tyrosine residues, that effect was not observed for this conjugate, 3-4a. The
most favorable interaction appears to be with the 20’-phenyl of TPP; this phenyl group is in
association with Leu764 that is contained in “Hydrophobic Pocket II” (5.91 Å).

The

interactions with Phe832 at 15’-phenyl of TPP (7.07 Å) and pi-interactions of the pyrrole
between phenyls 15’ and 20’ of TPP with Phe699 (6.91 Å) are less favorable. However, the
region containing Phe699 contains several hydrophobic residues, which may be the driving
force for the porphyrin to primarily position itself there (Gly695, Ser696, Gly697, Ala698,
Phe699, Gly700). This region is called the “glycine rich nucleotide-phosphate binding loop,”
which is located on the N-terminal lobe (N-lobe) of the EGFR sequence.1b Conjugate 3-4a
docking results are depicted in Figure 3.10 a-d.
Conjugate 3-6a (Figure 3.11 a) has no favorable interactions at the ATP binding site.
This BMN has one cyano group and one cyanoacetamide group, rather than two cyano groups
(conjugate 3-4a). The alkene and phenyl ring of the BMN in conjugate 3-6a have substantial
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interactions with the porphyrin, resulting in a conformationally constrained porphyrintyrphostin conjugate (Figure 3.11 b, c, d). Despite the amide inherently pulling electron
density from the terminal NH2 of conjugate 3-6a, the interaction is favorable enough to
hydrogen bond with Pro770 (4.87 Å) and the cyano group interacts closest with Leu694 (5.80
Å). The halogen bonding effect for conjugate 3-6a is insignificant compared to the piinteractions of the alkene and phenyl ring with the porphyrin. Porphyrin interactions for this
conjugate are minimal with other amino acid residues. The 10’-phenyl of TPP is closest to
Phe771 (6.70 Å), which is not a favorable hydrogen bonding distance. The phenyl of the BMN
interacts favorably with Leu768 (3.55 Å), which is a residue in the “hinge region” of the ATP
binding site. This is probable because Leu768 is a residue close to “Hydrophobic Pocket I.”1c
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Figure 3.10.
(a) Structure of Conjugate 3-4a. (b) Lowest Energy Conformation of Conjugate 3-4a.
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Figure 3.10. (Continued)
(c) Visualization of 3-4a (Malononitrile interactions).
(d) Visualization of 3-4a (porphyrin interactions).
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Figure 3.11.
(a) Structure of Conjugate 3-6a.
(b) Lowest Energy Conformation of Conjugate 3-6a.
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Figure 3.11. (Continued)
(c) Visualization of Conjugate 3-6a (BMN interactions).
(d) Visualization of the Conjugate 3-6a (porphyrin interactions).
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Malononitrile-terminated porphyrin conjugate 3-7 docking resulted in two low energy
docked structures (Figure 3.12 b-d), however, unlike the binding of erlotinib (Figure 3.9 a-d)
at the “Hinge Region” of EGFR, the low energy structures had close interactions with Leu694 at
CN-1 and Gly772 at CN-2 (as labeled in Figure 3.12 c,d). The first conformer showed
hydrogen bonding for CN-1 at Leu694 (3.95 Å) and for CN-2 at Gly772 (3.54 Å). The second
conformer was further away from the Leu694 and Gly772 residues with CN-1 at 5.03 Å and
CN-2 at 5.42 Å, from Leu694 and Gly772, respectively. The second conformer also had a
higher energy than the first (16.7 kcal/mol), suggesting this may be an unfavorable
conformation. Figure 3.12 b show optimized structures of both porphyrin-malononitrile
terminated conformers. Figures 3.12 c and 3.12 d show the distances for malononitrile
positions CN-1 and CN-2 at Leu694 and Gly772. For these conformers, we hypothesized that
hydrogen bonding interactions occur at Thr766 or even Met769, as predicted previously in
several different binding modes;1a however, this was not the case. The cyano substituents (CN-1
and CN-2) were closest to the “Solvent Accessible Area” of EGFR, as described in Figure 3.2
c. The porphyrin’s position for this docking calculation of conjugate 3-7 (Figures 3.12 e, f),
illustrated that in both conformers, hydrophobic interactions occur at the 10’-position of the
porphyrin with Gly772, with a minor hydrophobic interaction with C-lobe residue, Ala816, and
also with “glycine-rich loop” residue, Phe699.
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Figure 3.12.
(a) Structure of Conjugate 3-7.
(b) Lowest Energy Conformations of 3-7 (Conformer 1 - green; Conformer 2 - blue).
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Figure 3.12. (Continued)

(c) Visualization of 3-7, Conformer 1 (interactions at CN-1 and CN-2).
(d) Visualization of 3-7, Conformer 1 (porphyrin interactions).
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Figure 3.12. (Continued)
(e) Visualization of 3-7, Conformer 2 (Interactions at CN-1 and CN-2).
(f) Visualization of 3-7, Conformer 2 (Porphyrin Interactions).
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The position of porphyrin-quinazoline conjugate 3-13 (Figure 3.7) was unexpected
(Figure 3.13 a-c); the entire conjugate spanned part of the N- and C-lobes and the ATP binding
site. Due to the size of the search space, which was consistent for each experiment, it was
hypothesized that the bulkier nature of the quinazoline would push the porphyrin into the
“Solvent Accessible Area” (Figure 3.2), which is near “Hydrophobic Pocket I.” Due to the span
of conjugate 3-13, the quinazoline actually interacts most favorably with residues in the N-lobe.
An important (and recognized)1b hydrogen bonding interaction at Asn676 with the 6-position
oxygen of the OMe substituent (3.90 Å) is evident. The 7-OMe, on the other hand, is not within
any favorable length of any residues (>9 Å) and does note protrude into the “Solvent Accessible
Area.”1b The aniline-H (4-NH’) hydrogen bonds with Ala674 (4.87 Å) and the N1 of the
pyrimidine ring interacts favorably with Arg807 (3.94 Å) conjugate 3-13 in the A-loop. The
porphyrin of conjugate 3-13 is close to the “Hydrophobic Pocket II” (5’-phenyl, Leu764, 6.78
Å), but spans to interact with Phe771 (15’-phenyl, 7.62 Å). These porphyrin interactions for
(Figure 3.13 c) are unfavorable because they are too far away. The interaction of the 20’-phenyl
of TPP with Leu768 at only 2.81 Å, now in “Hydrophobic Pocket I” is favorable, however.
(a)

Figure 3.13.
(a) Lowest Energy Conformer of Conjugate 3-13.
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(b)

B(D03)!
!12.7$4!
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B@C*)7$
12.7$4$
$$

Figure 3.13. (Continued)
(b) Visualization of 3-13 with Quinazoline (outset).
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(c)
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Figure 3.13.
(Continued)
(e) Visualization of 3-13 (porphyrin interactions).
The docking result of porphyrin-quinazoline conjugate 3-19 (Figure 3.14) is similar to
the result obtained with conjugate 3-13. We hypothesized that conjugate 3-19 would have more
favorable interactions in the “hinge region,” due to its substituents being almost identical to
erlotinib (Figure 3.9 a). We also hypothesized that the 3-PEG will guide the terminal
quinazoline (3-19) into the ATP active site, keeping the porphyrin macrocycle outside of the
binding region. However, this binding mirrored that of conjugate 3-13; the 6-OMe of 3-13 did
not interact with Asn676, the N1 of the quinazoline ring did interact with Asn676, however, in
favorable distance (3.90 Å). The 6-position NH (through which the pegylated porphyrin (2-14)
is conjugated to the quinazoline ring) shows potential hydrogen bonding with Pro675 at 6.24 Å.
The aniline-H interacts with Gln677 (3.48 Å), while the 3’-Bromine of aniline ring of
quinazoline conjugate 3-19 halogen bonds with Asp746 (4.82 Å). These results were surprising
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(c)
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Figure 3.14. (a) Lowest Energy Conformer of Conjugate 3-19. (b) Visualization of 3-19 at
Quinazoline. (c) Visualization of 3-19 (porphyrin interactions).
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Table 3.2. Summary of Molecular Mechanics and Docking Results.

Cmpd.

Fig.
3.11*

3-4

3-6

3-7+

MM2
Energy in
kcal/mol
(MacroModel
or ChemBio
3D)

32.7252

383.4892

255.9212

155.6810

No. of
Rotatable
Bonds
(Vina)

10

22

20

21

No. of
Conform
ers
(Vina)

Conformer
Energies in
kcal/mol
(Vina)

Residues
of
“Halogen
Bonding”
Distances
in Å (Vina/
PyMol)

9

1) -5.2
2) -5.1
3) -5.0*
4)–6) -4.8
7)–9) -4.7

Thr766,
4.85*

42.5

Thr830,
3.80 (CN1); Phe832,
2.65 (CN2)

N/A

36.0

Leu694,
5.80 (CN1); Pro770,
4.87
(CONH2-2)

N/A

1) 16.0
2) 16.7

1) Gly772,
3.54 (CN1); Leu694,
3.95 (CN2)
2) Gly772,
5.42 (CN1); Leu694,
5.03 (CN2)

N/A

1

1

2

Residues of
Quinazoline
Bonding
Distances in
Å (Vina/
PyMol)

Porphyrin
and/or
Other PiInteractions
in Å
(PyMol)

Met769,
3.53*

N/A

Phe832,
7.07 (15’);
Phe699,
6.91 (15’pyrrole);
Leu764,
5.91 (20’)
Phe771,
6.70 (10’);
Leu678,
3.55
(PhenylBMN)
1) Gly695,
7.28 (5’);
Gly772,
4.38 (10’);
Ala816, 6.76
(15’)
2) Phe699,
7.18 (5’);
Gly772,
4.80 (10’);
Ala816, 6.69
(15’)

Ala674, 4.87
Leu764,
(NH’);
6.78 (5’);
Arg807,
Phe771,
3-13
280.6689
22
1
105.4
N/A
3.94 (1-N);
7.62 (15’);
Asn676,
Leu768,
3.90 (62.81 (20’)
OMe)
Gln677,
3.48 (NH’);
Phe832,
Asp746,
Asn676,
5.87 (5’);
3-14
180.6822
19
1
58.0
4.82 (3’4.93 (1-N);
Leu768,
Br)
Pro675, 6.24
2.58 (20’);
(6-NH)
* The third conformer (-5.0 kcal/mol) was used to measure the distance of the atoms from the respective residues,
as published.1b + Porphyrin distance for both conformers were similar, <0.5 Å apart.
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because the design of conjugate 3-19 is similar to that of erlotinib. Porphyrin interactions were
similar to the observed docking results of conjugate 3-13, but the 20’-phenyl was closer to
Leu768 (2.58 Å) and a pi-interaction with Phe832 at the 15’-phenyl is important (5.87 Å).
3.5 Conclusion
Tyrphostin-based porphyrin conjugates have been synthesized and subjected to
molecular docking calculations. There are two types of tyrphostin molecules that have been
synthesized, the BMNs and quinazolines. To synthesize BMNs, Knovenagle condensation was
conducted in basic conditions, then adding malononitrile or cyanoacetamide (compounds 3-3
and 3-6). To synthesize the malononitrile-terminated porphyrin conjugate 3-7, carboxylic acidterminated porphyrin 2-14 was converted to the aldehyde via a silyl ester intermediate, then
reduced to the aldehyde, which could then be used in a Knovenagle condensation with
malononitrile. Conjugate 3-7 was subjected to cellular studies and was found to localize in the
lysosomes. Two quinazolines were synthesized; one quinazoline was synthesized to allow for
conjugation of porphyrin 2-14 through the pyrimidine ring (compound 3-12), while the other
quinazoline was synthesized to allow for conjugation of porphyrin 2-14 through the quinazoline
phenyl ring (compound 3-18). Computational experiments on tyrphostin-based porphyrin
conjugates gave insight to the potential binding of these molecules within the EGFR ATP active
site. The conjugate that was most localized within the EGFR ATP active site was conjugate 36a. We hope to compare these molecules to peptidic-based porphyrin conjugates and assess
their binding for CRC. Future work includes synthesizing conjugates 3-4a, 3-6a, and 3-19 via
coupling conditions (HOBt/DIEA/TBTU), purifying by silica gel chromatography as well as
HPLC, and characterizing them by MS and NMR. The reaction conditions of conjugate 3-7 will
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be optimized to obtain higher yield of conjugate. These conjugates will be subjected to cellular
studies to observe their affinity for CRC.
3.6 Experimental
Synthesis of 2-(4-nitrobenzylidene)malononitrile (3-2): Malononitrile (0.495 g, 7.5 mmol)
was dissolved in EtOH in a vial (7.5 mL). At the same time, 4-nitrobenzaldehyde, 3-1 (1.133 g,
7.5 mmol) was stirred in a 50 mL round bottom flask (RBF) in EtOH (7.5 mL). The
malononitrile solution was added dropwise to the RBF containing 3-1. After stirring to allow for
formation of homogeneous solution, piperidine (4.9 mL, 0.05 mmol) was added. The reaction
was monitored by TLC. Afterward, the solution was diluted with 80 mL DCM, washed with
water (4x), dried with anhydrous NaSO4, and the solvent was removed in vacuo. The product
was recrystallized with (hot) EtOH/water and dried by vacuum filtration. Some insoluble
product formed was not included with recrystallization. The mother liquor was stored in a
refrigerator (~3oC). Crystallized product was stored in an oven (50oC) overnight to yield 49%
(0.7270 g) of solid yellow crystals. (Literature ppm values correspond to what was obtained
here.)12, 25
Synthesis of 2-(4-aminobenzylidene)malononitrile (3-3): Compound 3-2 (0.300 g, 1.5 mmol)
and anhydrous tin(II) chloride (0.999 g, 105 mmol) were combined in EtOH and stirred. HCl
(0.753 mL, 30.56 mmol) was added slowly over 10 minutes. The entire mixture was stirred
under reflux for 12 h. The reaction was monitored by TLC. Excess EtOH was evaporated. The
remaining solution was poured into water and made basic with 15% NaOH solution. An orange
precipitate formed that was filtered off, washed with water and recrystallized from EtOH. The
orange solid was placed in an oven (50oC) overnight to yield 51% (0.1301 g) of yellow solid.
(Literature ppm values correspond to what was obtained here.)12, 25
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Synthesis of Pegylated BMN-Malononitrile (3-4): To a solution of Fmoc-1-amino-4,7,10trioxa-13-tridecanamine succinimic acid (noted as “Fmoc-3PEG” in Scheme 3.1a; 0.300 g,
0.553 mmol) in 0.7 mL DMF, was added DIEA (1.31 mL, 0.619 mmol). The solution was sirred
for 20 minutes before HOBt (0.084 g, 0.619 mmol) and TBTU (0.199 g, 0.619 mmol) were also
added to the reaction flask. The reagents were warmed to 40oC and allowed to activate the
terminal carboxylic acid of the Fmoc-3PEG for 1h. A solution of 3-3 (0.105 g, 0.619 mmol) in
0.3 mL DMF was added to the now activated Fmoc-3PEG. The entire solution continued
stirring under inert atmosphere at 40oC for 48h.

Product was observed by TLC and

confirmation of crude product was observed by ESI-MS. ESI-MS of C39H43N5O7: m/z Calcd.
693.79 [M+Na]+, found 716.5086.
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Figure 3.15 ESI-MS of 3-4.
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CN
CN

Synthesis of (E)-2-cyano-3-(4-nitrophenyl)acrylamide (3-5): To a RBF was added 3-1 (1.133
g, 0.010 mol) and 2-cyanoacetamide (0.631 g, 0.010 mol) and stirred/crushed very well to
ensure homogeneity. Urea (0.450 g, 0.001 mol) was added as a catalyst for the reaction. This
mixture was kept at 100oC with constant stirring for 10 minutes. The reaction mixture was
cooled to room temperature and solidification was observed. The resulting solid was washed
with cold water (3x) to remove the urea catalyst, then dried to obtain the product as a yellow
solid in 70% yield (1.5254 g). 1H-NMR (250 MHz, methanol-d4, ", ppm): 8.41 (2H, d, J=12
Hz), 8.29 (1H, s), 8.13 (2H, d, J=12 Hz), 8.05 (2H, s).
Synthesis of (E)-3-(4-aminophenyl)-2-cyanoacrylamide (3-6): Compound 3-5 (0.300 g, 1.381
mmol) and anhydrous tin (II) chloride (0.916 g, 4.835 mmol) were combined in EtOH and
stirred. HCl (0.691 mL, 28.030 mmol) was added slowly over 10 minutes. The entire mixture
was stirred under reflux for 12 h. The reaction was monitored by TLC. Excess EtOH was
evaporated. The remaining solution was poured into water and made basic with 15% NaOH
solution. A yellow-orange precipitate formed that was filtered off, washed with water and
recrystallized from EtOH. The yellow-orange solid was placed in an oven (50oC) overnight to
yield 60% (0.1551 g) of yellow solid. 1H-NMR (250 MHz, methanol-d4, ", ppm): 7.88 (1H, s),
7.71 (2H, d, J=8.7 Hz), 6.63 (2H, d, J=8.7 Hz), 6.39 (2H, s).
Synthesis of Malononitrile-terminated Pegylated Porphyrin (3-7): Compound 2-14 (0.020 g,
0.0279 mmol) was treated with 1 equivalent of Et3N (0.00286 g, 0.0279 mmol) and 1.5
equivalents of bromotrimethylsilyl bromide (0.006414 g, 0.0418 mmol) in dry DCM at 0oC
under inert atmosphere. Reaction was completed in 2 hours, as observed by TLC. Reaction
mixture temperature was brought down to -78oC and left at this temperature for 5 minutes to
ensure this temperature. DIBAL-H (0.00397 g, 0.0279 mmol) was added and reaction was
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monitored every 10 minutes. Optimum reaction time was 3 minutes. After reaction completion,
reaction was brought to 0oC and quenched with EtOAc (10 mL). Celite was added to mixture
(to remove unreacted metal), then sodium sulfate (to remove residual water). Reaction mixture
was warmed to room temperature. Additional EtOAc was added. Celite and sodium sulfate
were filtered. Solvent was removed by vacuum. Reaction was extracted with water (3 x 25 mL),
organic layers collected, and solvent was evaporated. HRMS-ESI m/z 952.37 [M+H]+,
calculated for C59H50N8O5 951.08. 1H NMR (400 MHz, CDCl3, ", ppm): -2.79 (s, 2H), 2.16
(m, 2H), 3.59-3.60 (m, 10H), 7.26 (s, 1H), 7.61 (t, 1H, J=4.0 Hz), 7.71-7.76 (m, 9H, m-, p-PhH), 8.20-8.30 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.30-8.31 (d, 2H, o-Ar-H, J=5.96 Hz), 8.79-8.8 (s,
2H, #-H, J=4.8 Hz), 8.84 ((broad), m, 6H, #-H).
Synthesis of 6,7-dimethoxyquinasolin-4(3H)-one (3-9): 2-amino-4,5-dimethoxybenzoic acid
(200 mg, 1.014 mmol) and formamidine hydrochloride (136.67 mg, 1.697 mmol) were ground
together in a small round bottom flask (50 mL) then spread evenly on the bottom of the flask.
The flask was purged with N2 gas under an air condenser for 30 minutes. The mixture was then
heated to 210oC for 15 minutes. Solidification was observed during heating. After cooling to
80oC, the mixture was sonicated with 0.33M NaOH. A purple-gray solid was collected on filter
paper using a water aspirator, then washed an additional 3 times with water. The residue was
dried in an oven (70oC) for 8 hrs to obtain 70% yield of purple-grey solid. ESI-MS of
C10H10N2O3: m/z Calcd. 206.20 [M+H]+, found 207.08. 1H-NMR (250 MHz, DMSO-d7, ",
ppm): 7.97 (1H, s), 7.43 (1H, s), 7.12 (1H, s), 3.89 (6H, s).
Synthesis of 4-chloro-6,7-dimethoxyquinazoline (3-10): Oxalyl chloride (559.4 µL, 6.412
mmol) and 1,2-dichloroethane (2 mL) were stirred in a capped vial for 10 minutes to ensure
homogeneity under N2 gas at room temperature. DMF (537 µL, 6.412 mmol) was added slowly
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to the vial. After gas evolution ceased, the vial solution was added to a stirring solution of 3-9
(0.885 g, 4.275 mmol) in 1,2-dichloroethane (20 mL) and refluxed for 4h. The reaction was
allowed to cool to 25oC then quenched with 0.5M Na2HPO4. This mixture was then cooled on
an ice bath for 3h. The purple-gray solid was collected using a vacuum filtration, washed with
water (3x), and left for 1 hour for initial drying. The residue was dried in an oven (70oC) for 8
hrs to obtain 97% yield (0.9346 g) of purple-grey solid. ESI-MS of C10H9ClN2O2: m/z Calcd.
224.64 [M+H]+, found 225.0412. 1H-NMR (250 MHz, DMSO-d7, ", ppm): 9.93 (1H, s), 7.97
(1H, s), 7.62 (1H, s), 7.16 (1H, s), 4.08 (6H, s).

Synthesis of N1-(tert-butyl)-N2-(6,7-dimethoxyquinazolin-4-yl)ethane-1,2-diamine (3-11): In
a small RBF, 3-10 (0.0270 g, 0.120 mmol), N-Boc-ethylenediamine (0.0074 mL, 0.117 mmol),
and K2CO3 (0.016 g, 0.120 mmol) under N2 gas at 60oC. The mixture was sonicated to ensure
solubility. The mixture was stirred for 48h to give desired product. ESI-MS of C16H24N4O2:
m/z Calcd. 304.39 [M+H]+, found 305.1868.

N1-(6,7-dimethoxyquinazolin-4-yl)ethane-1,2-diamine (3-12): Compound 3-10 (0.099 g,
0.000445 mol) and K2CO3 (0.100 g, 0.0447 mmol) were stirred vigorously in DMF (30 mL) for
0.5 h under N2 gas at 60oC. “Reagent Plus”-Ethylenediamine (0.00308 mL, 0.000461 mol) was
added and a brown solid product formed within 0.5 h, but maximum yield was obtained in 1 h.
Solvent was evaporated. Product was dissolved in 20% H2O/80% MeOH and filtered through a
Millipore PTFE Hydrophobic Millex-FG 0.2 µm filter unit. Product was purified by reversephase HPLC (20% H2O to 50% H2O gradient) on a Waters Atlantis T3 5 mm, 4.6x250mm
analytical column (C18) to obtain solvent gradient, then was subjected to preparative HPLC
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using Waters X-BridgeTM BEH300 Prep C18 5 µm, 10x250mm column, to yield 16%-30% of
product, in 99% purity. Rt = 6.36 minutes. HRMS ESI of C12H16N4O2: m/z Calcd. 248.28
[M+H]+, found 249.1443. 1H-NMR (400 MHz, DMSO-d7, ", ppm): 8.05 (1H, s), 7.43 (1H, s),
7.12 (1H, s), 3.89 (3H, s), 3.86 (3H, s).

Figure 3.16. ESI-MS of 3-11.
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Figure 3.17. ESI-MS of 3-12.

Figure 3.18. Analytical HPLC Chromatogram for 3-12.
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Figure 3.19. 1H NMR of Compound 3-12.
Synthesis of Porphyrin-Conjugate (3-13): Porphyrin 2-14 (0.00431 g, 0.00470 mmol) was
dissolved in peptide synthesis grade DMF (0.5 mL) under N2. DIEA (40 equiv) was added to the
mixture and stirred for 1 h. Coupling agents HOBt (0.000634 g, 0.00470 mmol) and TBTU
(0.00151 g, 0.00470 mmol) were added to the flask. After 1 h of stirring, quinazoline 3-12
(0.000528 g, 0.00234 mmol) was added. The mixture stirred at 50oCfor 48 h in the dark under
N2.Purification was conducted by! "ormal-phase chromatography using a gradient (EtAc
(80%)/DCM (10%)/MeOH (10%), EtAc (70%)/iPrOH (30%), EtAc (60%)/iPrOH (40%),
EtAc/CHCl3/MeOH

(1:1:0.1),

EtAc/CHCl3/MeOH/iPrOH

(1:1:0.1:0.1),

EtAc/CHCl3/MeOH/iPrOH (1:1:0.1:0.2)) achieved the product in 16% yield (0.00045 g) of a
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purple solid. ESI-MS of C68H64N10O8: m/z Calcd. 1149.30 [M+H]+, found 1150.3072; [M+K],
found 1188.3276. 1H-NMR (400 MHz, chloroform-d, ", ppm): 0.07 (s, 2 H) 4.08 - 4.11 (m, 6 H)
4.11 - 4.16 (m, 18 H) 6.72 - 6.89 (m, 14 H) 7.00 (s, 2 H) 7.06 - 7.21 (m, 13 H) 7.52 (s, 3 H). $
(nm) (%, Lmol!1 cm!1): 305.31 nm (2.223E+05) (Quinazoline); 424.19 nm (2.304E+05) (Soret
band).
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Figure 3.20. ESI-MS of 3-13.
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Figure 3.21. 1H NMR of Compound 3-12.
Synthesis of 7-nitroquinazolin-4(3H)-one (3-15): 2-amino-4-nitrobenzoic acid (200 mg, 1.010
mmol) and formamidine hydrochloride (357.08 mg, 4.43 mmol) were ground together in a small
round bottom flask (50 mL) then spread evenly on the bottom of the flask. The flask was
purged with N2 gas under an air condenser for 30 minutes. The mixture was then heated to
210oC for 15 minutes. Solidification was observed during heating. After cooling to 80oC, the
mixture was sonicated with 0.33M NaOH. A bright yellow solid was collected on filter paper
using a water aspirator, then washed an additional 3 times with water. The residue was dried in
an oven (70oC) for 8 hrs to obtain 60% yield of product. Proton NMR was used to confirm
structure of product. Literature ppm values correspond to the values obtained here.4b, 26
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Synthesis of 4-chloro-7-nitroquinazoline (3-16): Oxalyl chloride (559.4 µL, 6.412 mmol) and
1,2-dichloroethane (2 mL) were stirred in a capped vial for 10 minutes to ensure homogeneity
under N2 gas at room temperature. DMF (537 µL, 6.412 mmol) was added slowly to the vial.
After gas evolution ceased, the vial solution was added to a stirring solution of 3-15 (0.885 g,
4.275 mmol) in 1,2-dichloroethane (20 mL) and refluxed for 4h. The reaction was allowed to
cool to 25oC then quenched with 0.5M Na2HPO4. This mixture was then cooled on an ice bath
for 3h. The yellow solid was collected using a vacuum filtration, washed with water (3x), and
left for 1 hour for initial drying. The residue was dried in an oven (70oC) for 8 hrs to obtain
50% yield of yellow-orange solid. Proton NMR was used to confirm structure of product.
Literature ppm values correspond to the values obtained here.4b, 26
Synthesis of N-(3-bromophenyl)-7-nitroquinazolin-4-amine (3-17): In 20 mL of iPrOH was
added quinazoline 3-16 (0.050g, 0.239 mmol) and Cs2CO3 (0.155g, 0.477 mmol) for 0.5 h. 4bromoaniline (0.0821g, 0.477 mmol) was added to the solution. The mixture was refluxed for
1h then removed from heat to cool to RT. The solution was concentrated, then water was added
until the mixture was cloudy. A precipitate formed that was then filtered and dried overnight to
give 40% of desired product. Proton NMR was used to confirm structure of product. Literature
ppm values correspond to the values obtained here.4b, 26
Synthesis of N4-(3-bromophenyl)quinazoline-4,7-diamine (3-18): Compound 3-17 (0.020 g,
0.578 mmol) and anhydrous tin (II) chloride (0.384 g, 2.020 mmol) were combined in EtOH
and stirred. HCl (0.319 g, 8.860 mmol) was added slowly over 10 minutes. The entire mixture
was stirred under reflux for 16 h. The reaction was monitored by TLC. Excess EtOH was
evaporated. The remaining solution was poured into water and made basic with 15% NaOH
solution. A light yellow precipitate formed that was filtered off and washed with water (3x).
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The solid was placed in an oven overnight to yield 42% of product. Proton NMR was used to
confirm structure of product. Literature ppm values correspond to the values obtained here.4b, 26
Computational Experimentation: Molecular mechanics calculations at the MM2 level were
performed using MacroModel and/or Chem Bio 3D running on a Dell Linux Workstation
equipped with two dual-core Xeon processors or a Gateway Windows Workstation equipped
with Intel dual-core processor. The geometry of these conformers was optimized and energy
calculations were performed on the compounds in vacuum. Molecular docking was performed
using AutoDock Vina on a Gateway Windows Workstation equipped with Intel dual-core
processor. The structures of the conjugates were optimized using the aforementioned MM2
method and the receptor (PDB ID: 1M17) was used as is, with deletion of the bound ligand
(erlotinib, Figure 3.9 a) via AutoDockTools.23 Output files were prepared using a procedure by
Trott, et al.21 A test calculation was conducted to confirm accuracy of the “search space.”
The first calculation contained these parameters:
Total grid points/map: 15525
Points in each dimension: x – 24, y – 24, z – 26
Spacing: 1.000 (angstroms)
Center grid box: x – 20.0, y - -5.0, z – 50.0
The second calculation contained:
Total grid points/map: 16675
Points in each dimension: x – 28, y – 24, z – 22
Spacing: 1.000 (angstroms)
Center grid box: x – 30.0, y - 6.0, z – 60.0
The second calculation parameters gave the most accurate results for the test calculation of the
erlotinib ligand in the ATP site of EGFR. Those criteria were used for the additional porphyrin-
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tyrphostin conjugate docking calculations. All porphyrin-tyrphostin conjugates were energy
minimized (MM2) before docking. Visualization of bound porphyrin-tyrphostin conjugate and
receptor were conducted in PyMol using residue labels and the “measurement wizard” option in
PyMol.24
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CHAPTER 4. SYNTHESIS, CHARACTERIZATION, AND COMPUTATIONAL
STUDIES OF PORPHYRIN-PEPTIDIC CONJUGATES FOR USE AS IN VIVO
IMAGING AGENTS FOR COLORECTAL CANCERS (CRC)
4.1 Introduction
Previously, in Chapters 1-3, porphyrins and their importance for medicinal applications
was discussed in great detail. This Chapter, however, will primarily discuss the conjugation of
porphyrins to peptides, and to a protein, and investigate their potential as in vivo imaging agents.
The comparison of non-peptidic porphyrin conjugates, as discussed in Chapter 3, with the
peptidic conjugates in this Chapter is of great importance – each has specific advantages and
disadvantages. In general, peptides and/or proteins tend to undergo proteolytic degradation by
various proteases in cells, causing them to dissociate, therefore decreasing their efficacy as
pharmaceutical agents.1 A tyrphostin does not have the same dissociative properties, rather, they
present a higher structural stability, as they do not have the same labile peptidic bonds.
However, tyrphostins are much more hydrophobic, therefore potentially increasing the overall
aggregation of the porphyrin and, tend to show increased toxicity.2 Peptides and proteins, even
when conjugated to porphyrins, have proven to have high cellular uptake and low dark
cytotoxicity.3 In consideration of these characteristics of peptides and tyrphostins, the efficacy of
the synthesized porphyrin conjugates can be compared to find the most favored porphyrin
conjugate.
4.1.1 Prior Synthesis of Porphyrin-Peptide Conjugates
The Vicente Laboratory and others have investigated the!synthesis, characterization, and
medicinal application of porphyrin-peptide conjugates.3b-k, 4 In general, the porphyrin molecules
contain terminal amino or carboxyl functionalities that are then conjugated to the free N- or Cterminus of selected peptides.3-5 The process of conjugating the porphyrin to the peptide consists
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of several steps; the protocols have been optimized to improve yields of the conjugates. The
amino- or carboxyl-terminated porphyrin can be conjugated using solution-phase or solid-phase
conjugation procedures primarily with the following coupling agents in DIEA and DMF: HOBt
and TBTU. The porphyrins were first conjugated to water-soluble molecules, such as a PEG,
then, using the aforementioned coupling agents, the molecule was coupled to the selected
peptides, such as cell penetrating peptides (CPP), a nuclear localization signal (NLS), or
bifunctional CPP-NLS or NLS-CPP sequences up to thirty amino acids (Figure 4.1).3
In regard to cellular uptake, Dr. Vicente’s group found that conjugating a peptide, with an
affinity for cancer cells, did increase the cell targeting and uptake of the porphyrin-based
molecule. In fact, the peptide and PEG groups work concurrently to improve the water-solubility
of the molecule, thereby decreasing aggregation, and subsequently increasing uptake of these
conjugates in cells. The PEG also was shown to inhibit steric and electrostatic interactions
between the peptide and the porphyrin, which would also increase cellular uptake. We have
been able to theoretically verify the structure of these conjugates using computational
chemistry.3c, 3j Dark cytotoxicity was also determined during in vitro studies. Molecules bearing
the HIV-1 TAT sequence, as referenced in Figure 4.1, were tested against FDA approved
Photofrin®.3j

This conjugate was less toxic than Photofrin®.3c,

3j

These results suggest the

potential of these conjugates as improved medicinal agents. Intracellular localization of the
porphyrin-peptide conjugates were analyzed using fluorescence microscopy. The porphyrinpeptide conjugates localized in several organelles, including the lysosomes3j and the endoplasmic
reticulum (ER), for example.3 Results indicate that cellular uptake, phototoxicity, and cellular
localization of porphyrin-peptide conjugates depends on both the structure of the porphyrin (with
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OH
O

or without a PEG linker) and the nature of the peptide sequence.3b-i, 3k
4.1.2 Conjugation of Porphyrin to Bovine Serum Albumin (BSA) Protein
The use of proteins as primary medicinal agents has been of great importance in recent
years. However, there are many issues with the use of proteins in pharmaceuticals. First,
proteins are extremely large macromolecules, usually consisting of hundreds of amino acids
which have varying folding attributes, such as some regions primarily existing as !-sheets, "helices, and often, have random coil conformations.6 Because of the differences in potential
structure, proteins cannot usually be characterized by NMR; proteins are characterized by
sequencing, circular dichroism (CD) and mass spectrometry (MS), therefore, unless the structure
has been obtained from protein crystallography, the molecule cannot be fully realized.
Additionally, there is the issue of potential aggregation, thereby decreasing the medicinal
efficacy of the protein. As discussed in Chapters 1 and 2, porphyrins are known for their
aggregation in solution. Other issues affect protein stability, such as temperature, pH,
concentration, and their solution environments.6 All of these matters may contribute to their
degradation – an issue that is of extreme importance for their therapeutic relevance. For this
project, however, conjugating a protein, such as BSA or EGF, to a porphyrin would provide for a
method to compare the results of smaller peptidic conjugates to the larger protein conjugates.
BSA, a protein used frequently in medicinal applications, was used in this project to determine
the degree of non-covalently bound (NCB) porphyrin in our experiments.4b BSA is a large
protein consisting of 607 amino acid residues, with a molecular weight of 69,293 Da and varies
in structure depending on its environment.7 In any case, this protein was an essential piece of
determining the potential of NCB porphyrin in our conjugates.
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4.1.3 Types of Peptidic Molecules Utilized in This Project
The peptidic ligands used in this work, LARLLT8 (6-mer, EGFR L1) and
(G)YHWYGYTPQNVI9 (13-mer, EGFR L2), were shown to have high affinity for EGFR in
vitro and in vivo. Two methods were employed to discover these ligands and their affinity for the
receptor. The 6-mer was found by using computational chemistry software, AutoDOCK.10 The
computations in this study focused on one ligand-one enzyme binding. This was one of the
ligands with the lowest binding energy suggesting that the ligand is one of the most stable for an
EGFR “active” site in the receptor’s inactive conformation. In these studies, a different site was
chosen than the typical EGF binding site. In fact, a site in Domain I of EGFR was chosen,
consisting of these amino acids: Gln164, Cys163, Ser162, Glu110, Glu073, and Arg074. From
these results, a library of peptides were designed to be complimentary to these amino acids.11
Conversely, the 12-mer was found using a “phage display” approach, a technique in which a
library of peptides were expressed on the outside of a phage virion, and genetic material
encoding each peptide is contained within the phage. Essentially, a connection between the
peptide sequence and the DNA is formed. Then, by using an in vitro selection process called
panning, each phage, which contains a different peptide sequence, is exposed to a plate
containing the target of interest and any phage that does not bind is washed away. Because
computational calculations were not conducted on this peptide, the exact binding region was not
determined. However, the experiment entailed the competitive inhibition of a high concentration
of EGF (0.5 mM) using this peptide. Since this 12-mer inhibited binding of EGF, it is clear that
this peptide most likely binds within the EGFR active site, which contains EGF. Therefore, its
size, structural characteristics, and electronic behavior are favorable for the EGF site. If EGF can
be inhibited, then this can also be used for treatment clearly preventing the over-expression of
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the receptor. The EGFR L1 and EGFR L2 peptides were exposed to EGFR over-expressing cells
in vitro and to H1299 xenograft mouse models in vivo.8-9 For each peptide (EGFR L1 and EGFR
L2) there was high internalization of the peptides and low cytotoxicity.8-9 Therefore, we believe
that these peptides, when conjugated to porphyrins, will provide with a feasible mechanism in
the development of in vivo imaging agents.
4.2 Synthesis of Porphyrin-Peptide Conjugates Using Peptides with Affinity for EGFR
4.2.1 Synthesis of Peptides, EGFR L1 and EGFR L2
The peptides mentioned in the previous section, EGFR L1 and EGFR L2, were synthesized
using Fmoc-solid phase peptide synthesis, or SPPS, at the LSU Protein Facility. While solid
supports vary, the PAL-PEG-PS resin was used to achieve amide C-terminus, which provides
stability for the peptide. This resin is used frequently in peptide synthesis. The structure of the
resin and peptides used are shown in Figure 4.2. The peptides were cleaved from the resin using
an acidic “cleavage cocktail” (TFA/liquefied phenol/TIS/H2O) and purified by RP-HPLC using a
gradient of water and acetonitrile in 1% TFA before conjugation to porphyrins. The relative
retention times for EGFR L1 and EGFR L2 were 17 minutes and 23 minutes, respectively, which
is also a measure of hydrophobic character of the peptides. The column used for purification
was a Waters XBridgeTM C18 (analytical and preparative).
The structures of these peptides vary greatly. EGFR L1 is shorter in length, yet its make
up is polar, due to the presence of arginine and threonine residues. EGFR L1 D1 is in similar
length, but the peptide is stabilized by the N-methylation on its N-terminus. N-methylation of
peptides has proven to decrease the amount of proteolytic degradation in cells.12 While N-methyl
amino acids are not commonly found in nature, alkylation of the N-terminus increases
lipophilicity of the peptide, thereby increasing the peptide’s solubility in non-aqueous solvents,
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but also, similar to porphyrins alone, can improve the permeability of the peptide for the area of
choice; in this case, cells which greatly over-express EGFR.12 Using an N-methylated peptide
should help to increase the affinity of the porphyrin-peptide conjugate as well as increase the
stability of the porphyrin-peptide conjugate. Conversely, EGFR L2 is longer in length, yet is
more hydrophobic in nature compared to EGFR L1; the presence of larger tyrosine and
tryptophan residues contribute to this. EGFR L2 is also bulkier, presenting the issue of potential
pi-interactions with the porphyrin. EGFR L2, however, contains an additional glycine on its Nterminus and is therefore not sterically hindered at this position, which is where the carboxylic
acid-terminated TPP derivative will be conjugated. EGFR L1 does not contain a glycine at its Nterminus, rather, it contains a lysine side chain. The lysine at the N-terminal end of EGFR L1 as
well as the N-methylated EGFR L1 indicate these peptides are more sterically hindered at their
N-terminal ends, where the porphyrin will be conjugated, compared to the N-terminus of EGFR
L2. Another difference between EGFR L1 and EGFR L2 are their charges at physiological pH.
EGFR L1 contains an arginine (pKa ~ 12.5), which an amino acid that is protonated at
physiological pH.3c EGFR L2, however, does not contain any charged amino acids and is
therefore a neutral peptide at physiological pH. The positive charge on the arginine guanidinium
group is delocalized and can form multiple hydrogen bonds.3c,

3e, 13

Also, the arginine

guanidinium group is planar and can to bind to negatively charged species (e.g. phosphates).3c, 3e,
13

It has been reported that arginine-rich peptides have a unique ability to cross cellular

membranes – an important characteristic for medicinal agents.13 Arginine-rich, cationic
porphyrin-peptide conjugates (as shown in Figure 4.1) have been observed to have rapid cellular
uptake, as well as high levels of cellular uptake, compared to other porphyrin-peptide
conjugates.3c, 3e The high cellular uptake levels of the arginine-rich, cationic porphyrin-peptide
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conjugate was attributed to the structure of the positively charged guanidinium group, due to its
charge, and its planarity, increasing its ability to form hydrogen bonds with negatively charged
species.3c, 3e
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NH2

4.2.2 Synthesis of Porphyrin-Peptide Conjugates
The synthesis of porphyrin-EGFR peptide conjugates was investigated using several different
methods. As shown in Figure 4.1, the porphyrin-peptide conjugates were synthesised consisted
of mostly using SPS (Solid Phase Synthesis) with the mono-amino porphyrin, 2-3 or the monocarboxylic acid terminated porphyrin 2-5. After introduction of a spacer and/or a PEG linker, the
peptides were conjugated by SPS or SNS (SolutioN phase Synthesis) to the porphyrin. The the
best method for conjugating the peptides to 2-5 or 2-7 was observed to SNS. Additionally, the
coupling conditions varied for these conjugates. Previously, it was reported that the solid phase
conjugations took place in HOBt and TBTU, but in this case, the solution phase conjugations
gave low yields using these agents, and rather, HOBt and HBTU were used to achieve optimal
results. In fact, several coupling agents and reaction conditions were investigated. Table 4.1
illustrates the different types of coupling conditions used for this experimentation. The best
reagent conditions are highlighted in gray. The Scheme for the synthesis of these molecules is
shown in Scheme 4.1.
As stated above, the coupling agents varied. Various coupling agents were used in an
attempt to optimize yields. These reagents are: HOBt/TBTU, HOBt/HBTU, and PyAOP. The
structures of these coupling agents are shown in Figure 4.3. The structures of each coupling
agent are very similar. HOBt is added to coupling conditions to prevent racemization.14 The
benzotriazole ester intermediate (-OBt) is less reactive than the O-acylisourea, therefore
preventing additional side reactions.14 Usually, a “preactivation” step is used to prepare the
carboxylic acid for coupling the N-terminal end of an amino acid.14a The base, DIEA, was added
to the carboxylic acid porphyrin (2-4, 2-7, or 2-14) and allowed to react for several minutes (10
minutes – 1.0 h), after which HOBt and TBTU/HBTU were added to the reaction mixture. The
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amine terminated spacer, PEG, and/or peptide were added, and the reaction continued, usually
for at least 48 h. TBTU was developed first as an improvement upon traditional EDCI and DCC
couplings, and it was proven to be a stronger coupling agent.14 HBTU, a close derivative, also
illustrates high coupling yields, upwards of 95% in many cases.14a HBTU, however, produces
toxic by-products.15 Previous work states that the counterions of TBTU and HBTU, BF4- and
PF6-, respectively, do not have any effect on the high coupling rate or the decrease in
racemization in peptide couplings.16 PyAOP, conversely, is a coupling reagent of the
“phosphonium” family, proven to be an even stronger coupling agent than TBTU or HBTU.14a
In fact, PyAOP is more typically effective than any OBt analog, and can be used alone, without
any additives.14a The differences in yields of peptide porphyrin conjugates, 4-5, 4-6, 4-7, 4-8, 49, and 4-10 using TBTU, HBTU, or PyAOP are not solely dependent on the structure of these
coupling agents.
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P

N

BF4

N

PF6

PyAOP

HBTU

Figure 4.3. Coupling Agents Used in this Project.
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Table 4.1 Synthesis Attempts for This Series of Porphyrin-Peptide Conjugates.
Compound

Phase of
Synthesis

Coupling
Conditions

Solvents

Conditions,
Duration

Approximate
Yield

SPS

HOBt/TBTU

DMF

6 equiv DIEA, 4872 h, RT

<1%

SNS

HOBt/HBTU

DMF

6 equiv DIEA, 48
h, RT

19%-21%

SPS

HOBt/TBTU

DMF

6 equiv DIEA, 72
h, RT

<1%

SNS

HOBt/HBTU

DMF

6 equiv DIEA, 36
h, RT

34%

SNS

HOBT/TBTU

DMF

6 equiv, DIEA, 48
h -72 h, RT

<1%

SNS

HOBt/HBTU

DMF

6 equiv DIEA, 36
h, RT

5%

SPS

HOBt/TBTU

DMF

10 equiv DIEA, 5
d, RT

59%

SPS

HOBt/TBTU

DMF

6 equiv DIEA, 36
h, RT

<1%

SNS

HOBt/TBTU

DMF

6 equiv DIEA, 36
h, RT

<1%

SNS

HOBt/TBTU

DCM

6 equiv DIEA, 36
h, RT

<5%

SNS

HOBt/HBTU

DMF

10 equiv DIEA,
48 h, RT

10%-40%

SNS

PyAOP

DMF

10 equiv DIEA,
72 h, RT

<1%

SPS

HOBt/TBTU

DMF

6 equiv DIEA, 48
h, RT

10%

EGFR L1 NL
(4-5)

EGFR L1 3
PEG (4-7)

EGFR L1 D1
3PEG (4-8)

EGFR L2 NL
(4-6)

EGFR L2
3PEG (4-9)

EGFR L2
NL-TPP-NH2
(4-10)

Legend: SPS – Solid Phase Synthesis; SNS – SolutioN phase Synthesis; NL – “no PEG linker”
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CHO

1. BF3-Et2O
2. DDQ, DCM
3. NaOH, THF/H2O

CHO

HOBt/TBTU, DIEA, DMF
NH

(9%)

N
H

HN

N

CO2Me

N

O
OH

O

H2N

NH

RT, 48 h
(90%)

N

NH

RT, 48 h
(99%)

N

N

O

HN

OH
O

HN

O

2-6

1. HOBt/TBTU,
DIEA, DMF
2. NH2-3PEG-tBu
(Structure 2.3a)

HN

O
HN
O

2-5

TFA/DCM

N

O

RT, 48 h
(61%)

NH

N

O

N

HN

HN
NH
O
O

2-7
2-13
Method A:
1. HOBt/HBTU, DIEA, DMF
2. Peptide (R)
RT, 48 h
(19% - 21%)

NH

N

Method B:
1. HOBt/TBTU, DIEA, DMF
2. Peptidyl Resin (R)
RT, 72 h
(59%)

N

1. TFA/DCM
RT, 4h
(99%)

O

O

NH

N

O

N

HN

HN

HN

HN

O R

O

2. HOBt/HBTU, DIEA, DMF
3. Peptide (R)
RT, 48 h
(5% - 40%)

O

O
O

NH
O
O
O

4-5, 4-6

2-14, 4-7, 4-8, 4-9

4-5: R = LARLLT (EGFR L1)
4-6: R = GYHWYGYTPQNVI (EGFR L2)

O

2-14: R = OH
4-7: R = EGFR L1
4-8: R = EGFR L1 D1
4-9: R = EGFR L2

O R

Scheme 4.1. (a) Synthesis of Porphyrin-Peptide Conjugates 4-5 through 4-9.
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NH2

(98%)
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N
HN

O
N
H

O

OH

Method B:
1. HOBt/TBTU, DIEA, DMF
2. Peptidyl Resin (R)
RT, 72 h
(10%)

2-4

O
NH
N

N
HN

4-10
4-10: R = EGFR L2

Scheme 4.1. (Continued)
(b) Synthesis of Porphyrin-Peptide Conjugate 4-10.
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4.2.3 Preliminary Cell Studies for Porphyrin-Peptide Conjugates
To investigate the biological properties of our conjugates, we subjected several
conjugates to cell assays for cytotoxicity and uptake. Porphyrin-peptide conjugates 4-5, 4-7, and
4-9 were subjected to HEp2 cells (a human epidermoid carcinoma, and larynx cancer cell line) to
observe cellular uptake levels.17 These results are shown in Figure 4.4. The cellular uptake data
shows that each porphyrin-peptide conjugate 4-5, 4-7, and 4-9 are taken into HEp2 cells more
than porphyrin 2-14, which was used as a control. Conjugate 4-7, however, has the highest
cellular uptake. This conjugate contains the EGFR L1 peptide, which has an arginine residue.
This result is in agreement with literature data; the positively charged peptide is rapidly taken
into cells in comparison to peptides that do not contain an arginine.3c, 3e, 13a, b Similarly, conjugate
4-5 also contains the EGFR L1 peptide and has higher levels of cellular uptake than the
conjugate 4-9, which has EGFR L2. EGFR L2 is neutral at physiological pH and is expected to
have lower cellular uptake values in comparison to EGFR L1. Conjugate 4-7 contains a PEG
linker, which has been shown in previous investigations to increase cellular uptake of porphyrinpeptide conjugates.3j, k These results suggest that the nature of the EGFR L1 peptide, in particular
the protonated arginine in the peptide sequence, as well as the presence of a PEG linker, are
important for cellular uptake.
Phototoxicity studies were carried out in human HEp2 cells with compounds 2-14, 4-5,
and 4-7. Porphyrin conjugates can show high phototoxicity after activation of the porphyrin
macrocycle with light due to the production of singlet oxygen and other cytotoxic species that
destroy tumor cells.3b, 18 For in vivo imaging, increased phototoxicity levels will decrease the
effectiveness of this technique.19 Figure 4.5 shows the results of phototoxicity of 2-14, 4-5, and
4-7 in human HEp2 cells using 1 J/cm2 light dose. Conjugate 4-7, was illustrated in this work to
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Figure 4.4. Uptake of Porphyrin 2-14 and Porphyrin-Peptide Conjugates 4-5, 4-7, and
4-9 in Human HEp2 Cells at a 10 µM concentration (for each conjugate).
have the highest phototoxicity levels compared to conjugate 4-5 and the control, porphyrin 2-14.
Conjugate 4-7 contains the PEG linker with EGFR L1 peptide, while conjugate 4-5 contains the
EGFR L1 peptide, but does not contain a PEG. Conjugate 4-5, therefore, may be effective as an
in vivo imaging agent due to its increased cellular uptake and low phototoxicity levels.
In another preliminary cellular study, porphyrin-peptide conjugates 4-5, 4-7, and 4-9
were taken up by COS7 cells, a kidney cell line from the African green monkey species that does
not over-express EGFR,20 and A431 cells, a human carcinoma cell line that greatly overexpresses EGFR on its cell surface; the receptor is found at 3x106 per cell21 and makes up
approximately 0.2% of the carcinoma proteins.21-22! The results of this study, obtained by Dr.
Inder Sehgal, are shown in Table 4.2. There is evidence that the conjugate that is most preferred
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Figure 4.5. Phototoxicity of Porphyrin 2-14, Conjugate 4-5, and Conjugate 4-7 in
Human HEp2 Cells Using a Cell Titer Blue Assay and a Light Dose of 1 J/cm2.

for the A431 cells, or the conjugate with the most affinity for EGFR, is conjugate 4-9, which has
the EGFR L2 peptide. The primary goal of these syntheses is to develop a porphyrin-peptide
conjugate that has an affinity for EGFR, and this data suggests that the porphyrin-peptide
conjugate that has a higher affinity for EGFR is 4-9. This is a promising result for our studies,
although the fluorescence values seemed lower than anticipated. While the porphyrin-peptide
conjugates 4-5, 4-7, and 4-9 have higher fluorescence levels in the COS7 cell line, the EGFR L2based porphyrin conjugate 4-9 maintains a high fluorescence intensity in both the COS7 cells
and in A431 cells.
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a - Net mean [and standard deviation] of pixel intensities taken
from a histogram of the bitmap image of cells. Cells were
imaged for 2 seconds at 200x through a Texas Red filter set with
emission detection between 607 and 682 nm.
4.3. Synthesis of Porphyrin-BSA Conjugate
To further assess the activity of the porphyrin-peptide conjugates, we wanted to compare
the activity of these molecules with a porphyrin-EGF conjugate. As a model study, further
conjugation of the porphyrin with a protein, BSA, was used. EGF is more expensive and this
study served as a preliminary investigation. In order to determine the amount of NCB porphyrin
in a conjugation reaction with a protein, the pegylated porphyrin 2-14 was conjugated to BSA
protein. The amount of NCB porphyrin is impotrant to consider because the presence of NCB
porphyrin may decrease selectivity for porphyrin conjugates.4 This is of great importance
because we desire a highly specific porphyrin-peptide conjugate. The conjugation was carried
out by dissolving porphyrin 2-14 in DMF, then adding NHS and DCC to the reaction mixture.
This coupling reaction facilitates the formation of the NHS ester, which adds to the terminal
carboxylic acid of porphyrin 2-14. The reaction took place at room temperature for 12 h under
nitrogen. The reaction was monitored by TLC to ensure formation of the terminal NHS ester.
BSA protein was added to the reaction mixture and the conjugation of BSA to pegylated
porphyrin 2-14 was completed in 16 h. The porphyrin-protein conjugate was purified using a G!
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25 column, yielding enough porphyrin-protein conjugate 4-11 to prepare a 3.0 mg mL-1 solution
for gel electrophoresis. (The concentration is approximately 3.0 mg mL-1, which is standard,
according to the literature.4b) A description of the process of conjugation is noted in Figure 4.6.
The evidence of the product was observed by gel electrophoresis, which is illustrated by the
molecular weight at approximately 40kD. At the higher concentration, 3.0 mg mL-1 (Figure 4.6
a), NCB porphyrin is evident; there several bands below 10kD that illustrate the presence of
porphyrin that did not bind to BSA. However, at half of the initial concentration (1.5 mg mL-1,
Figure 4.6 b) the band of NCB porphyrin is not detected by the naked eye. This result is
important because porphyrins can be given to a patient at high concentrations, however, this
proves that if some of the porphyrin is ineffective or unspecific for the treatment, there is a loss
of efficacy for the agent. These results illustrate that NCB porphyrin could be an issue with
lowered specificity of our porphyrin-peptide conjugates.! In order to avoid NCB porphyrin,
processes, such as gel electrophoresis, must be implemented to remove the porphyrin. Future
studies will include quantifying the amount of NCB porphyrin observed by exising the NCB
porphyrin band from the gel and using an acetone precipitation method.4b
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1. NHS, DCC
DMF, RT, 12 h

NH

2. BSA (protein),
DMF, RT, 16 h

N
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O

O
O
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O
O

4-11
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O

O
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Scheme 4.2. Synthesis of Porphyrin-BSA Protein Conjugate.
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BSA

Figure 4.6. Gel Electrophoresis of Porphyrin-BSA Protein Conjugates.
(a)

(b)

Lanes
(a) 3.0 mg/mL Concentration
(1) BIO-RAD KaleidoscopeTM marker, (2) Pure BSA, (3) – (5) Porphyrin-BSA Conjugate,
(6) BIO-RAD Precision Plus ProteinTM marker, (7) Porphyrin-BSA Conjugate, (8) – (9)
Pure BSA.
(b) 1.5 mg/mL Concentration
(1) BIO-RAD KaleidoscopeTM marker, (2) Pure BSA, (3) – (5) Porphyrin-BSA Conjugate,
(6) BIO-RAD Precision Plus ProteinTM marker, (7) Porphyrin-BSA Conjugate, (8) Pure
BSA.
4.4. Selected Computational Studies of Porphyrin-Peptide Conjugates
Chapter 3 described several computational studies that would be relevant for this project.
This includes molecular mechanics and molecular docking studies on our porphyrin conjugates
using force fields to minimize energies/geometries and subsequently using a docking program to
observe potential binding of the conjugates. The same was done for the porphyrin-peptide
conjugates 4-5, 4-6, 4-7, and 4-9, for this project.
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4.4.1 MM2 Force Field Application for Porphyrin-Peptide Conjugates
Instead of using ab initio calculations for these porphyrin-peptide conjugates, energy and
geometries were minimized using the MM2 method (in vacuum), which is typically used for
large organic molecules.23 With this data, we observed important aspects about our porphyrinpeptide conjugates. It is obvious from Figure 4.7 that the conjugates that do not contain a PEG
have substantial electrostatic interactions with the porphyrin ring.

This was previously

confirmed in our group; the lack of PEG may hinder the peptide from solely arriving at the active
site of EGFR.3g, 3j Conversely, when the PEG was included in the computational studies, the
peptide is positioned away from the porphyrin, even in the case of EGFR L2, the peptide which
contains several hydrophobic, aromatic residues that may favor potential pi-interactions with the
porphyrin. It is evident, then, that having a PEG is geometrically favorable for these conjugates.
4.4.2 AutoDOCK4 for Porphyrin-Peptide Conjugates
In Chapters 1 and 3, a thorough discussion of docking software, AutoDOCK and
AutoDOCK Vina were described. The importance of using these applications is to observe
potential binding of a ligand within the active site of the molecule of interest.

With the

assistance of our collaborator, Dr. S. Jois at the University of Louisiana-Monroe, selected
conjugates were docked in AutoDOCK 4 using an active conformation of EGFR (PDB ID:
1M17). The docked conjugates 4-6 and 4-7 are shown in Figures 4.9 and 4.10. In each figure,
the porphyrin is outside of the active site, therefore suggesting that the porphyrin should not
interfere with the binding of the peptide to the receptor. This potential binding illustration is also
confirmed by the MM2 minimized geometry of conjugate 4-6 (Figure 4.7); although the overall
conjugate is more constrained, EGFR L2 still positions itself away from the porphyrin. Figure
4.8, on the other hand, confirms the importance of the PEG for these conjugates. As observed in
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Figure 4.8, EGFR L1 positions itself away from the porphyrin as well.

This is in great

comparison to the MM2 optimized geometry in Figure 4.7; the EGFR L1 porphyrin conjugate
without a PEG is highly constrained, and therefore, may not bind as efficiently as EGFR L2
without a PEG linker.

NH
N

N
HN

O
HN
O

O

R

R = LARLLT (EGFR L1)
4-5, 4-6 R = GYHWYGYTPQNVI (EGFR L2)

4-5

4-6
Figure 4.7. MM2 Energy Minimized Porphyrin-Peptide Conjugates 4-5 and 4-6.
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R = GYHWYGYTPQNVI (EGFR L2)
4-7, 4-9
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Figure 4.8. Selected MM2 Energy Minimized Porphyrin-Peptide Conjugates 4-7 and 4-9.
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Lowest Energy Conjugate
(Light Pink)
Figure 4.9
AutoDOCK Results for
Conjugate 4-6.
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O
R = GYHWYGYTPQNVI (EGFR L2)

4-6

Pictured: Eight (8) low energy docked
structures in EGF binding site on EGFR.

Lowest Energy Conjugate
(Red)
Figure 4.10
AutoDOCK Results
for Conjugate 4-7.
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R = LARLLT (EGFR L1)

4-7

Pictured: Three (3) low energy docked
structures at EGF binding site on EGFR.
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4.5 Conclusion
Porphyrin-peptide conjugates 4-5, 4-6, 4-7, 4-8, and 4-9 aim to improve the selective
delivery of fluorescent porphyrin molecules into CRC cells. The approach involves conjugation
of peptidic biomolecules, via a small peptide ligand to a porphyrin through a short glycine spacer
and/or a PEG linker. The two peptides used for conjugation were EGFR L1 and EGFR L2, which
differ in length of amino acids, hydrophobic character, and overall charge at physiological pH
(Figure 4.2). The method of conjugation of porphyrins 2-7 or 2-14 to EGFR L1, EGFR L1 D1,
or EGFR L2, gave the highest yields with SPS (Scheme 4.1). Preliminary cell studies illustrate
that in HEp2 cells, Conjugates bearing the EGFR L1 peptide have increased cellular uptake
compared to conjugate 4-9, which bears EGFR L2 (Figure 4.4). Additionally, conjugate 4-7 has
the highest cellular uptake, which may be due to the effect of the PEG linker and the cationic
peptide EGFR L1. Conversely, conjugate 4-7 has the highest phototoxicity levels in comparison
to conjugate 4-5 (Figure 4.4). The porphyrin-peptide conjugates designed in this study should
have lower phototoxicity levels for in vivo imaging application of CRC. This data suggests that
conjugate 4-7, due to its increased cellular uptake and low phototoxicity, has promising
characteristics for use as an in vivo imaging agent (Figure 4.5). However, the porphyrin-peptide
conjugates should also have a specific affinity for cells that over-express EGFR, like CRC.
Therefore, a study was carried out to assess the potential of conjugates 4-5, 4-7, and 4-9 to have
more affinity for A431 human carcinoma cells. In this study, conjugate 4-9 had the most affinity
for the A431 cells, evidenced by data in Table 4.2 and Figure 4.5. A porphyrin-BSA conjugate
was also synthesized to assess the amount of NCB porphyrin as a preliminary study.
Future work includes synthesizing a porphyrin-EGF conjugate to compare the effect of
this conjugate (through cellular uptake, phototoxicity, dark toxicity, and affinity for EGFR) to
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porphyrin-peptide ligands.

Lastly, porphyrin-peptide conjugates were subjected to

computational studies to assess their lowest energy conformations in the EGF binding site of
EGFR. These computational results suggest that porphyrin-peptide conjugates may bind at the
EGF binding site. In future work, yields of porphyrin-peptide conjugates will be optimized by
using the best conditions for conjugation. Conjugates will be purified by HPLC and
characterized by MS, UV-VIS, fluorescence, and NMR. Additionally, cell studies will be
conducted on all porphyrin-peptide conjugates again and subcellular localization of the
conjugates will be observed by fluorescence microscopy.

4.6 Experimental
Synthesis of Conjugate EGFR L1 NL (4-5): To a peptide synthesis vial was added porphyrin
2-7 (0.006 g, 0.00839 mmol) in peptide synthesis grade DMF (0.05 mL) and DIEA (6-10 equiv)
under inert atmosphere. The carboxylic acid was allowed to activate for 1 h at RT before adding
the coupling agents, HOBt (0.00133 g, 0.00839 mmol) and HBTU (0.00318 g, 0.00839 mmol).
The mixture stirred for an additional hour before adding purified EGFR L1 (0.0115 g, 0.0168
mmol). After 48 h, the crude conjugate was analyzed for its molecular weight by MALDI-MS.
The mixture was dried down under vacuum, filtered with a Millipore PTFE Hydrophobic MillexFG 0.2 µm filter unit, and subjected to RP-HPLC on a Waters XBridgeTM C18 column
(analytical and preparative) and using a water/acetonitrile gradient in 0.01% TFA (35%
H2O/65% ACN, 10% H2O/90% ACN, 35% H2O/65% ACN). The product was obtained in 21%
yield (95% purity). Rt = 5.06 minutes. MALDI-MS m/z 1325.789 [M-59]+ (Arginine related
ion), 1383.793 [M+H]+, calculated for C78H91N15O9 1382.65.
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!Figure 4.11. HRMS ESI of Conjugate 4-5.

Figure 4.12. Analytical HPLC Chromatogram of Conjugate 4-5.
Synthesis of Conjugate EGFR L2 NL (4-6): To a peptide synthesis vial was added porphyrin
2-7 (0.0930g, 0.00954 mmol) and DIEA (6 equiv) in 0.7 mL of peptide synthesis grade DMF.
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This mixture was stirred for 1 h before HOBt (0.00129 g, 0.00954 mmol) and TBTU (0.00306 g,
0.00954 mmol) were added to the vial and continued to stir for an additional hour.
Simultaneously, resin bound EGFR L2 (0.00760 g, 0.00477 mmol) was added to a peptide
synthesizer and swelled for 1 h in peptide synthesis grade DMF (1.5 mL). The activated
porphyrin and coupling agents were then transferred to the peptide synthesizer, purged with N2,
then capped tightly. The peptide synthesizer was then attached to the mechanical rotater and the
reaction continued for 48 h at RT. After reaction completion, excess unreacted porphyrin and
coupling agents were washed away using DMF, MeOH, and DCM until the supernatant was
colorless. After drying under vacuum aspirator for 0.5 h, the resin was subjected to a “cleavage
cocktail” consisting of 1 mL of TFA (88%), liquefied phenol (5%), triisopropylsilane (2%), and
water (5%) was added to the resin beads for 4 h. The resin was filtered and washed with TFA (3
x 1 mL). The green filtrates were combined, evaporated, and washed with cold anhydrous ether
until precipitation occurred. The precipitates were washed again with cold anhydrous ether and
dried under vacuum (or lyophilized in 50% H2O/50% ACN). A pre-filtration step was conducted
using a filtered with a Millipore PTFE Hydrophobic Millex-FG 0.2 µm filter unit. Purification
was conducted by RP-HPLC using a water/acetonitrile gradient in 0.01% TFA (10% H2O/90%
ACN, 90% H2O/10% ACN, 10% H2O/90% ACN) on a Waters XBridgeTM C18 Column to yield
59% of conjugate (89% purity). Rt = 30.13 minutes. MALDI-TOF-TOF m/z 1599.082 [MC94H83N15O11] (Porphyrin and peptide to amino acid residue #7 (tryptophan)), 1618.902 [(MC94H83N15O11)+H2O]. 2333.568 [M+K]+, 2295.057 [M+H]+, calculated for C124H132N24O21
2294.52.
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Figure 4.13. MALDI-TOF-TOF of Conjugate 4-6.

Figure 4.14. High Resolution MALDI of Conjugate 4-6.
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Figure 4.15. Analytical HPLC Chromatogram of Conjugate 4-6.
Synthesis of Conjugate EGFR L1 3-PEG (4-7): To a peptide synthesis vial was added
porphyrin 2-14 (0.002 g, 0.00218 mmol) in peptide synthesis grade DMF (0.03 mL) and DIEA
(6-10 equiv) under inert atmosphere. The carboxylic acid was allowed to activate for 1 h at RT
before adding the coupling agents, HOBt (0.000588 g, 0. 00218 mmol) and HBTU (0.00165 g,
0.00218 mmol). The mixture stirred for an additional hour before adding purified EGFR L1
(0.00298 g, 0.00435 mmol). After 48 h, the crude conjugate was analyzed for its molecular
weight by MALDI-MS. The mixture was dried down under vacuum, filtered with a Millipore
PTFE Hydrophobic Millex-FG 0.2 µm filter unit, and subjected to RP-HPLC on a Waters
DeltaPak C18 column (analytical) using a water/acetonitrile gradient in 0.01% TFA (10%
H2O/90% ACN, 90% H2O/10% ACN, 10% H2O/90% ACN). The product was obtained in 31%
yield (95% purity). Rt = 22.24 minutes. MALDI-MS m/z 1325.789 [M-59]+ (Arginine related
ion), 1383.793 [M+H]+, calculated for C78H91N15O9 1382.65.

!

129

Figure 4.16. MALDI-TOF of Conjugate 4-7.

Figure 4.17. MALDI-TOF of Conjugate 4-7.
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Figure 4.18. Analytical HPLC Chromatogram Conjugate 4-7.
Synthesis of Conjugate N-Methylated EGFR L1 D1 3-PEG (4-8): To a peptide synthesis vial
was added porphyrin 2-14 (0.002 g, 0.00218 mmol) in peptide synthesis grade DMF (0.03 mL)
and DIEA (6-10 equiv) under inert atmosphere. The carboxylic acid was allowed to activate for
1 h at RT before adding the coupling agents, HOBt (0.000588 g, 0. 00218 mmol) and HBTU
(0.00165 g, 0.00218 mmol). The mixture stirred for an additional hour before adding purified Nmethylated EGFR L1 D1 (0.00305 g, 0.00435 mmol). After 48 h, the crude conjugate was
analyzed for its molecular weight by MALDI-MS. The mixture was dried down under vacuum,
filtered with a Millipore PTFE Hydrophobic Millex-FG 0.2 mm filter unit, and subjected to RPHPLC on a Waters Delta Pak C18 or a Waters XBridgeTM C18 (analytical) column using a
water/acetonitrile gradient in 0.01% TFA (10% H2O/90% ACN, 90% H2O/10% ACN, 10%
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H2O/90% ACN). The product was obtained in 4.4% yield. Rt = 48.0 minutes. MALDI-MS m/z
568.199 [M+3H]+, 1680.991 [M+2K]+, 1736.911 [M+HOBt] calculated for C88H110N16O13
1599.91.

Figure 4.19. MALDI-TOF-TOF of Conjugate 4-8.

Figure 4.20. MALDI-TOF-TOF of Conjugate 4-8.
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Synthesis of Conjugate EGFR L2 3-PEG (4-9): To a peptide synthesis vial was added
porphyrin 2-14 (0.002 g, 0.00109 mmol) in peptide synthesis grade DMF (0.03 mL) and DIEA
(6-10 equiv) under inert atmosphere. The carboxylic acid was allowed to activate for 1 h at RT
before adding the coupling agents, HOBt (0.000588 g, 0. 00109 mmol) and HBTU (0.00165 g,
0.00109 mmol). The mixture stirred for an additional hour before adding purified EGFR L2
(0.00174 g, 0.00218 mmol). After 48 h, the crude conjugate was analyzed for its molecular
weight by MALDI-MS. The mixture was dried down under vacuum, filtered with a Millipore
PTFE Hydrophobic Millex-FG 0.2 mm filter unit, and subjected to RP-HPLC on a Waters
DeltaPak C18 column or Waters XBridgeTM C18 (analytical) using a water/acetonitrile gradient
in 0.01% TFA (10% H2O/90% ACN, 90% H2O/10% ACN, 10% H2O/90% ACN). The product
was obtained in 10%-40% yields (98% purity). Rt = 19.30 minutes (Purity is for normalized
data).

MALDI-MS m/z 1138.550 [M-C67H63N9O9]+, 1161.534 [(M-C67H63N9O9)+Na]+,

2612.278 [M+5Na]+, 2499.183 [M+H]+, calculated for C133H150N25O25 2498.76.!!

Figure 4.21. MALDI-TOF-TOF (a) of Conjugate 4-9.
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Figure 4.21. MALDI-TOF-TOF (b)of Conjugate 4-9.

Figure 4.22. MALDI-TOF-TOF (c) of Conjugate 4-9.
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Figure 4.23. Analytical HPLC Chromatogram of Conjugate 4-9.
Synthesis of Conjugate EGFR L2 NL with Diglycolic Anhydride Porphyrin 2-4 (4-10): To a
peptide synthesis vial was added porphyrin 2-4 (0.010g, 0.0134 mmol) and DIEA (6 equiv) in
0.7 mL of peptide synthesis grade DMF. This mixture was stirred for 1 h before HOBt (0.00725
g, 0. 0134 mmol) and TBTU (0.00430 g, 0. 0134 mmol) were added to the vial and continued to
stir for an additional hour. Simultaneously, resin bound EGFR L2 (0.00107 g, 0.00670 mmol)
was added to a peptide synthesizer and swelled for 1 h in peptide synthesis grade DMF (1.5 mL).
The activated porphyrin and coupling agents were then transferred to the peptide synthesizer,
purged with N2, then capped tightly. The peptide synthesizer was then attached to the mechanical
rotater and the reaction continued for 48 h at RT. After reaction completion, excess unreacted
porphyrin and coupling agents were washed away using DMF, MeOH, and DCM until the
supernatant was colorless.

After drying under vacuum aspirator for 0.5 h, the resin was

subjected to a “cleavage cocktail” consisting of 1 mL of TFA (88%), liquefied phenol (5%),
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triisopropylsilane (2%), and water (5%) was added to the resin beads for 4 h. The resin was
filtered and washed with TFA (3 x 1 mL). The green filtrates were combined, evaporated, and
washed with cold anhydrous ether until precipitation occurred. The precipitates were washed
again with cold anhydrous ether and dried under vacuum (or lyophilized in 50% H2O/50%
ACN). MALDI-TOF-TOF m/z 1733.833 [M-C99H92N16O14] (Porphyrin and peptide to amino
acid residue #8 (threonine)), 1657.727 [(M-C96H85N15O13]. 2333.568 [M+K]+, 2295.057 [M+H]+,
calculated for C125H133N23O22 2309.52.

Figure 4.24. MALDI-TOF-TOF of Conjugate 4-10.
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CHAPTER 5. BODIPY PEPTIDOMIMETIC CONJUGATES TARGETED TOWARD
HER-2 AS THERAPEUTIC AGENTS FOR BREAST CANCER
5.1 The Importance and Versatility of BODIPYs
As illustrated in Chapter 1, much work has been conducted on the development of novel
BODIPYs (Figure 5.1), due to their usefulness in science and medicine.1 While derivatives of
“porphyrin’s little sister”2 were first synthesized in 1968,3 interest in this field has greatly
increased since the 1990s.1a This is mostly an effect of the realization for BODIPYs to be used in
cellular imaging techniques.1a In order for a molecule to be considered as useful for medical
imaging or treatment, there are several criteria that the molecule must meet, primarily its low
toxicity to normal tissues. Like porphyrins, BODIPYs are highly fluorescent, and depending on
the substitution on the BODIPY core, can emit wavelengths into the visible and near-IR (NIR)
range. This is one of the main reasons these molecules can be used as fluorescent labels that are
attached to proteins,1 antibodies,1 DNA,1 or oligosaccharides.4
!
8

7

2

6
N

N

5

B

F

1

8

7

1

2

6
N

N

5

3

B

F

F

F

3
"

Figure 5.1. BODIPY Structure.

The primary aspects of BODIPYs that secure their attractiveness as fluorescent imaging
agents are the following: they are stable in different environments (acidic, basic, various
temperatures),1,

5

tend to have a lower degree of aggregation compared with porphyrin

derivatives,4 have high fluorescence quantum yields,1-2,

4-5

possess high molar extinction

coefficients, and have inconsequential triplet state formation (a quality of importance when
discussing their fluorescence capabilities),1-2, 5 are soluble in a variety of solvents (including
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water, depending on the degree of water-soluble moieties on the BODIPY scaffold),1-2, 4-5 and
can emit at wavelengths greater than 500 nm.1-2, 5
It is also important to consider the major disadvantage of using BODIPYs, as well as
other organic dyes, in general for imaging applications. One of the most prominent issues is that
the Stokes’ shift in organic dyes tends to be small (less than 15 nm).5b, 6 A small Stokes’ shift is
an indication that the molecule has a tendency for self-absorption, thus decreasing emission
wavelength intensity, one of potential causes of an “inner filter effect.”6-7 This is a crucial
consideration because the techniques and applications for which BODIPY dyes are used, such as
biological imaging4, 6 or as molecular probes,6 require large Stokes’ shifts to avoid the issue of
lower fluorescence emission intensities.6 Most recently, BODIPY dyes have been developed
with Stokes’ shift values of approximately 96 nm.6 For molecules with very small Stokes’ shifts,
however, additional considerations are taken when conducting fluorescence measurements.
There is a need for narrowband filters to be incorporated into the fluorescence instrumentation,
or, a highly selective excitation source must be used, both of which are expensive to incorporate
into fluorescence measurements.5b, 8 It is usually proposed that in order to modify the Stokes’
shifts, that two chromophores be incorporated into one molecule, with one being an energy donor
(high energy absorbing chromophore) and the other being an energy acceptor (lower energy
emitting chromophore).5b In another approach, Ziessel and colleagues modified the fluorines in
F-Bodipy with anthracene and pyrene. The largest Stokes’ shift attained, using this methodology,
was 54 nm (Figure 5.2 A).5b In most recent work, Chen & colleagues modified the BODIPY
core at the meso-, 2-, and 6- positions with phenyl, and thiophene substituents, respectively
(Figure 5.2 B).6
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Figure 5.2. Selected BODIPY Structures with Stokes’ Shifts >50 nm
(A) Ziessel et al.5b (B) Chen et al.6
It is important to note that the fluorescence quantum yields for the compounds illustrated in
Figure 5.2 were 25% (in DCM)5b and 20.6% (in PhCH3)6, for 5.2 (A) and 5.2 (B), respectively.
While other compounds listed in these publications had Stokes’ shifts smaller than 50 nm,
several of the quantum yields reached 85%-90%.5b, 6 Also, while the Stokes’ shifts improved, the
applications in which these molecules may be used will require the addition of water-soluble
substituents, which may alter the Stokes’ shift.
5.2 BODIPY Syntheses
With the increase of BODIPY-related papers being published, that the synthesis of the
BODIPY core follows three general methods: 1. Condensation from pyrrole and aldehyde, 2.
Condensation via pyrroles and acid chlorides (or anhydrides), 3. Condensation from
ketopyrroles.1 Other BODIPY derivatives consist of the addition of heteroatom substituents (as
illustrated in Figure 5.2 (B)), substitution of the fluoride atoms with various groups bonded to
the boron (illustrated in Figure 5.2 (A)), extended conjugation of the BODIPY core or through
vinyllic substitution at the 3- and/or 5-positions of the BODIPY, among others.1 These three
methods mentioned above provide routes to synthetically useful BODIPY molecules for use in
biology, medicine, and energy-transfer applications.1-4, 5b, 9
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5.2.1 BODIPY Synthesis from Pyrrole and Aromatic Aldehyde
BODIPY derivatives can be synthesized via condensation of an !-free pyrrole and an
aromatic aldehyde (Scheme 5.1).1 The reaction is catalyzed by TFA or a Lewis acid, in varying
solvents, depending on the solubility of the reactants. This reaction generally proceeds at room
temperature and produces a dipyrromethane, an intermediate that is not often isolated before
pursuing subsequent procedural steps. The dipyrromethane is then oxidized to dipyrromethene
using DDQ or p-chloranil. Boron trifluoride diethyl etherate (BF3.Et2O) is used to complex the
pyrrolic nitrogens to boron. This remains a primary method to synthesize a BODIPY, more
specifically, through the use of aromatic aldehydes, creating a meso-substituted aromatic group
at position 8 (Scheme 5.1, for example).1, 3, 10 Additionally, in the case of Scheme 5.1, using an
alternative method, such as the use of an acyl chloride, to synthesize this particular BODIPY
may have caused chemoselectivity issues, inevitably yielding a 2-ketopyrrole instead of the
desired phenolic product.1, 10-11 Yields for the synthesis of a symmetric BODIPY vary greatly on
the substituents on the pyrrole and aldehyde. Our group has produced BODIPYs using this
method in in 55-90% yields.12 This method can be generalized to most substituted pyrroles and
aldehydes and usually produces symmetric BODIPY systems with 8-aryl substitution.
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Scheme 5.1. Synthesis of BODIPY via Condensation of Pyrrole and Aromatic Aldehyde.
(Example by Loudet et al.1a,b)
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5.2.2 BODIPY Synthesis from Pyrroles and Acylated Compounds (Acetone, Acid
Chlorides, and Anhydrides)
The first BODIPY synthesized by Treibs and Kreuzer in 1968 involved the condensation
of 2,4-dimethyl-1H-pyrrole with acetone using BF3.Et2O as the catalyst (Scheme 5.2).3 While
only 9% yield was obtained of this product, this later propelled the syntheses of other BODIPY
dyes by this method. It is important to note that this particular reaction Scheme 5.2 involved
conjugation at positions 3 and 5 of the BODIPY core. The substituents at these positions varied
from more electron-donating aromatics (e.g. 4-MeOC6H4, 2-MeOC6H4) to electron-withdrawing
aromatics (e.g. C6H4, 1-C10H7, 4-FC6H4).13 The unfortunate result of this type of reaction for the
BODIPY core is that unstable dipyrromethene intermediates (hydrochloride salt derivatives) are
formed and cannot be isolated.1 The BODIPY core is finalized by complexation of the boron
difluoride to the pyrrolic nitrogens using base (Et3N or iPr2EtN) and subsequent addition of
BF3.Et2O in a suitable solvent.1, 13!
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Scheme 5.2. Synthesis of BODIPY via Condensation of Pyrrole and Acetone.
(Example by Loudet et al.1a,b)
A similar method has been considered as one of the most efficient methods in obtaining
8-substituted BODIPY dyes. In work published by Burgess et al, a condensation of pyrrole and
an aromatic acid chloride (4-iodobenzoyl chloride) resulted in the aromatic substituent at
position 8 of the BODIPY in yields from 36%-99% (Scheme 5.3).13

!

144

I

I

I

Et3N, BF3.Et2O
N
H

R
COCl

ClCH2CH2Cl
85oC

NH

Toluene, 80oC

N
R

R

N
R

N

B
F

F

R

R = (a) C6H4 (36%), (b)1-C10H7 (90%), (c) 4-MeOC6H4 (99%), (d) 4-FC6H4 (99%), (e) 2-MeOC6H4 (94%)

Scheme 5.3. Synthesis of BODIPY via Condensation of Varying !-Substituted Pyrroles and
Aryl Acid Chloride (4-iodobenzoyl chloride).
(Example by Loudet et al.1a,b)
It bears mentioning that non-aromatic acylated substituents can also be incorporated onto
the BODIPY at the meso-position. Such a method might include using an anhydride, such as
glutaric anhydride, to end in a carboxylic acid-terminated BODIPY, which can be carried into
other syntheses, such as the conjugation of peptides, proteins, or peptidomimetics to the
BODIPY for biological and medicinal applications.1, 14 It has been reported that alkylation (in the
case of glutaric anhydride) or arylation (in the case of 4-iodobenzoyl chloride) at the mesoposition does not red shift absorption or emission of the BODIPY.1
5.2.3 BODIPY Synthesis from Ketopyrroles
In the case of the BODIPY used in this study, another synthesis must be conducted due to
the unsymmetrical nature of this BODIPY. The aforementioned methods, in sections 5.2.1 and
5.2.2, will strictly yield symmetrical BODIPY cores. The method used to obtain unsymmetrical
BODIPYs is through the use of ketopyrroles, although these must be prepared before
condensation with another pyrrole. This method, however, can produce symmetrical products,1, 5a
but is most favorable for unsymmetrical BODIPY dyes because the ketopyrrole is usually
created first (requiring an additional step in the synthesis).1 The acid catalyst for this
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condensation method, phosphorous oxychloride (POCl3), is often used.1, 5a, 15 Other examples of
this condensation also use TFA.5a,

15

The final complexation step requires the Lewis acid,

BF3.Et2O, yielding the BODIPY core of interest. An example of the acidic condensation of a
ketopyrrole with another varyingly substituted pyrrole is shown in Scheme 5.4. The
formylpyrrole in the Scheme (5.4) could be synthesized via the method by Treibs and Kreuzer
(Scheme 5.1).3 Although the synthesis of the BODIPY used in this project is not published, due
to its existence being proprietary from InvitrogenTM (now, Life TechnologiesTM), it is proposed
that this BODIPY would undergo synthesis via the ketopyrrole method, due to its varying
functionalities on each pyrrole. The structure of 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-5indacene-3-pentanoic acid succinimidyl ester, or BODIPY ® FL succinimidyl ester (SE), is
illustrated in Figure 5.3.!!
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Figure 5.3. Structure of BODIPY ® FL succinimidyl ester (SE).
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5.3 HER-2 and its Implication in Breast Cancer
Growth factors, more specifically, the human epidermal growth factors, EGFR/HER1/ERBB1, HER-2/ERBB2, ERBB3 and ERBB4, are important to consider in the proliferation of
tumors. HER-1 and HER-2 have been associated with various cancers through their overexpression on the cell surfaces of these tumors.16 The four variations of human EGFR are similar
in structure and activity. Each receptor exists as a monomer, consisting of an extracellular
domain (containing four domains (I-IV)), a transmembrane domain (or the “membrane-spanning
region”), a cytosolic tyrosine-kinase-containing domain, and the regulatory domain, through
which cell signaling to the nucleus occurs.16a, 16h, i, 17 The process of cell signaling is important to
the overall activity of a cell, as this activity dictates the type of proteins necessary for accurate
cellular function. Additionally, although the growth factors have similar features and objectives,
there is a staunch difference between HER-2 and the other ERBBs. The primary difference is in
the ligand binding; ERBBs 1, 3, and 4, each contain a specific binding ligand, a molecule which
attaches to the receptor prior to dimerization.16e, f For example, for HER-1/ERBB1, the binding
ligand is epidermal growth factor (EGF), a polypeptide consisting of fifty-three amino acids.16c
Once EGF binds to the active site on the inactive, or tethered confirmation of HER-1/ERBB1,
the confirmation is then “activated” and may subsequently pair, or dimerize, with another growth
factor.16a, 16e, f There are other ligands which bind to HER-1, such as transforming growth factor! (TGF-!) or amphiregulin (AR).16a, 18 However, for ERBB3 and ERBB4, other ligands bind
preferentially, most notably the neuregulins (NRGs).16a, 19 HER-2 has been implicated as the only
growth factor that permanently exists in an “activated” confirmation and does not require any
ligand binding to achieve activity. HER-2 has been identified as the growth factor receptor that
binds to each of the other ERBBs at a very high rate.16a, 20 While ERBB1, ERBB3, and ERBB4
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may each homodimerize, or the process of two of the same ERBBs combining in the
extracellular domain, it is prominently found that HER-2 consistently binds preferentially to each
of these receptors through heterodimerization.16a Also, HER-2 can bind to itself repeatedly, thus
initiating the over-expression of this receptor due to high concentrations of HER-2 at the plasma
membrane.16a To illustrate these concepts, two Figures (5.4 and 5.5) propose structures and
binding mechanisms for the ERBBs. Figure 5.4 highlights a general structure of the non-ligand
binding, activated HER-2 exhibiting each of its domains. Figure 5.5 illustrates the dimerization
of activated HER-2 with another tethered ERBB monomer, such as EGFR (HER-1) or ERBB3.
In this Figure (5.5), it is shown that a ligand must bind to the previously inactivated monomer
before heterodimerization with HER-2. The generalized ligand binds to domains I and III of the
ERBB extracellular domain. Examples of this include EGF and the NRGs.16a
This project’s focus is to develop molecules, more specifically, peptidomimetics, that
preferentially attach to HER-2, which has been studied over the past decade as a target for the
treatment of breast cancer.16h, i While HER-2 positive breast cancer is one tumor subtype,21 there
are breast tumors that are basal-like,21a, b, 22 luminal-like (most common form),21a, b, 23 and normal
breast tissue-like.21a, b, 24 HER-2 over-expressed breast cancers, however, are very aggressive.
These types of breast cancers over-express HER-2 by over 30% and, unfortunately, have a very
unfavorable prognosis - varying between 60-72 months, unless found at a very early stage.20-21 If
efforts are placed toward developing highly specific molecules for HER-2, this could improve
the current treatment options. Currently, individuals who have been diagnosed with HER-2
positive breast cancer are treated with high molecular weight, uncharacterized antibodies
(mAbs), for example, Tratstuzumab (Herceptin; manufactured by Genentech/Roche) or
Pertuzumab (Omnitarg; nanufactured by Genentech).21b Trastuzumab binds to domain IV of
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ERBB2, while Pertuzumab binds to domain II of ERBB2. Neither of these mAbs are highly
effective in treating HER-2 positive breast cancers because of the ability of the cancer cells to
further mutate, thus gain increased resistance to these agents. In fact, the efficacy of these mAbs
has been thoroughly studied through clinical trials; Trastuzumab only assists in treating one-third
of HER-2 over-expressed breast cancer, while Pertuzumab only treats breast cancers which are
HER-2 positive, but contain low levels of the receptor.16a These facts also accentuate that each
mAb binds to different domains of HER-2; binding of Trastuzumab to domain IV is a completely
uninvolved region in the homo- or hetero-dimerization of ERBBs, while the binding of
Pertuzumab to domain II is the essential region for either dimerization form (as illustrated in
Figure 5.5).16a, 20 In any case, these mABs are not extremely effective for treatment. Therefore,
developing smaller, highly specific, fully characterizable molecules, such as peptidomimetics,
may increase survival time of individuals with HER-2 positive breast cancers, whether this
receptor is over-expressed or not.

Although smaller molecules, such as the tyrphostins

mentioned in Chapter 3, that bind to the ATP site of the ERBB tyrosine kinase domain, have
been approved for clinical use in the treatment of cancers that over-express other ERBBs, there
has not been a molecule of low molecular weight approved for the treatment of HER-2 breast
cancers.
5.4. Development and Biological Studies of HERP5 Peptidomimetic
This work focuses on conjugation of fluorescent BODIPY (Figure 5.3) to a
peptidomimetic - a low molecular weight peptide that simulates the functionality and structure of
a larger peptide or protein - illustrated to have an affinity for HER-2 through recent in vitro
studies by Satyanarayanajois and colleagues.16h This three amino acid peptidomimetic was
developed through computational experimentation and subsequently tested in cell culture to
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Figure 5.4. HER-2 Generalized Structure With Essential Regions.

Figure 5.5. Heterodimerization of HER-2 with Another ERBB Monomer.
!
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determine its inhibitory effect when bound to HER-2. Figure 5.6 shows the structure of the
peptidomimetic, termed HERP5.16h,

i

Although other peptidomimetics were developed, the

combination of computational work and biological study on this derivative of HERP5 verifies
the great potential for this molecule.
5.4.1 Computational Development of HERP5
The use of computational chemistry in drug development has become of utmost
importance in recent years. Programming of new computational software has opened the arena of
biological docking to organic chemists and biologists alike. Using docking programs, such as
AutoDOCK,25 allows for synthetic methods to be realized, and in many cases, proves to be a
very effective method for finding active sites, low energy conformations, and geometrically
stable molecules, which all bind to a molecule of choice in consideration of an implicit or
explicit environment.25-26 This is the case for the development of the HERP5 peptidomimetic
(Figure 5.6).
1-Napthylalanine
Phenylalanine
O
HN
H2N

N
H
O

R
O

R = -OH, -NH2
HN
H2N

NH

Arginine

Figure 5.6. HERP5 Peptidomimetic (Compound 5-1).
EGFR and other members of the ERBB family have been well characterized by crystal
structure. This is evidenced by the vast information available about EGFR on the Protein Data
Bank website.27 Additionally, there are many ligands known to bind to ERBBs 1, 3, and 4,
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preferentially.16a For determination of peptidomimetic HERP5, the crystal structure of HER-2 in
complex with Trastuzumab (Herceptin) was used (PDB ID: 1N8Z).16h, i, 18 There are three regions
deemed important for binding Herceptin to HER-2: two regions contain integral electrostatic
interactions with the mAb, while another region serves as a hydrophobic binding region for
Herceptin.16h,

18

The electrostatic regions of the binding site between HER-2 and Herceptin

consist of acidic and basic residues, such as arginine (R) and lysine (K), whereas the
hydrophobic space of the site is occupied by phenylalanine (F) and proline (P). The hydrophobic
region is bordered on each side by the electrostatic regions. Therefore, the peptidomimetics were
designed using a generalized structure order: an N-terminal arginine, followed by a
conformationally constrained hydrophobic "-amino acid (such as 1-naphthyl alanine), and Cterminated with phenylalanine. Using a hydrophobic "-amino acid like 1-naphthyl alanine
minimizes proteolytic degradation of the peptide and reduces the amount of flexibility of the
peptide in biological conditions (aqueous), therefore restricting the possible conformation of the
molecule (i.e. random coil, "-sheet, or !-helix).16h, 18 A "-sheet confirmation of the HERP5
peptide was confirmed in recent work.16i On the other hand, supplementary computational
(docking) showed favorable results. Two software programs, AutoDOCK25 and INSIGHT II,28
were used to determine the chemical space for the molecule and also achieve the most
energetically favorable conformations of the HERP5 peptidomimetic.

In this work, five

derivatives of HERP5 were reported with low energies between -13.87 to -13.31 kcal/mol.16h
5.4.2 Antiproliferative Activity of HERP5
The antiproliferative activity of HERP5 was studied in three different cell lines: HCT 116
(human colon cancer cells), MCF-7 (human breast cancer cells), and SKBR-3 (human breast
cancer cell line with epithelial morphology). The IC50 micromolar concentrations for HERP5 in
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these three cell lines were 25.7 (HCT 116), 16.9 (MCF-7), and 0.396 (SKBR-3), giving the
lowest inhibitory concentrations compared to six other peptide derivatives that were studied.
This data confirms that this molecule should be further investigated by conjugation to a
fluorescent marker as potential treatment for HER-2 positive breast cancers.
5.5 Synthesis of BODIPY-HERP5 Conjugates
The synthesis of the BODIPY-HERP5 conjugates was accomplished using three
methods: 1. Synthesis of a C-terminal tert-butyl ester protected HERP5 peptide and subsequent
solution phase conjugation to BODIPY, 2. Synthesis of HERP5 conjugate via solid phase peptide
synthesis (SPPS) on the Rink Amide resin (C-terminal amide functionality), and 3. Synthesis of
HERP5 conjugate via SPPS on the Wang resin (C-terminal carboxylic acid functionality).
5.5.1 Synthesis of BODIPY-HERP5 tert-Butyl Ester Terminated Conjugate
The first synthesis of unprotected 5-1 was customized by NeoMPS (San Diego, CA,
USA) and a later purchase of the free peptide was made from New England Peptide (Gardner,
MA, USA). It was first attempted that 5-1 be directly conjugated to the commercially available
5-3, under basic conditions (Et3N) to allow for direct and, apparently unproblematic, conjugation
to 5-3. However, after several studies, it was verified by NMR that 5-1 tends to dimerize and
polymerize when using these conditions, thus suggesting that one end of 5-1, N- or C-terminal,
must contain a protecting group before conjugation with the fluorophore. This method, then,
protects the C-terminus of 5-1 with a tert-butyl ester, which is stable under the basic conditions
needed for conjugation. The tert-butyl ester can be formed by several methods, including strong
acidic conditions. Mechanistically, the reaction is acid catalyzed with sulfuric acid, then tertiary
butanol is added to complete the esterification.

To prevent water from forming, causing

hydrolysis of the ester, anhydrous magnesium sulfate was added.29 The primary issue with this
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method is that the yields were moderate (54%) and did not give enough product for further
significant study. Several trials were conducted with the aim to optimize the with consistently
moderate yields obtained. To proceed with the conjugation, after aqueous work-up in sodium
bicarbonate, the product was immediately subjected to solution phase conjugation to 5-3 in DMF
for 72h, as shown in Scheme 5.5. The yield for this synthesis was 20%, giving less than 0.001 g
of product, 5-4. If this method continued, the C-terminal ester would have been deprotected with
TFA, however, this method was abandoned and additional conjugations took place via SPPS
(Scheme 5.6).
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Scheme 5.5. Synthesis of BODIPY-HERP5 tert-Butyl Ester Terminated Conjugate.
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O

5.5.2 Synthesis of BODIPY-HERP5 Rink Amide Conjugate
After achieving moderate yields of 5-4, it was proposed that the synthesis of these
conjugates can be performed via SPPS. Therefore, the peptide, 5-1, was synthesized on two
different resins, one being the Rink Amide resin (Figure 5.7), and the other, the Wang Resin
(Figure 5.8). This resin was selected for several reasons. First, this resin provides the final
cleaved peptide with a C-terminal amide functionality, which gives a stable C-terminus and
avoids protection of the C-terminal carboxylic acid, as was conducted to afford product 5-2. The
peptide, synthesized via benchtop SPPS by our group, yielded the C-terminal amide HERP5 (56) anchored to the Rink Amide resin. The Fmoc-group remained on the N-terminal arginine to
preserve the structure and function of the peptide between syntheses, as illustrated in compound
5-6 and the Fmoc-group was cleaved using piperidine and DBU (in DMF) prior to coupling,
giving compound 5-7. Conjugation of 5-3, as shown in Scheme 5.7, to this resin involved
reaction of the succinimidyl ester in Et3N and DMF for one hour before adding this !solution to a
peptide synthesis chamber containing the swelled 5-7 peptide.

The conjugation, again,

proceeded for a total of 72 h. The progress of the reaction was monitored by selecting a few resin
beads from the chamber, subjecting them to the “cleavage cocktail” consisting of TFA (88%),
liquefied phenol (5%), triisopropylsilane (2%), and water (5%) for 4 h, then submitting this small
sample for mass spectrometry analysis. Once the mass of the conjugate was confirmed, the
entire conjugate was cleaved from the resin using the aforementioned cleavage cocktail, dried,
and washed with cold ether to remove scavengers. Because of the more hydrophobic nature of
this conjugate, it was purified by preparative TLC (10% MeOH/90% DCM) and yielded 60% of
conjugate 5-8. This process of synthesis improved the conjugation yield significantly.
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Figure 5.7. Structure of Rink Amide Resin.
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Scheme 5.6. Synthesis of BODIPY-HERP5 Rink Amide Conjugate.
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5.5.3 Synthesis of BODIPY-HERP5 Wang Conjugate
As stated previously in Section 5.4 of this Chapter, the computational studies and
antiproliferative activity was conducted using the C-terminal carboxylic acid HERP5 (5-1).
Therefore, the peptide 5-1, had to be synthesized on another type of resin, the Wang resin
(Figure 5.8). This resin provides the final cleaved peptide with a C-terminal carboxylic acid
functionality. This peptide was also synthesized via benchtop SPPS by our group and yielded the
Fmoc-protected C-terminal HERP5 (5-9) anchored to the Wang resin. The Fmoc-group remained
on the N-terminal arginine, once again, to preserve the structure and function of the peptide
between syntheses, then was cleaved right before conjugation. Conjugation of 5-3, as shown in
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Scheme 5.8, to this resin involved reaction of the succinimidyl ester in Et3N and DMF for one
hour before adding this solution to a peptide synthesis chamber containing the swelled 5-10
peptide. The conjugation proceeded for a total of 72 h. Selecting a few resin beads from the
chamber, subjecting them to the “cleavage cocktail” for 4 h, then submitting this small sample
for mass spectrometry analysis, was used again to monitor the progress of the reaction. Once the
mass of the conjugate was confirmed, the entire conjugate was cleaved from the resin (using the
aforementioned cleavage cocktail), dried, and washed with cold ether to remove scavengers.
Because of the more hydrophobic nature of this conjugate, it was purified by preparative TLC
(10% MeOH/90% DCM) and yielded 45% of conjugate 5-11. Although the yield was not as
high as the resulting 5-8 conjugate, the conjugation yield was better than the original process
(compound 5-4).
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Figure 5.8. Structure of Wang Resin.

O

O
O

HN
HN

O

N
H
O

Wang Resin

O
O

HN

DMF, Piperidine, DBU
H2N

3 washes, 0.5 h (total)

N
H
O

Wang Resin

O
O

5-10
HN

HN
H 2N

5-9
H 2N

NH

N
O
N

N

B
F

O

F

F

B

N
F

(60%)

O
5-3

N

1. Et3N, DMF, 1h
2. 5-10, DMF, 72h
3. TFA/Phenol/TIS/H2O, 4h

NH

O

O
H 2N

H
N
NH

H
N

NH

O

5-11

Scheme 5.8. Synthesis of BODIPY-HERP5 Wang Conjugate.
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O
HN
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OH

!5.6 Conclusion

This chapter aimed to illustrate the different synthetic methodologies to obtain BODIPYs
as well as give an overview of the synthetic methods to obtain two BODIPY-peptidomimetic
conjugates. The most effective method for conjugating BODIPY 5-3 was via SPPS. Future
cellular studies will illustrate the efficacy of these BODIPY-peptidomimetic conjugates to image
and/or potentially treat cancers that have an over-expression of HER-2.

5.7 Experimental
Synthesis of tert-butyl Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe (5-2): In a small
round bottom flask, anhydrous magnesium sulfate (0.232 mg, 0.001928 mmol) in 3 mL of dry
DCM was stirred vigorously for 10 minutes. Excess concentrated sulfuric acid (92.00 mg, 0.9380
mmol) was added to the flask. The mixture was stirred for 1 h. 5-1 (0.25 mg, 4.8206E-4 mmol)
was then added to the mixture. The flask was sonicated to ensure solubility and stirred for an
additional 5 minutes before adding tertiary butanol (0.228 uL, 0.002410 mmol). The flask was
stoppered and stirred for 24 h at 25oC under N2 gas. The reaction was quenched with saturated
sodium bicarbonate (3 mL) by adding this to the reaction flask until all of the magnesium sulfate
had dissolved. The organic phase was separated, washed with brine, dried with Na2SO4, and
purified by preparative TLC to afford the t-butyl protected HERP5 (5-2) in 54% yield (0.15 mg).
1

H NMR (400 MHz, Acetone) d ppm 0.82 - 0.91 (m, 6 H) 1.28 (br. s., 9 H) 1.51 - 1.62 (m, 1 H)

2.94 (br. s., 4 H) 3.25 - 3.32 (m, 1 H) 4.57 - 4.63 (m, 1 H) 5.34 (t, J=4.57 Hz, 1 H) 6.24 - 6.31
(m, 1 H) 7.21 (s, 1 H) 7.31 (d, J=4.26 Hz, 1 H) 7.42 - 7.47 (m, 1 H) 7.50 - 7.64 (m, 3 H) 7.77 7.89 (m, 1 H) 7.93 (d, J=7.31 Hz, 1 H) 8.02 (s, 2 H) 8.15 - 8.24 (m, 1 H). MALDI-TOF:
C32H44N604 [M]+: 577.351, calcd. for C32H45N604: 577.71.
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Synthesis of BODIPY succinimidyl ester tert-butyl Arg-[3-amino-3-(1-napthyl)-propionic
acid]-Phe (5-4): To a small round bottom flask was added 5-3 (0.826 mg, 0.001979 mmol) in
peptide synthesis grade DMF (1 mL). Compound 3 was sonicated to ensure solubility. Six (6)
equivalents of triethylamine (1.65 uL, 0.001979 mmol) were added to the flask. Compound 5-3
was activated for 4.5 h under inert conditions (N2 gas) before compound 5-2 (2.3 mg, 0.001979
mmol) in 0.5 mL peptide synthesis grade DMF was added to the flask. Conjugation took place
for 72 h under nitrogen. Confirmation of mass was observed by ESI-MS. HRMS (ESI) [M-tBu]:
820.73, calcd. for C48H59BF2N8O5: 876.84; MALDI-TOF (Figure 5.10) C48H61BF2N8O52+
[M+H]: 880.196, calcd. for C48H59BF2N8O5: 879.49.
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Figure 5.9. Compound 5-2 MALDI-TOF.

Figure 5.10. 1H NMR of Compound 5-2.!
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Figure 5.11. Compound 5-4 MALDI-TOF.
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Fmoc Deprotection of Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Rink Amide
Resin (5-7): Resin 5-6 (0.0025 g, 0.004794 mmol) was swelled in peptide synthesis grade DMF
for 1 h. A fresh “deblock solution” (25.00 mL) was prepared consisting of piperidine (1.25 mL),
DBU (0.50 mL), and DMF (23.25 mL). The deblock solution was added to the chamber such that
it completely covered the resin beads over three timed settings: 1 x 8 min, 1 x 5 min, 1 x 7 min.
The final step requires washing with DMF (5 times with vigorous stirring) and vacuum drying.
The peptide was used immediately in the following step. ESI-MS. 740.338 [M+H]+, Calculated
for C43H45N7O5 739.86.

Figure 5.12. Compound 5-7 MALDI-TOF.
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Conjugation of 5-3 to Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Rink Amide
Resin (5-8): To a reaction vessel was added compound 5-3 (0.0015 g, 0.002397 mmol) and
solubilized in 0.5 mL DMF. Triethylamine (0.002 mL, 0.002397 mmol) was added to the vessel
and stirred to activate the ester. The reaction continued for 1 hr. This solution was added to the
peptide synthesis chamber containing 5-7 (0.0025g, 0.004794 mmol). The reaction proceeded
with shaking for approximately 72 h under N2. The beads were then washed with DMF 4 times,
to remove residual 5-3, until the filtrate was colorless. A “cleavage cocktail” consisting of 1 mL
of TFA (88%), liquefied phenol (5%), triisopropylsilane (2%), and water (5%) was added to the
resin beads for 4 h. The resin was filtered and washed with TFA (3 x 1 mL). Filtrates were
combined, evaporated, and washed with cold anhydrous ether. Purification was conducted by
preparative TLC (10% MeOH/90% DCM) to yield 51% of conjugate. 1H NMR (400 MHz,
DMF) d ppm 0.13 (br. s., <1 H) 0.87 (br. s., 4 H) 1.43 (br. s., 1 H) 1.51 - 1.60 (m, 4 H) 1.64 (br.
s., 3 H) 2.04 (d, J=2.44 Hz, 3 H), 2.14 (br. s., 3 H) 3.11 (br. s., 2 H) 3.16 (br. s., 1 H) 3.21 (br. s.,

Figure 5.13. MALDI-TOF of Compound 5-8.!
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1 H) 3.28 (br. s., 2 H) 3.39 (br. s., 2 H) 3.92 - 3.99 (m, 2 H) 5.36 (br. s., 1 H) 5.43 (br. s., 1 H)
6.65 (s, 1 H) 7.19 (br. s., 2 H) 7.24 (br. s., 2 H) 7.30 (br. s., 1 H) 7.32 (br. s., 1 H) 7.42 (br. s., 1
H) 7.49 - 7.73 (m, 3 H) 8.40 (d, J=4.87 Hz, 2 H) 8.51 (br. s., 1 H). MALDI-TOF [(M+H)-BF2]:
C44H54N9O4 772.59, calcd. for C44H54N9O4 771.95. # (nm) ($, L mol!1 cm!1): 565 nm
(1.84E+05), 463 nm (4.85E+05).

Figure 5.14. 1H NMR of Conjugate 5-8.
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Figure 5.13 and Table 5.1: MALDI-TOF-TOF Fragmentation of Conjugate 5-8.!
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Fmoc Deprotection of Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Wang Resin (510): Resin 5-9 (0.0050 g, 0.004794 mmol) was swelled in peptide synthesis grade DMF for 1 h.
A fresh “deblock solution” (25.00 mL) was prepared consisting of piperidine (1.25 mL), DBU
(0.50 mL), and DMF (23.25 mL). The deblock solution was added to the chamber such that it
completely covered the resin beads over three timed settings: 1 x 8 min, 1 x 5 min, 1 x 7 min.
The final step requires washing with DMF (5 times with vigorous stirring) and vacuum drying.
The peptide was used immediately in the following step. MALDI-TOF 741.551 [M+H]+,
calculated for C43H44N6O6 740.85.

Figure 5.16. Compound 5-10 MALDI-TOF.
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Conjugation of 5-3 to Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Wang Resin (511): To a reaction vessel was added compound 5-3 (0.0021 g, 0.002397 mmol) and solubilized in
0.9 mL DMF. Triethylamine (0.006 mL, 0.002397 mmol) was added to the vessel and stirred to
activate the ester. The reaction continued for 1 hr. This solution was added to the peptide
synthesis chamber containing 5-10 (0.0050 g, 0.004794 mmol). The reaction proceeded with
shaking for approximately 72 h under N2. The beads were then washed with DMF 4 times, to
remove residual 5-3, until the filtrate was colorless. A “cleavage cocktail” consisting of 1 mL of
TFA (88%), liquefied phenol (5%), triisopropylsilane (2%), and water (5%) was added to the
resin beads for 4 h. The resin was filtered and washed with TFA (3 x 1 mL). Filtrates were
combined, evaporated, and washed with cold anhydrous ether. Purification was conducted by
preparative TLC (10% MeOH/90% DCM) and analytical HPLC (ACN/H2O) to yield 45%-65%
of conjugate. 1H NMR (400 MHz, DMF) d ppm 2.00 (br. s., 3 H) 2.42 (d, J=10.96 Hz, 2 H) 2.47
(br. s., 1 H) 2.54 (d, J=4.87 Hz, 2 H) 2.58 (s, 1 H) 2.76 (br. s., 2H) 3.20 (br. s., 2 H) 3.24 (br. s., 1
H) 3.37 (br. s., 3 H) 3.96 (br. s., 4 H) 4.14 (d, J=15.23 Hz, 2 H) 4.24 (br. s., 1 H) 4.63 (s, 2 H)
4.75 (br. s., 1 H), 4.80 (br. s., 2 H) 4.92 (br. s., 1 H) 6.26 - 6.39 (m, 2 H) 7.26 (s, 1 H) 7.35 (br. s.,
2 H) 7.69 - 7.78 (m, 4 H) 7.99 (s, 1 H) 7.95 (s, 1 H) 8.12 (s, 1 H), 8.47 (br. s., 1 H) 9.03 (s, 1 H).
MALDI-TOF [M+H]: C44H52BF2N8O5 821.41, calcd. for C44H51BF2N8O5 820.73. # (nm) ($, L
mol!1 cm!1): 485 nm (4.49E+05), 351 (5.90E+05).
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Figure 5.17. HRMS ESI of Conjugate 5-11.

Figure 5.18. 1H NMR of Conjugate 5-11.!
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Figure 5.19 and Table 5.2: MALDI-TOF-TOF Fragmentation of Conjugate 5-11.!
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